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Abstract
Systems biology in industrial biotechnology and disease
Systems biology is a paradigm in biological science that has provided an alternative
approach to the traditional reductionistic way of performing biological research.
Rather than focusing on the individual parts of a biological system, the systems
are recognized as inherently complex. Therefore the study of the entire system,
such as with omics approaches, is more likely to be able to identify and explain
the emergent properties of these systems. To power this, high-throughput tech-
nologies, allowing for data generation at a previously unparalleled scale, has been
used in bottom-up approaches to perform data-driven research. Integrated and
combined with top-down approaches, such as systems modeling, it is possible to
investigate complex biological systems. In this thesis I provide examples of how
systems biology, using DNA microarray based transcriptomic research, can be ap-
plied in biological research related to industrial biotechnology and disease.
With regard to industrial biotechnology, we have performed a tiling DNA mi-
croarray experiment identifying transcriptionally active regions in the genome of
the gram-positive bacteria Bacillus subtilis. This organism is widely used in the
industry for enzyme production and increasing systemic knowledge of B. subtilis is
important for improving the efficiency in industrial applications. Here we extend
an existing segmentation method to provide a thorough mapping of transcrip-
tion and identify 125 novel putative antisense transcripts as well as 54 non-coding
RNAs not previously described. Furthermore we identify conserved 3’ UTRs that
could be involved in protein-assembly or transport. Secondly we have performed
an analysis of DNA microarray data on a Saccharomyces cerevisiae mutant which
has been genetically engineered to have increased tolerance towards glucose and
alcohol stress. Here we find that the increased fitness of the strain is only present
in leucine poor media and that increased uptake or utilization of leucine is respon-
sible for the phenotype.
In relation to disease research we have been a part of an Alzheimer’s Disease
drug discovery consortium. Alzheimer’s Disease is the most common neurodegen-
erative disease leading to a progressive cognitive decline and threatens to become
an even larger burden on society than it is today. Using gene expression anal-
ysis on a disease model we have identified gene targets for small molecule drug
discovery of which small molecules targeting two genes are in lead development.
Additionally by integrating expression data with protein interaction and pheno-
typic interaction data we have identified ADAM23 as associated with the disease
in humans. Lastly gene expression profiling investigates the mechanism by which
the probiotic bacterium Lactobacillus acidophilus NCFM induces a viral response
from the immune system. This has been shown in clinical trials to reduce the risk
of viral infections such as common cold and influenza and we find that the viral
response is mediated by IFN-β in a TLR2 dependent mechanism.
RESUME` vii
Resume`
Systembiologi i industriel bioteknologi og sygdomme
Systembiologi er et paradigme indenfor biologisk videnskab der i forhold til tra-
ditionel reduktionisme har en alternativ tilgangsvinkel til biologisk forskning. I
stedet for at fokusere p˚ade enkelte dele af et biologisk system skal systemerne
forst˚as som komplekse i deres natur. Derfor er det med undersøgelser af hele sy-
stemet, hvilket er muligt med “omics”tilgange, mere sandssynligt at identificere
og beskrive disses emergente egenskaber. En af drivkrafterne bag dette er high-
throughput teknologier der muliggør at genere data i en hidtil uset skala og disse
er blevet anvendt i bottom-up tilgange til at udføre data-drevet forskning. Via
integrering med top-down tilgange, som systemmodellering, er det muligt at un-
dersøge komplekse biologiske systemer. I denne afhandling giver jeg eksempler p˚a
hvordan systembiologi baseret p˚a DNA mikroarray transkriptomics, kan anvendes
i biologisk forskning relateret til industriel bioteknologi og sygdomme.
Med hensyn til industriel bioteknologi har vi udført et tiling DNA mikroarray
forsøg hvor vi identificerer transkriptionelle aktive regioner i genomet af den gram-
positive bakterie Bacillus subtilis. Denne organisme er meget anvendt i industrien
til produktion af enzymer og det er vigtigt at øge den systemiske viden om B. sub-
tilis for at øge effektiviteten i industrielle form˚al. Her udbygger vi en eksisterende
segmenteringsmetode til at udføre en grundig kortlægning af transkriptionen og
identificerer 125 nye formodede antisense transkripter s˚avel som 54 ikke tidligere
beskrevede ikke-kodende RNA. Derudover identificerer vi en konserveret 3’ UTR
som kan være involveret i protein-samling og transport. For det andet har vi udført
en analyse af DNA mikroarray data af en Saccharomyces cerevisiae mutant som
er blevet genetisk konstrueret til at have øget tolerance overfor glukose og alkohol
stress. Her finder vi at stammens øgede egenthed kun er tilstedet i leucin fattige
medier og at øget optag eller udnyttelse af leucin er ansvarlig for fænotypen.
I relation til sygdomsforskning har vi været del af et konsortium med det form˚al
at udvikle nye lægemidler mod Alzheimers sygdom. Alzheimers sygdom er den mest
hyppigt forekommende nervedegenerative sygdom og medfører tiltagende kognitiv
forfald, og sygdommen truer med at blive en endnu større byrde for samfundet
end den er idag. Her har vi ud fra gen ekspressionsanalyse af en sygdomsmodel
identificeret gener der kan være m˚al for sm˚a molekylære lægemidler, og lead mo-
lekyler er ved at blive udviklet for to af disse. Integration af ekspressionsdata med
protein-protein interaktionsdata og fænotypedata har derudover ført til identifika-
tionen af ADAM23 som associeret med sygdommen i mennesker. Som det sidste
har gen ekspressionsanalyse givet indsigt i den mekanisme hvorved den probiotiske
bakterie Lactobacillus acidophilus NCFM kan inducere et viralt respons fra immun-
systemet. Dette har i kliniske studier vist at reducere risikoen for virus infektioner
som forkølelse og influenza og her viser vi at det virale respons er medieret via
produktion af IFN-β i en TLR2 afhængig mekanisme.
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Chapter 1
Introduction
1.1 Systems biology
The field of systems biology is not uniformly defined and covers several aspects.
One view is that it can be thought of as a paradigm of biological research where
data integration and understanding emergent properties of complex biological sys-
tems is in focus. It has been well formulated using analogies of a radio or an
airplane, where knowing the individual parts of these systems is not sufficient for
describing how the machine functions. To understand the complex properties and
functionalities of these, knowledge of the wiring and interplay of the individual
parts is critical [1, 2]. Likewise, the genome sequence of an organism and identi-
fication of its genes is not sufficient for describing the complex properties of that
biological system. Although reductionistic approaches has proven adequate when
the number of parts is relatively low, such as modeling planetary movement in
the solar system, biological systems are inherently complex. The change from
reductionism to studying systems as a whole, is at the fundamental level for un-
derstanding complex processes and diseases.
One factor in the emergence of this holistic approach has been the development
of experimental techniques that has allowed for massive parallel generation of data
describing different aspects of biology. These include technologies for studying
genomes, genetics, transcripts, proteins, metabolites, protein-protein interactions,
protein-DNA interactions and more, leading to the generation of the “omics” con-
cept. Generally termed “bottom-up”, these approaches are used to describe the
system starting from the lowest state (e.g. genes, proteins, metabolites) and are at
the base of highly data-driven research (Figure 1.1) [3]. These may be integrated
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Figure 1.1 – Approaches to systems biology as omics-based (bottom-up) and model-
based (top-down). By integrating omics approaches with modeling better under-
standing of biological systems can be achieved. Reprinted with permission from [7].
with “top-down approaches” such as system and network models, where models
are build covering elements from a lower state. Using this combined approach it
is possible to perform research from which induction of biological knowledge and
novel hypotheses may be obtained [4–6]. In this view systems biology is perceived
as an iterative approach generating biological insight by combining “traditional”
life science experiments (mainly high-throughput) with model development and
evaluation (Figure 1.2).
Data integration
By the generation of massive amounts of data from several aspects of biology,
integration of different data types has become of increasing importance. One ad-
vantage of data integration is that the type of errors from orthogonal data sources
are not likely to be the same, hereby increasing the power and value of the data.
However one of the most obvious reasons for data integration is that the complex
problems in systems biology are only solvable if multiple parts of the underlying
biology can be studied and combined [7]. For example for common complex disor-
ders such as cancers, diabetes, obesity and brain diseases, there are probably many
different, and rare, genetic factors responsible for disease development. Addition-
ally the majority of these may only have a weak impact on disease risk making
the discovery of these not straightforward. The complexity of these diseases can
be emphasized by the fact that at the time of writing, 35 genes have been associ-
ated with Late-Onset Alzheimer’s Disease [8]. However, recent large scale Genome
Wide Associations Studies (GWAS) have had success in identifying the genetics of
some common and low-penetrance Single Nucleotide Polymorphisms (SNPs) as-
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Introduction to Systems Biology
Technical University of Denmark
From model to experiment and back...
Figure 1.2 – Systems biology as an combined and iterative discipline. To be able
to explain complex biological systems the combined effort of high-throughput exper-
iments, data integration, model development and evaluation allow for the revision
and development of new hypotheses.
sociated with common diseases [6, 9–11]. From a drug discovery perspective the
nature of these rare disease alleles with low penetrance may increase the risk of
drug development. Drugs targeting these may not have a huge clinical impact,
because they will only be effective in a minority of the patients.
From protein sciences it has been established that proteins function together
in complexes and knowledge of these interactions have become of vital importance
for studying diseases. When a protein in a complex is dysfunctional it will often
disrupt the functionality of the entire complex [12]. In this sense diseases are mod-
ular – similar disease phenotypes are seen when any of the proteins in the complex
are disrupted [13–15]. Because of this protein-protein interaction networks have
become important and powerful resources for studying cellular processes, and are
at the core of Integrative Systems Biology. In our study of Alzheimer’s Disease
(AD) we integrate transcriptomic data with inferred protein-protein interaction
networks and phenotypic data assembled from the Online Mendelian Inheritance
in Man (OMIM) database. From this we identify a candidate gene (ADAM23 ) and
show that the protein product is up regulated and associated with AD in human
post-mortem brain tissue.
In our tiling DNA microarray study of B. subtilis (Paper I) we take a different
integrative approach not utilizing protein-interaction networks. This is primarily
because the goal of the study is to expand the understanding of the transcrip-
tome including findings such as UnTranslated Regions (UTRs), operon structure
and novel non-coding RNA (ncRNA). These findings achieve increased confidence
by integration with known and predicted sigma factor binding sites and Rho-
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independent terminators.
1.2 Transcription
In the majority of all living organisms DeoxyriboNucleic Acid (DNA) contains the
genetic information needed to develop and perform the functions of a particular
organism. DNA contains the blueprint of how to build the components of the liv-
ing organism such as proteins and RiboNucleic Acid (RNA) molecules. Following
the central dogma information flows from the stretches of DNA, that are known as
genes, via RNA to proteins, that are the primary active gene products. This occurs
by transcription in which information is transferred from DNA to messenger RNA
(mRNA), and then by translation that through mRNA instructs ribosomes in how
to assemble a particular protein. Hence the mRNAs present at a given time will
to a large extent represent the active genes in a cell at that moment (Figure 1.3).
Even though almost all cells in multicellular organisms contain the same genetic
information (DNA) they have very diverse roles and functionalities, because only
subsets of genes are active at certain cell stages or developments. By identify-
ing all the transcripts present and measuring their expression levels and changes,
information about active and repressed processes can be obtained. And though
RNA transcripts primarily are the information carriers and therefore only proxies
leading to protein expression, the relatively ease of use, makes transcriptomics an
excellent tool for studying biology.
Genes
When doing biological research, one of the concepts that is most often used is
“gene” and most scientists within the field has a sense for what a gene is. However
when writing this thesis I have realized that a gene might not be such an easy entity
to define. Since the invention of the term “gene” by Wilhelm Johannsen in 1909
to describe inheritable biological traits, a concept developed by Gregor Mendel
in 1866, the definition has changed several times [16]. When I first encountered
biological chemistry during my studies a decade ago, a gene was defined as an
inheritable discrete DNA (or RNA) element that contribute to the phenotype.
Except for rRNA and tRNA they were generally defined as protein-coding and 98%
of the DNA not coding for genes were thought of as primarily non functional and
termed “junk DNA”1. However today tiling DNA microarrays, Next Generation
Sequencing (NGS) and other transcriptomic technologies have shown that not only
protein coding genes are transcribed. Generally the transcriptome of eukaryotic
and especially mammalian organisms have been shown to comprise of a myriad
of transcripts where NGS studies have shown that 30-40% of all sequence reads
to map to unannotated regions [17–19]. A source of these transcripts have been
1Any discrepancies to actually knowledge at that time is entirely at my own responsibility.
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DNA
mRNA
mRNA
Protein
Ribosome
Figure 1.3 – The central dogma in molecular biology showing the general transfer
of information within cells. Information flows from DNA (information storage) to
mRNA (information carrier) via transcription and hereafter translation where ribo-
somes synthesize proteins (active cell machinery) using this information. Generally
mRNA abundance is assayed using DNA microarrays.
shown to be bi-directional promoters from where there seem to be a tendency of the
transcriptional machinery to start transcription from regions that are nucleosome
free [20]. Natural antisense transcription has increased in abundance to such an
extent that antisense transcription is thought of as a pervasive feature of eukaryotic
and mammalian genomes [21]. These discoveries challenge the definition of a gene.
Determinants of transcription
To start transcription from a DNA region, the DNA must be accessible to the cel-
lular machinery. There are some differences between prokaryotes and eukaryotes
in how and where transcription occurs. For eukaryotes, DNA is packed as chro-
matin, stored in the cell nucleus and generally exists as closed or open forms known
as hetero- and euchromatin. For DNA to be available for transcription it needs
to be unwound to euchromatin before general transcription factors, RNA poly-
merase and mediators can bind [22]. Regarding prokaryotes, that does not contain
a nucleus, the chromosome is present in the cytoplasm where it is generally less
condensed. Here RNA polymerase and sigma factors initiate transcription by un-
winding the coiled DNA. Generally transcription is more complex in eukaryotes
compared to prokaryotes, one example being that eukaryotes has three different
types of RNA polymerases whereas prokaryotes (bacteria) has only one [23,24].
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The promoter region, which is where transcription initiates, is subjected to sev-
eral different regulatory mechanisms. Relatively close upstream and downstream
regions can be the target of transcription factors leading to repression or activa-
tion of transcription from the promoter. Typically the transcription factors work
in concert to mediate their regulation and prediction of this is not a straightfor-
ward task. Additionally enhancer and silencer regions, which does not necessarily
have to be close in terms of DNA sequence to the transcription start site, influ-
ence eukaryotic transcription. There are even examples of enhancers found within
introns and on different chromosomes [22, 25, 26]. However, similarly as with the
understanding of genes, the abundant existence of bi-directional promoters chal-
lenge the consensus view of a promoter.
Regarding termination of transcription in eukaryotes, different mechanisms ex-
ists for the three RNA polymerases. In the case of RNA polymerase II, which is
responsible for the production of protein-coding mRNA, termination generally oc-
curs when a cleavage-specific RNA sequence is synthesized. This leads to cleavage
of the 3’ and polyadenylation, a signal involved in nuclear export, translation and
stability. Alternative polyadenylation can occur which can influence exon confor-
mation and include or exclude miRNA binding sites in the 3’ of the transcript [24].
On the contrary polyadenylation of RNA in bacteria is needed for efficient degra-
dation of RNA molecules [27].
The understanding of bacterial promoters as a concept is thought of as rela-
tively well established, however mapping of Transcription Start Sites (TSSs) is far
from accomplished. This is exemplified by the fact that for the model organism
of gram-positive bacteria, B. subtilis, only 660 TSSs are known [28]. This should
be seen in the perspective of our tiling array study of B. subtilis (Paper I) where
more than 3.500 Transcriptionally Active Regions (TARs) are identified. Addi-
tionally polycistronic operons can be transcribed from more than one promoter
and contain internal read-through terminators allowing for several different tran-
scripts from the same region. Termination of transcription in bacteria generally
occurs by Rho-independent or Rho-dependent termination. In the former tran-
scription is terminated when a hairpin structure followed by uracils, known as a
terminator structure, is formed, whereas the latter approach is dependent on the
binding of the protein Rho [23]. Hopefully the findings of our study will attribute
to improving the mapping of TSSs and transcripts, as well as the understanding
of transcription in B. subtilis.
What is in a transcript?
When performing transcriptomics all identifiable transcripts and their abundance
from a genome is studied. Simplified mRNA transcripts can be thought of as
information carriers for protein-coding genes, leading to protein production from
the information in the gene. However transcripts does not only contain the coding
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sequence that instructs how the protein has to be assembled. For eukaryotes,
transcripts contain a mixture of introns and exons, where introns are spliced out
of the transcript leading to a transcript consisting of exons. Alternative splicing
of the transcript including or excluding different exons lead to different coding
sequences and hence alternative proteins [24]. Transcripts have been identified that
are composed of exons from different genes and even from different chromosomes
[16, 19]. For prokaryotes genes are often structured into operons where several
genes are present on the same transcript, but each of the coding sequences are
translated into separate proteins.
Transcripts also contain UnTranslated Regions (UTRs), which in the 5’ and 3’
of the transcript is target of many regulatory events. The length and utilization
of UTRs for regulatory mechanisms has been driven by evolution, and the average
length of 3’ UTRs correlates with organismal complexity [29]. Paper I shows that
for the B. subtilis transcriptome the 5’ UTRs are longer compared to 3’ UTRs, a
finding in good correlation with the above. Examples of transcriptional regulation
in UTRs are transcriptional attenuation in bacteria where secondary structure
in the 5’ of the transcript can block transcription by forming hairpin structures.
For eukaryotes microRNA is a widespread example of additional features within a
transcript, as they can be encoded from within introns or 3’ UTRs, from where they
are spliced and processed to functional miRNAs. These can bind to complementary
mRNA and induce transcript cleavage or translational inhibition. Interestingly
30% of the human mRNA pool is thought to be regulated by miRNAs [30].
Natural antisense transcription
The discovery that natural antisense transcription is a pervasive feature of eukary-
otic genomes has introduced a complexity not previously recognized. Additionally
one must question the ability of the traditional protein-coding gene centric tran-
scriptomic approaches such as non-tiling DNA microarrays for gene expression
profiling. Although the large amount of positive results already obtained from
these technologies are probably still essentially true, many underlying changes and
mechanisms must have escaped our attention. Especially in complex diseases such
as cancers, diabetes and brain diseases where the exact underlying mechanisms
have been hard to fully identify. An example directly relevant to the Alzheimer’s
Disease work in this thesis is that an antisense transcript BACE1 -AS has been
shown to mask the miRNA binding site in the 3’ of the BACE1 transcript. This
leads to increased stability of the BACE1 transcript, coding for a crucial protein
in the production of the Aβ peptide [31]. This and other examples demonstrate
that the traditional understanding of antisense transcription as being exclusive
negative regulators of their sense transcript is not true. Both anti-correlated (dis-
cordant) and correlated (concordant) relationships between sense and antisense
transcript pairs have been shown, however the mechanisms by which they occur
are not all well understood. Several mechanisms of action have been proposed
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and to a greater or lesser extent validated, however the general consensus is that
natural antisense transcripts are heterogeneous, both in term of composition and
mode of action. Regarding their generation they can be produced head-to-head
with overlapping 5’, tail-to-tail with overlapping 3’ or fully/partial overlapping in-
side the sense transcript. Functionalities such as epigenetic regulation, including
DNA methylation and chromatin modifications, genomic imprinting, alternative
splicing, transport modification, modification of mRNA stability and translation
has been shown. Additionally endogenous small interfering RNA (siRNA) are gen-
erated from double-stranded RNA [17–21].
Generally antisense transcription has not been pronouncedly described for bac-
teria, with the example of B. subtilis having only two known antisense transcripts.
In Paper I using tiling DNA microarrays we identify 125 putative novel antisense
transcripts for B. subtilis verifying and expanding the phenomenon in bacteria.
Among these we even describe an antisense transcript tail-to-tail with sigA, the
major housekeeping sigma factor in B. subtilis. The antisense transcripts observed
are generally expressed at relatively low levels and experiments using Next Gen-
eration Sequencing is likely to improve greatly on the resolution and mapping of
these. Additionally the presence of several antisense transcripts has recently been
shown for Listeria monocytogenes and the archaea Sulfolobus solfataricus [32,33].
1.3 Next-Generation RNA-sequencing
When writing a thesis largely based on analyzing transcriptomic data it is impos-
sible not to mention the emergence of Next Generation Sequencing technology.
For more than a decade DNA microarrays have been a key tool in biological re-
search, allowing highly parallel studies of gene expression. However, just as DNA
microarrays revolutionized biological research NGS is now introducing a new rev-
olution. The technology enables high-throughput and deep sequencing of DNA,
and has been used to sequence and re-sequence genomes at a fraction of the cost of
traditional Sanger sequencing. Besides this, NGS can be used for gene expression
analysis (RNA-seq) and show several advantages compared to DNA microarrays,
primarily because NGS relies on direct measurement of sequence reads and not
the inferring of nucleotide concentration from hybridization levels. As an analogy
one can think of RNA-seq as providing “digital measurements” of transcript abun-
dance, whereas DNA microarrays in some sense is an analog system. This allows
for single base resolution, low background noise and a high dynamic range. Addi-
tionally novel transcriptomic features such as discovery of non-coding RNA, novel
exons, poly-adenylation sites, rare transcripts and novel splice variants is greatly
enhanced by the fact that the cDNA sequence is directly identified [19, 34, 35].
Furthermore it is possible to identify and monitor SNPs within RNA sequences
and to perform allele-specific transcription.
Although NGS is a developing technology one may expect it to outperform
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DNA microarray based methods for the majority, if not all, of the traditional
DNA microarray applications. Although the process may be gradual, the em-
phasis and new developments in the near future are likely going to be based and
focused on NGS technology. However, as RNA-seq is still based on investigating
the transcriptome the majority of the data analysis methods and data integration
approaches will be overlapping.

Chapter 2
The DNA microarray technology
The purpose of DNA microarray technology is to determine the abundance of spe-
cific RNA or DNA molecules in an experiment. The technology was developed
from the classical molecular biology techniques Southern blotting and northern
blotting that are used to detect and measure the relative abundance of DNA or
RNA molecules, respectively [36,37]. The underlying principle in DNA microarrays
is a massive parallelization of these blots, where the arrays of today incorporate
the technological improvements from multiple fields. The use of DNA microarrays
have additionally evolved from expression analysis to several other applications
and is a multi-discipline field involving physics, chemistry, biology, statistics and
informatics. Whether the goal of the DNA microarray experiment is to measure
relative abundance of messenger RNA, identify alternative splicing events, novel
transcripts, chromosomal DNA variations, transcription factor binding sites or
SNPs associated with disease, the basic principle is always the same – hybridiza-
tion of complementary nucleotide sequences.
A short story of DNA microarrays
A common conception is that DNA arrays was developed in the late 1980s and
appeared in scientific publications in the beginning and mid 1990s. However, DNA
arrays, in the sense of parallel blots on filter paper called dot blots, was introduced
in the late 1970s for homology studies and for keeping libraries of complementary
DNA (cDNA) clones. Similarly expression analysis, that has been the primary
application of DNA microarrays for a more than a decade, began in the early
13
14 CHAPTER 2. THE DNA MICROARRAY TECHNOLOGY
1980s using filter papers spotted with cDNA clones. This was achieved by blotting
from cDNA libraries to two filter papers and then hybridizing radioactive labeled
cDNA from two different samples to each filter. Further technological advances
in e.g. the Polymerase Chain Reaction (PCR) automation lead to the adaption
to membranes instead of filters and the emergence of a more robust and higher
throughput system known as macroarrays in the early 1990s [38,39].
As the name implies microarrays were developed as a result of miniaturiza-
tion of the macroarray technology. At Stanford University, Schena et al. in 1995
published a study where 45 Arabidopsis thanliana cDNA clones were spotted on
microscope glass slides [40]. This together with fluorescent labeling and the use
of confocal laser scanners enabled mRNA abundance measurements of high sensi-
tivity. For these cDNA arrays two-color labeling was used, meaning that samples
were labeled with separate dyes and then mixed prior to hybridization on glass
slides. By scanning for each dye, the relative abundance of mRNA species between
two samples can be measured in just one microarray experiment [41].
In 1991 Fodor et al., later co-founder of the company Affymetrix, developed an
array manufacturing approach using technology from the semiconductor industry,
photolitography, and combinatorial chemistry. In this approach light is used to
control the synthesis of nucleotides on a quartz wafer by applying pre-designed
masks that will either block or allow light to hit selected areas. Each of these
areas, also termed features, contains millions of copies of certain 25-mer oligonu-
cleotides allowing the detection of its complementary oligonucleotide. In contrast
to cDNA microarrays, manufacturing of these oligonucleotide arrays only requires
knowledge about the genome sequence, no cDNA library is needed as the probes
are manufactured in situ [42]. However due to the use of relatively short probes,
several probes are needed for each gene in order to achieve reliable measurements.
Additionally both perfect match (PM) and mismatch probes (MM) have tradi-
tionally been used, where the MM probes are similar to the PM probes except
for the middle base substituted by the complementary base. Theoretically this
would allow for probe background detection, however using these have not proven
beneficial for the data quality. Affymetrix arrays today utilize background probes
with similar GC content to estimate background signals.
In addition several other companies have ventured in to the DNA microarray
industry. Similar to the Affymetrix approach, two other companies use in situ
synthesis of oligonucleotides. Roche NimbleGen utilizes a photolitography method
for the manufacturing of microarrays where micromirrors instead of pre-designed
masks, guide the light to control the synthesis at each spot. Agilent uses ink-jet
printing and phosphoramidite chemistry where the oligonucleotides are synthesized
by dropping nucleotides in the desired order at the spots [43,44].
Another strategy for microarray manufacturing, used by Illumina, is bead ar-
rays, where probes are linked to beads. In contrast to the previous approaches,
the beads containing the probes are randomly distributed on the array surface
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Name Technology Features/Array Probe length Detection
cDNA arrays Spotted 98k NAa Two-color
Affymetrix Photolitography 6.8M 25 One-color
NimbleGen Photolitography 2.1M <85 One and Two-color
Agilent Ink-jet 1M 60 One and Two-color
Illumina Bead based 1.2M >100 One and Two-color
Table 2.1 – Overview of the major DNA microarray technologies available. a Probe
length is defined by the cDNA or PCR product spotted and can vary.
and then decoded prior to hybridization. This is possible since a DNA barcode
is incorportated into each probe sequence. An overview of the major microarray
technologies is shown in Table 2.1.
2.1 Applications
The popularity of DNA microarrays was mainly founded by the ability to fast pro-
file thousands of genes as long as a cDNA library or genome sequence was available.
Additionally sharing of data from microarray experiments in large databases such
as NCBI Gene Expression Omnibus (GEO) and EBI Array express has proven
valuable. This enables other researchers to re-analyse and combine data sets in
novel ways, an approach we used for Paper II [45, 46]. Today, the applications of
DNA microarrays have evolved into a variety of fields – here I briefly describe the
major applications (see Figure 2.1).
Expression analysis
In 1997 the first gene expression profiling experiment covering all protein-coding
genes of an organism was performed on S. cerevisiae investigating transition from
fermentation to respiration [47]. Following this experiment, these microarrays
were used to assay other cellular phenomenons in yeast such as the cell cycle and
sporulation [48–50]. From these it was clear that whole-genome DNA microar-
ray experiments made it possible to characterize the genetic wiring responsible for
complex cellular processes.
A very common application of DNA microarrays is to compare gene expression
between Case and Control, often being disease vs. healthy tissue or gene knock-
out/overexpressor vs. wild-type. In addition to providing information on which
genes that may be responsible for a particular disease phenotype, it can also help
identifying candidates for drug intervention. Knocking out a gene in an organism
and measuring the corresponding changes in gene expression will provide infor-
mation on processes this gene may be involved in or part of controlling. More
advanced experimental designs such as a two-factor ANOVA design enables the
identification of genes differentially regulated by two different factors and their
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interaction.
Another approach is to profile different tissues creating tissue expression maps.
Knowing where a gene is expressed can provide clues of functionality but can also
help to indicate whether a drug targeting this gene is likely to have unintended
effects. Additionally approaches like this can identify chromosomal stretches or
regions of co-expressed genes that associate to different tissues. One such gene
atlas for human and mouse tissues is available from Su et al. (2004) [51]. Fur-
thermore gene expression signatures have been widely used to classify cancers and
to predict treatment outcomes based on selection of differentially regulated genes.
From these types of experiments prognostic information can be achieved on tumor
sensitivity and whether survival or relapse can be expected from treatment with a
particular drug.
Tiling arrays
Rather than probing certain areas of genes or exons, another approach is to design
tiling DNA microarrays that cover genomic regions or the entire genome inde-
pendent of gene organization. Spacing of the probes can be overlapping, end-to-
end or average spaced depending on application and array technology. In general
oligonucleotide tiling arrays are preferable compared to PCR or Bacterial Artificial
Chromosomes (BAC) arrays as the two latter will have both nucleotide strands of
the probe present, meaning that they are not strand-specific [52]. Whole-genome
tiling is possible on single arrays for organisms with small genomes, whereas current
technology requires several arrays to tile the entire human genome. Such arrays
allow the identification of novel features such as novel genes and exons, non-coding
and small RNAs, novel splicing, antisense RNAs and elucidation of transcript or-
ganization such as bacterial operons. In addition to the above, tiling arrays are
also at the core of Chromatin ImmunoPrecipitation on chip (ChIP-chip), DNA
methylation on chip, array CGH and Copy Number Variation (CNV) studies, and
re-sequencing using DNA microarrays.
Chromatin immunoprecipitation on chip
Chromatin is the complex between DNA and protein that form the chromosomes
and this technique aims at identifying specific proteins binding to DNA. Originally
published in 2000 and 2001 the authors investigated where several transcription
factors involved in carbon source, mating pheromones and cell cycle control bound
to the genome of S. cerevisiae [53, 54]. The approach is a merger of Chromatin
ImmunoPrecipitation and DNA microarray technology (ChiP-chip). By crosslink-
ing the chromatin using formaldehyde and thereafter shearing it by sonication,
fragments of protein-DNA complexes can be extracted using antibodies for the
protein of interest. By reversing the crosslink between the purified protein-DNA,
the DNA can be isolated, labeled and hybridized to tiling arrays making it possi-
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Figure 2.1 – Applications of DNA microarray technology in biology.
ble to identify the DNA regions that the particular protein of interest binds [55].
ChiP-chip has been used to decipher genetic regulatory networks at varying condi-
tions by identifying targets of transcription factors, binding of histones and other
DNA-binding proteins [56].
DNA methylation
The field of epigenetics revolves around the question of heritable changes in gene
expression and phenotype that can not be explained by changes in the DNA se-
quence. One of the major mediators of this effect is DNA methylation of cytosines,
being when a cytosine followed by a guanine (termed CpG) is methylated to 5-
methylcytosine. These methylation patterns changes during cell differentiation
and to external stimuli such as maternal care during early childhood and chemical
compunds. Implications of DNA methylation have been shown on gene expres-
sion where methylation of promoters leads to gene silencing and demethylation of
promoters to gene expression. This is often seen in cancers leading to silencing of
tumor suppressor genes or over-expression of oncogenes. Additionally microRNA
expression has been found to be controlled by DNA methylation [57–59].
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Genotyping & Single Nucleotide Polymorphisms
The conceptually simplest form of genetic variation between genomes within the
same species is when a base is substituted with another base, also known as Single
Nucleotide Polymorphisms (SNPs). For more than 2.200 mendelian, and hence
inherited, disorders known genes has been identified for which a SNP in a gene
is the cause of the disorder [9]. Generally these have high penetrance and are
relatively easy to identify compared to low penetrance SNPs that are thought to
be involved in many common disorders. For the identification of these, Genome-
Wide Association Studies (GWAS) using DNA microarray technology have been
applied, where a large number of SNPs are screened for disease association. In the
HapMap project SNPs have been collected and validated with currently more than
3.1 million SNPs identified and more than 10 million predicted to exist [6,60–62].
Copy number variations
Chromosomal Copy Number Variations (CNVs) are defined as chromosomal areas
that are either deleted or duplicated (or multiplicated) in the genome of a cell.
They have been found to comprise a significant portion of genetic variation in the
human genome – in terms of nucleotides covered it involves more bases than SNPs.
The HapMap project have estimated CNVs to exist for ∼30% of the human refer-
ence genome and CNVs have also been reported to have higher “mutation” rates
than SNPs. The functional role of a CNV can be through several mechanisms
such as altered gene dosage, gene interruption and gene fusion – hence they have a
large impact on the phenotype. In this respect, CNVs are associated with human
diseases such as cancers, brain diseases and numerous other phenotypes. They are,
however, also associated with evolution of the human genome by gene duplication
and exon shuﬄing, and are hereby involved in the development of human beneficial
traits such as cognition [63,64].
Resequencing
Initially the inventors of the Affymetrix technology envisaged DNA microarrays
to be used in re-sequencing and mutation detection [65]. The approach for se-
quencing using DNA microarrays is to compare the sequence in question against a
reference genomic sequence and design tiling probes covering the sequence. This
approach have been used for genotyping disease genes involved in breast can-
cer (BRCA1), cystic fibrosis (CFTR) and the HIV protease (HIV-1 PR) [66–68].
Additionally small genomes such as the mitochondrial genome and stretches of
pathogenic genomes have been re-sequenced for forensics and detection of hu-
man pathogens [69]. Resequencing arrays have been directly developed for use in
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drug discovery such as Affymetrix Drug Metabolizing Enzymes and Transporters
(DMET) and Roche AmpliChip CYP450, that resequences key drug metaboliz-
ing genes. Especially the CYP2D6 and CYP2C19 proteins are involved in the
metabolism of ∼25% of all administered drugs with the implications that different
genotypes will affect the metabolizing speed [70].
2.2 Experimental preparation
When designing a microarray experiment several aspects are important to ensure
success. They may seem obvious, however keeping them in mind is important –
and as always the “garbage in, garbage out” phrase applies. Some key points are
(a) Construct a hypothesis and a subsequent experimental setup that allows for
the hypothesis to be partially or fully proved true. (b) Keeping the goal of the
experiment in mind and the experimental setup relatively simple is more likely
to give interpretable results. (c) The importance of biological replicates allowing
for statistical interpretation of the data. (d) Minimize and balance effects such as
sampling time, growth conditions, handling procedures and dye swap. The pro-
cedures presented below is primarily described for gene expression profiling and
RNA tiling experiments.
While performing the experiment handling of RNA samples must be performed
rapidly. This is due to the fact that mRNA is being rapidly degraded by RNases,
and cells to be extracted are therefore normally snap frozen in liquid nitrogen or
immersed in RNA protecting solutions. Several methods are available for RNA
extraction, where the most common ones are using guanidinium thiocyanate, phe-
nol and chloroform extraction or solid-phase (column) based extraction [71, 72].
One obvious disadvantage of using solid-phase techniques is that RNA molecules
shorter than 200 nucleotides are not extracted, which can have implications for
experiments where small RNA, non-coding RNA and microRNA are studied. As
mRNA only represents 1-5% of the total RNA an enrichment of mRNA can be per-
formed in eukaryotes using techniques that target the polyA-tail [72]. Extracted
mRNA is transcribed into double-stranded DNA using Reverse Transcriptase PCR
(RT-PCR) and can hereafter be used as template for in vitro transcription (IVT)
creating amplified RNA (aRNA) or be directly labeled. If aRNA is produced it
is normally labeled during the IVT by incorporation of biotinylated nucleotides.
Hereafter the cDNA or aRNA is fragmented and hybridized to DNA microarrays,
washed and stained depending on the technology. Last, the DNA microarrays
are scanned using a laser scanner and intensity readings for each feature is gen-
erated. The general approach for expression profiling using Affymetrix GeneChip
hybridizations is shown in Figure 2.2.
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Figure 2.2 – Working scheme for Affymetrix GeneChips. From Affymetrix.
2.3 Data analysis
Several methods have been developed for analysis of DNA microarray generated
data, some are commercial, whereas others are free. Of the free software, the
statistical programming language R provides the base for the Bioconductor project
which is an open source platform for computational biology and bioinformatics
[73,74]. There are several packages containing software for data analysis and among
the most used within DNA microarray analysis are the affy and limma packages
[75, 76]. These provide basic tools for processing and analysis of Affymetrix and
cDNA data, respectively. Many other packages exists for the other applications
of DNA microarrays mentioned in section 2.1, see www.bioconductor.org. This
section will focus on data analysis for gene expression analysis and tiling array
data analysis, primarily using Affymetrix and NimbleGen technology, respectively.
Preprocessing
The intensity readings from the thousands to millions of features on the DNA mi-
croarrays have to be preprocessed before statistical testing and biological informa-
tion can be extracted. This preprocessing is needed because raw intensity readings,
in addition to gene specific signals, contain variance and noise that can lead to false
biological conclusions. Uninteresting variation originates from sources such as un-
intended effects during sample preparation such as dye labeling and chemistries,
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hybridization conditions and photodetection during scanning [77]. These effects
are primarily observed between different arrays, however within array variations
may also occur. In general three preprocessing steps are needed, background cor-
rection, normalization and gene expression index calculations. Tools for all three
steps are implemented in the R package rma [78].
Background signal, which is ambient non-specific signals, can arise from several
sources such as non-specific binding to the surface of the array, effects from the
washing stage and optical noise from the scanner [79]. This may have a pronounced
effect when using two-colour microarrays where variance stabilizing methods have
been shown to perform best in terms of precision and bias. Importantly the back-
ground correction method of subtracting signal from the background of a spot
has been found to perform worse than using non-corrected values [79]. Regarding
Affymetrix arrays background is estimated from the signal intensities themselves,
where observed intensity is modeled as the sum of a signal from an exponential
distribution and a background component from a normal distribution [78,80]. Ad-
ditionally gcrma utilizes the GC content of each probe to estimate probe affinity.
This type of probe affinity background correction may be useful for tiling array
data (see section 2.5).
For normalization several methods exists. The simplest solution is scaling each
array by a factor relative to the array with median of the median intensities – this
was originally proposed by Affymetrix and generally performs poor [81]. One of the
reasons for this is that the effect of global variations is primarily signal-dependent
(see Figure 2.3 a and b) meaning that a non-linear normalization method is needed
to normalize the data. The most commonly used non-linear normalization methods
are the invariant set method, LOWESS regression, qspline and quantile normaliza-
tion [81–84]. For quantile normalization (rma) the highest value from each array is
replaced by their average, then the next-highest value from each array is replaced
by their average and so forth. Hence quantile normalization forces the intensity
distributions to be equal and can be thought of as a one of the most rigorous
normalization methods.
For DNA microarrays that utilize several probes per gene or exon, the intensi-
ties are condensed into one value termed an expression index. As of today several
methods have been proposed, with the rma approach shown to be the best per-
forming. Here a robust fitting technique that protects against outliers, median
polish, is used to condense probe level intensities to expression indexes [78].
Statistical testing
In addition to the variations described above biological systems contains stochastic
noise, emphasizing the need for statistical testing to identify the true biological
effects. For this parametric statistical tests such as the t-test and the ANalysis Of
VAriance (ANOVA) are often used, testing either the means or variance to assess
the null hypothesis. If the null hypothesis, that the means are equal, is rejected
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Figure 2.3 – Effect of normalization on 12 Affymetrix Gene Chip Mouse genome
430 2.0 arrays (Chapter 6). a. Density plot of raw intensities before normalization
for each array, showing differences in the intensity distributions. b. MvA plot
comparing two samples. The log2 mean for each probe is plotted vs. the log2 ratio
of each probe. Deviations from 0 shows non-linear relationship between the samples.
The red line is a fitted spline. c. Density plot of qspline normalized intensities where
intensity distributions have been normalized and are now highly similar. d MvA
plot as in b, but data normalized with qspline. The signal-dependant bias has clearly
been removed by the normalization.
(p-value ∼0) the gene is found to be differentially regulated. One-way ANOVA can
be applied when multiple levels of the same factor is tested, such as treatment of
cells with three or more types of stimulants and time series. Factorial ANOVA can
be used when two factors are analyzed, normally in a 2 by 2 factorial experiment.
An example of this could be a design with a genetic factor and an environmental
factor such as wild-type vs. gene knockout and medium vs. medium + alcohol
and glucose, such as used in Paper II (Chapter 4).
The assumptions for the tests are that the populations compared follow the
normal distribution, have equal variance (the Student’s t-test) and are indepen-
dent. Additionally large sample sizes are needed to generate enough statistical
power, however DNA microarray experiments typically only have three or a few
more biological replicates. As the assumptions are rarely fulfilled, the p-value is
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therefore not strictly trustable and false positives are an issue in DNA microarray
experiments. A solution for the normality issue is to use non-parametric tests that
does not assume normality, however these have lower statistical power. Instead the
statistical tests are used for ranking the data in a meaningful way. Additionally
tests based on Bayesian statistics that are more robust to small sample sizes have
been developed for DNA microarrays [85].
As the statistical test is applied for each gene on the microarray this gives
rise to the issue of multiple testing. When a hypothesis is tested multiple times,
e.g. ∼30.000 times for an array covering the human genome, 300 of the genes
would be expected to have an p-value < 0.01. Therefore the significance values
must be adjusted for multiple testing to control the number of False Positives (FP,
type I errors). Two methods that has been suggested for this are by Bonferroni
and Benjamini-Hochberg, however these are often too strict for DNA microarray
data [86]. However through resampling the statistics by permuting the sample
classification, it is possible to estimate the False Discovery Rate (FDR) from the
data. The number of known true null hypotheses (from permutations) allows the
estimation of the FDR at given number of accepted genes as,
Pi =
FPq
i
(2.1)
where i is the number of accepted genes, Pi is the FDR at i and FPq is the
number of true null hypotheses from the permutations at the observed p-value q
or lower. Using this approach it is possible to control and accept a certain FDR
within the accepted genes.
2.4 Detecting trends
The primary output of gene expression profiling experiments are long lists of ta-
bles with significant differentially expressed genes. The data, perhaps containing
hundreds of differentially expressed genes, has to be interpreted in the biological
context of the experiment to enable a refined or new hypothesis to be formu-
lated. Several tools have been developed to enhance the biological interpretation
of microarray data and here classical tools such as Principal Component Analysis
(PCA), clustering and annotation enrichment will be discussed.
Principal Component Analysis
For identification of trends in DNA microarray experiments visualization of the
data is useful. However an experiment covering m genes each measured using n
arrays creates a m × n -dimensional space, which it is not possible to visualize
directly. This may be solved by dimension-reduction techniques such as PCA that
projects high-dimensional data to a low-dimensional space. This is performed
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by computing the first Principal Component (PC1) along the axis with the most
variation within the data followed by the second Principal Component (PC2) as the
axis containing the maximum variation orthogonal to PC1. For DNA microarray
experiments PCA is implemented as Singular Value Decomposition (SVD),
X = USV T (2.2)
where X is the expression data matrix, U are the left eigenvectors (eigenassays),
V are the right eigenvectors (eigengenes) and S are the singular values. The use of
SVD is exemplified in an experiment where mouse dendritic cells are stimulated
with two different bacteria in a 2x2 factorial ANOVA designed experiment (Chap-
ter 6). Figure 2.4a shows the information content in the singular values, showing
that the first dimension contains by far the most information. From Figure 2.4b it
can be seen that PC1 captures the variation between untreated and treated cells
(illustrated by the size of the circles) and that PC2 and PC3 together contain the
difference in response between the treatments. This is observed by Z9 treated cells
showing a similar response to NCFM + Z9 treated cells (yellow and green in lower
right corner) whereas NCFM treated are in the diagonal corner from these.
Clustering
In addition to PCA, cluster analysis may be used to reduce the dimensionality of
the data and to identify correlations within an experiment. Additionally clustering
approaches can be used to classify samples based on gene expression profiles, an
approach widely used for different cancer types or sub-types [87].
Clustering is based on calculating the distance between observations using a
distance measure. Several distance metrics and inter-cluster distance methods are
available, where the most commonly used distance metrics are euclidean, angle
vector and pearson correlation distance. These metrics determine how distance is
calculated, whereas inter-cluster linkage distance determine where in the clusters
the distance is calculated between. For expression data complete and average link-
age are preferred methods [88].
For this work Partitioning Around Mediods (PAM) clustering has been used. It
is similar to k-means clustering, but is more robust as it minimizes dissimilarities
instead of euclidean distances [89]. One object is selected as mediod for each of
the k clusters and the objects are clustered based on minimizing the sum of dis-
similarities to the mediods in iterative steps. The Pearson correlation coefficient
(rxy, eq. 2.3) is used to calculate the correlation between points x and y, which
will take a value between −1 and 1. This corresponds to genes anti-correlating
or correlating, respectively. As distance measures are positive, the dissimilarity
metric is calculated by transforming rxy to between 0 and 1, where genes with
similar profiles will have the distance of 0 and dissimilar genes 1 (eq. 2.4).
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Figure 2.4 – Singular value decomposition and clustering of 12 mouse samples
(Affymetrix). The experiment is designed as a 2x2 factorial ANOVA with L. aci-
dophilus NCFM and B. bifidum Z9 as the two factors. a. Individual components of
SVD and the singular value (information content). b. SVD plot of the 12 samples of
the first three components. x-axis: PC2, y-axis: PC3, size: PC1. Blue: untreated,
red: NCFM, green: Z9, yellow: NCFM+Z9. c. PAM clustering of a time-course
experiment where mouse DCs are stimulated with L. acidophilus NCFM for 0, 4,
10 and 18 hours.
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rxy =
∑n
i=1(xi − x¯)(yi − y¯)√∑n
i=1(xi − x¯)2
√∑n
i=1(yi − y¯)2
(2.3)
dis(x, y) = rxy × (−0.5) + 0.5 (2.4)
An example of PAM clustering on the 1000 most significant genes in a time
course experiment from Paper IV (Chapter 6) is shown in Figure 2.4c, where
different time-resolved responses are captured.
Annotation enrichment analysis
Co-regulated genes are likely to be involved in similar biological processes. To
systematically investigate this, ontologies such as Gene Ontology (GO) and Ky-
oto Encyclopedia of Genes and Genomes (KEGG) can be used [90, 91]. GO is a
collection of controlled vocabularies describing the biology of a gene product in
any organism. It is organized in three independent sets Molecular Function (MF),
Biological Process (BP) and Cellular Component (CC), each in a tree structure of
parent and child terms. Each ontology is structured as a directed acyclic graph
where the specificity of the term increases as one moves down the network. KEGG
is a database of protein networks and a chemical space providing a different angle
than GO.
For DNA microarray analysis these ontologies are useful for identifying en-
riched terms in e.g. a cluster of co-expressed genes. This can be done by sampling
without replacement using the hypergeometric distribution, also known as a hy-
pergeometric test or a one-tailed Fisher’s exact test. Other approaches are Gene
Set Enrichment Analysis (GSEA) or Parametric GSEA (PGSEA) that aims at
identifying changes in minimally changed gene expression experiments [92,93]. In
this approach pre-defined gene sets, such as GO terms or Molecular Signatures
Databases (MSigDB) [92] are tested for induction or repression using all genes
on the array. In Paper IV we use a defined gene set from GO to show that a
viral response is significantly induced in the experiment. These approaches are
useful as a parallel approach to GO term enrichment, but also for comparison of
different data sets. Comparing data sets at a pathway level is more general than
at gene-level and is more likely to yield interpretable results.
2.5 Tiling arrays
When designing arrays that tile regions or the entire genome of an organism, probe
affinity for the target becomes increasingly important. The freedom in chromo-
somal location of a probe is limited, especially if the array is designed with over-
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lapping probes. This makes it hard to avoid features such as cross-hybridization,
secondary structure, areas of low complexity and irregular probe-affinities derived
from base-content. Regarding base composition, especially guanine and cytosine
(GC) bases have higher binding energies and contributes more to probe Tm com-
pared to adenine and thymine. Solutions for this problem can be to normalize the
signal from each base in an iterative quantile normalization procedure or to use
genomic DNA hybridization as a reference [94, 95]. The design used in Paper I is
based on NimbleGen 375k arrays with probe lengths varying between 45 and 65
nt, making it possible to design iso-thermal probes.
Segmentation
A critical step when analyzing expression data from tiling arrays is to identify
transcript boundaries. This can be performed by segmentation methods where
breakpoints (or changepoints) are identified dividing the data in segments. The
problem is related to aCGH where areas of chromosomal copy number variations
(CNVs) have to be identified. To assess which approach to use we have tested
several existing segmentation methods: Circular Binary Segmentation (CBS) part
of the DNAcopy package developed for aCGH, Structural Change Model (SCM)
from the tilingArray package, and a Hidden Markov Model (HMM) based approach
developed by our collaborators using the data generated in Paper I [96–98]. The
benchmark of these are shown in Chapter 3. We decided to extend the SCM model
in an approach, in the following termed TAR method, and use this for segmenta-
tion of our data. As it is based on SCM a short description of this is given below.
SCM models the data as a piecewise constant function of chromosomal coordi-
nates, where zki is the signal from the k-th probe on the i-th replicate,
zki = µs + εki ts ≤ k < ts+1 (2.5)
where µs is the mean of the s-th segment, εki are the residuals and t2, . . . , ts
are the breakpoints on the chromosomal strand. Using dynamic programming
the model is fitted by minimizing the sum of squared residuals (from eq. 2.5:
εki = zki − µs),
G(t1, . . . , tS) =
S∑
s=1
I∑
i=1
ts+1−1∑
k=ts
(zki − µˆs)2 (2.6)
where S is the number of segments, I is the number of replicate arrays and µˆs
is the arithmetic mean of zki in segment s. That minimizing the sum of residuals is
a good approach for defining breakpoints (segments) is exemplified in Figure 2.5.
An example of the outcome of the segmentation methods is shown in Figure 2.6.
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Figure 2.5 – Fitting the SCM model to B. subtilis tiling data from 320 to 321
kb with (a) one segment or (b) two segments. Segment mean is given by µS and
residuals for individual probes per replicate array are given by εki. By minimizing
the sum of squared residuals (eq. 2.6) the breakpoints (segment boundaries) can be
identified, in this case S = 2 (b).
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Figure 2.6 – Segmentation of the first 10kb of B. subtilis positive strand using
different methods. Black: CBS, red: HMM, green: TAR, magenta: SCM, blue:
SCM+gDNA norm. For the HMM and SCM+gDNA normalization methods, the
underlying data is different from the data shown due to different normalization
methods. Known transcripts are: dnaA-dnaN, yaaA-recF-yaaB-gyrB and gyrA. Red
triangles: known Rho-independent terminators, green circles: known SigA binding
sites.
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Chapter 3
Genome-wide tiling of B. subtilis
This chapter describes our efforts in reporting the first tiling array data from the
Gram-positive model organism Bacillus subtilis. B. subtilis is a rod-shaped bac-
terium, able to form endospores and naturally found in soil and on plants. It is
generally regarded as safe and is used in cooking for fermenting bean products
around the world, such as B. subtilis natto used for the traditional Japanese dish,
natto. It is widely used in the industry for enzyme production as it is safe, easy
to transform with foreign DNA and has excellent protein export capabilities.
B. subtilis is closely related to the pathogen Bacillus anthracis of which the
spores are the cause of anthrax. Additionally it is related to other pathogens, one
such being Staphylococcus aureus that is becoming an increasing burden for the
health care system due to the emergence of multidrug-resistant strains. This work
was performed as a part of the BaSysBio EU-FP6 project.
Experimental considerations
Initially we wanted to perform the experiment using cell cycle synchronized B.
subtilis. To date the cell cycle of living organisms have been studied using tran-
scriptomics for the majority of the branches of life, such as human cells, Sac-
charomyces cerevisiae, Schizosaccharomyces pombe and Arabidopsis thaliana for
eukaryotes, Caulobacter crescentus for gram-negative bacteria and Sulfolobus aci-
docaldarius for archaea [50, 99–103]. However no study has yet been performed
on gram-positive bacteria making this an experiment worth striving for. By using
tiling arrays we would, a part from the traditional analysis of protein-coding genes,
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have been able to identify small RNAs and antisense transcripts expressed in a cell
cycle manner. The synchronization approaches that we attempted were using a
temperature sensitive mutant in DNA replication initiation, Percoll gradient frac-
tionation and centrifugational size selection [104–107]. Additionally I visited Prof.
Stanley Brul’s lab at Universiteit van Amsterdam in the hope of using germinating
spores to establish cell cycle synchronized cultures [108], however again without
satisfying results. The requirements for running the experiments were to achieve
two consecutive cell cycles synchronized, however from the different approaches
tested we were able to synchronize one cell cycle regularly with the cells going out
of sync in the second cycle. However, while performing test experiments of the
tiling arrays, which we designed for the BaSysBio project, we discovered that the
data was of high quality. We therefore decided to thoroughly analyze these data
assaying the B. subtilis transcriptome during exponential growth in rich (Luria-
Bertani, LB) and poor media (M9).
Tiling arrays
Using OligoWiz 2.0 [109] we designed tiling DNA microarrays with overlapping iso-
thermal probes covering the entire genome of B. subtilis with a spacing of 22 nt
on each strand. In combination with a strand specific labeling protocol developed
by NimbleGen, we are able to generate a comprehensive dataset of transcriptional
signals from both chromosomal strands. As the arrays were designed and run be-
fore the re-sequencing of B. subtilis (AL009126.2) we re-annotated the probes to
the updated sequence (AL009126.3) at the time of publication. The effects are
fairly small with only ∼300 probes of 375.000 that could not be mapped due to
low homology. As the re-sequencing also introduces ∼2.000 extra nucleotides in
the genome seven small regions have gaps with the most affected being trpF. This
is in good agreement with the fact that the laboratory strain used for more than
25 years is a tryptophan auxotroph, and that the trp region has not been under
evolutionary pressure.
Segmentation methods
To perform the segmentation of our data we tested three different existing methods
and the TAR method that we developed. The latter was an adaption of the SCM
method addressing the issue, that the number of segments S has to be guessed
or estimated using a penalized log-likelihood criteria, however this is not straight-
forward for real biological data [96]. Instead by deliberately overestimating the
number of segments and introducing a joining step the issue is avoided. The algo-
rithm for this is to accept all segments with mean signal (µs) above background and
then join neighboring segments if, (a) five probes on each side of the breakpoint
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Figure 3.1 – Benchmark of segmentation methods using B. subtilis tiling data,
positive strand. Black: CBS, red: HMM, green: TAR, magenta: SCM, blue:
SCM+gDNA norm. For the SCM approach the number of segments used were
the same as for the TAR approach. a. Known Transcription Start Sites (TSS) iden-
tified within 20 nt. b. Known genes as they are identified. True positives: known
annotated genes identified fully inside a segment, false positives: known annotated
genes but on the opposite strand inside a segment. c. Known transcripts from
Hoon et al. [110]. True positives: Segment containing known transcript within 100
nt upstream and downstream of breakpoints. False positives: Segment containing
known transcript on the opposite strand.
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are above background, and (b) a Student’s t-test does not reject the hypothesis
that probes in each segment belong to the same signal-intensity distribution with
a p-value > 1 × 10−10. To test the performance of this and the other methods
we performed benchmarks against (a) known Transcription Start Sites (TSS), (b)
annotated genes inside segments, and (c) known transcripts (Figure 3.1). The
SCM methods were benchmarked using the number of segments identified from
the TAR approach.
From this the best performing method was the found to be the TAR approach,
whereas the HMM approach generally performed poor. The poor performance
of the latter approach was probably due to estimating too long segments, as it
shows similar performance in the TSS benchmark (Figure 3.1a), whereas bench-
mark against known genes (b) and known transcripts (c) had poor performance.
Additionally we found that normalization with gDNA hybridization signal did not
improve SCM predictions. This is possibly due to local structures such as Rho-
independent terminators that can form hairpins and hereby avoid detection. The
extent of this is likely to vary between organisms depending on the use of Rho-
independent terminators – with regard to B. subtilis transcriptional control is to
a large extent dependent on this phenomenon [111].
3.1 Paper I
From our experiments we are able to provide a genome-wide view of RNA expres-
sion combined with Rho-independent terminator and sigma factor binding site
predictions and annotations. We identify putative novel non-coding RNAs and
reveal that antisense transcription may be much more pronounced than previously
thought – prior to this study only two antisense transcripts were known in B. sub-
tilis. Supplementary material are found in Appendix A. Included are Fig S1, Fig
S3-9 and 6 pages of Fig S2 (the pages mentioned in the paper). Full supplementary
figures and tables are available at the publishers web-site as Online Open material:
http://www3.interscience.wiley.com/journal/122536032/suppinfo.
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Summary
The majority of all genes have so far been identified
and annotated systematically through in silico gene
finding. Here we report the finding of 3662 strand-
specific transcriptionally active regions (TARs) in the
genome of Bacillus subtilis by the use of tiling arrays.
We have measured the genome-wide expression
during mid-exponential growth on rich (LB) and
minimal (M9) medium. The identified TARs account for
77.3% of the genes as they are currently annotated and
additionally we find 84 putative non-coding RNAs
(ncRNAs) and 127 antisense transcripts. One ncRNA,
ncr22, is predicted to act as a translational control on
cstA and an antisense transcript was observed oppo-
site the housekeeping sigma factor sigA. Through this
work we have discovered a long conserved 3! untrans-
lated region (UTR) in a group of membrane-associated
genes that is predicted to fold into a large and highly
stable secondary structure. One of the genes having
this tail is efeN, which encodes a target of the twin-
arginine translocase (Tat) protein translocation
system.
Introduction
The bacterial genome is a highly compact structure. Both
strands are densely covered by genes, of which a large
part is organized into the even more gene-dense arrange-
ments of operons. Recent technological advances have
allowed for an empirical assessment of the prevalence of
transcriptionally active regions (TARs) across an entire
genome – by the use of either high-throughput sequencing
of RNA-derived cDNA (Nagalakshmi et al., 2008) or high-
density oligo-nucleotide tiling arrays (Tjaden et al., 2002;
Bertone et al., 2004; David et al., 2006; Li et al., 2006;
Reppas et al., 2006). Where the studies of Tjaden and
co-workers and Reppas and co-workers investigated the
transcriptional landscape of Escherichia coli, we report
here the first findings of a high-density tiling-array study
performed on the Gram-positive Bacillus subtilis. B. subtilis
was first described in 1835 by the German scientist Chris-
tian Gottfried Ehrenberg as the hay/grass-associated bac-
terium, Vibrio subtilis (Ehrenberg, 1835). In 1872 another
German scientist, Ferdinand Julius Cohn, renamed it
Bacillus subtilis (Cohn, 1872). In 1876 Cohn showed for the
first time that B. subtilis is capable of changing into an
endospore state, and hereby surviving environmental
changes not suitable for vegetative growth (Cohn, 1876).
In 1930 the American bacteriologist, Harold Joel Conn,
published a description of the Marburg strain of B. subtilis
(American Type Culture Collection No. 6051) (Conn, 1930;
Teas, 1949) and in 1947 this particular strain was subjected
to both X-rays and UV light by Burkholder and Giles
(Burkholder and Giles, 1947; Teas, 1949). Charles Yanof-
sky provided a number of stable auxotrophs, which had
been isolated from these experiments, to John Spizizen
(Spizizen, 1984), which studied their ability to develop
natural competence (Spizizen, 1958; Zeigler et al., 2008).
Further investigations resulted in the development of a
highly efficient two-step protocol for transformation of the
#168 strain (Anagnostopoulos and Spizizen, 1961), a
success drawing the attention of the research community
to such an extent that this strain was selected as the
B. subtilis model strain. Today B. subtilis is widely used as
an industrial production strain, and has even been shown
to possess probiotic properties (Huang et al., 2008). And
now, more than 10 years after fully sequencing and anno-
tating the genome the first time (Kunst et al., 1997) and
only shortly after the recent re-sequencing (Barbe et al.,
2009), we experimentally validate and extend these
efforts.
Results and discussion
Identification of transcriptionally active regions (TARs)
Hybridization of labelled RNA to densely tiled microarrays
allows for a high-resolution mapping of genome-wide
expression on both strands, and we have found that
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during growth in rich medium (LB) B. subtilis expresses
2291 transcriptionally active regions (TARs), whereas the
corresponding number using minimal medium (M9) is 2464
TARs (all listed in Table S1). To determine how many of
these were unique we have calculated the TAR overlap
between the two conditions (see Fig. S1). If less than 5% of
the TAR overlapped we define it as a unique TAR and
likewise we define a common TAR if more than 85%
overlap. This leads to the identification of 1094 common
TARs, whereas 317 and 346 TARs are unique for LB and
M9 respectively (Fig. 1A). In total 3662 non-redundant
(overlap < 85%) TARs have been identified.An overview of
the results in terms of identified genes, gene-like features
and TARs can be seen in Table 1. Additionally we have
annotated the TARs with experimentally verified and HMM
predicted sigma factor binding sites and experimentally
verified and predicted Rho-independent terminators (see
Experimental procedures). A total of 10.5% and 27.3% of
the TARs have been annotated with at least one experi-
mental or predicted sigma factor binding site, respectively,
and similarly 6.2% and 54% with an experimental or pre-
dicted Rho-independent terminator. Together the identified
TARs account for 77.3% of the genes as they are currently
annotated, and the overlap between the two media is 2843
genes corresponding to 64% of the 4422 known genes
(Table S2). The whole-genome expression data, along
Fig. 1. Expression in LB and M9.
A. Diagram showing the overlap between TARs identified in the two media. No overlap: less than 5% overlap; Partial overlap: between 5%
and 85% overlap (can overlap multiple TARs); Complete overlap: overlap of 85% or more.
B. Box plot showing the log2-transformed signal range of the probes within annotated genes (non-y-genes), the regions between genes
(Intergenic), antisense to known annotation, rRNAs, y-genes, new genes and misc RNAs as by the re-annotation by Barbe et al.
C. Representation of the top 14 KEGG terms from genes uniquely expressed in LB and M9, and genes common to the two media.
D. Pie chart illustrating the physical position of the probes returning a signal above background. Blue: ORF/gene; dark orange: 5′ UTR;
orange: intergenic UTR; yellow: 3′ UTR; green: intergenic region (IR); magenta: antisense; red: misc RNA (Barbe et al., 2009).
E. Density plot showing the log2 lengths (nt) of 5′ UTRs (red) and 3′ UTRs (blue) as they are determined in the study.
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with the predicted transcripts, sigma factor binding sites
and Rho-independent terminators, are visualized in a
figure spanning 48 pages (Fig. S2) and we encourage the
reader to explore the findings.
Hybridization of labelled genomic DNA (gDNA) to the
tiling array results in a uniform signal level throughout the
genome (as can be seen in Fig. S2). However, we found
that low gDNA signals coincide with experimentally veri-
fied and predicted Rho-independent terminators (Fig. 3A).
This may be explained by the formation of stable struc-
tures possibly forming in both the probe and the target,
which hereby prevents detection (Ratushna et al., 2005).
These findings may also explain why normalization using
gDNA hybridizations, as performed by Huber et al., did
not improve the performance of our TAR findings (data not
shown) (Huber et al., 2006). This normalization are in
areas with Rho-independent termination introducing sig-
nificant noise and interferes with the determination of
correct transcript boundary.
We have benchmarked the prediction of TARs against
gene coverage, known transcription start sites (TSSs) and
signal autocorrelation (see Fig. S3). From this we see that
of 2500 genes predicted to be covered by TARs, only
~2.5% are estimated to be false positives, here defined as
TARs covering genes expressed at the opposite strand
(not taking possible antisense transcripts into account).
Regarding TSS, our findings are in general within 20 nt
from the experimentally verified starts. Additionally it is
interesting to note that we do observe a spatial gene
expression dependence – neighbouring genes tend to be
coexpressed in operons. Experimentally we verify the
TSSs of five of the determined transcripts using RNA
ligase-mediated rapid amplification of cDNA ends (RLM-
RACE) and the results are summarized in Table S3. The
verified transcript start sites are within 30 nt of our
findings.
Comparison in gene utilization using two different
growth sources
The distribution of the most common KEGG annota-
tions (Kanehisa et al., 2008) are shown for genes
expressed in both media (common) compared with genes
expressed uniquely to either of the conditions. As
expected, it becomes evident that B. subtilis utilizes dif-
ferent pathways when growing in the two different media.
One example is the difference in the Glycolysis/
gluconeogenesis, where a closer inspection reveals that
the gluconeogenesis is inactive when the cell is growing in
minimal medium, which is expected (Fillinger et al., 2000).
Likewise, a large portion of genes involved in the devel-
opment of competence (with the KEGG annotation Type II
secretion) is active when the cell is starving. Whereas,
many of the genes exclusively expressed when the cell is
growing in the rich medium include a large proportion of
genes encoding products responsible for uptake and
metabolism of various carbon sources, which is expected
from growth in a complex medium (Deutscher et al.,
2002). A puzzling observation is that sporulation genes,
based on KEGG annotation (Fig. 1C), are seen
expressed at conditions when sporulation should not
occur. However when investigated in detail it becomes
clear that the majority of these are expressed at levels
close to our detection limit and that the few highly
expressed are sporulation initiation control genes such as
response regulator aspartate phosphatase genes/
operons (Auchtung et al., 2006). To further ensure that
sporulation is indeed not occurring we have analysed the
expression of the sporulation regulons sF, sE, sG and sK
(Steil et al., 2005) and reassuringly we find that all of
these are expressed below background (shown in Fig.
S4). We therefore contribute the above phenomenon to
genes involved in sporulation control and/or genes with
divergent functionality.
Determination of untranslated regions (UTRs)
Forty per cent of the probes tiling the genome give a
signal above background. As is shown in Fig. 1D the
majority of these seemingly expressed elements are gen-
erally localized within regions expected to give a signal,
either within an annotated gene or in the putative untrans-
lated regions (UTRs) – as they have been determined in
this study. The majority of the probes located in the inter-
genic regions (IRs) and the antisense regions (ARs) have
signals below background level. Additionally 5.6% of the
Table 1. Overview of current annotation and the findings in this
study.
Type Current annotationa LB M9 Unique
Total CDS 4244 3189 3074 3420
Genes 1912 1514 1469 1627
y-genes 2332 1675 1605 1793
New genes 171b 106 103 119
rRNA 30 30 30 30
tRNA 86 82 83 83c
ncRNA 16d 50 68 84
Antisense 2e 60 99 127
TARs – 2291 2464 3662f
a. GenBank (AL009126.3).
b. Genes annotated as new from Barbe et al. (2009).
c. The missing tRNAs are: trnD-Leu2, trnSL-Arg1 and trnSL-Arg2.
d. Ando et al. (2002); Suzuma et al. (2002); Licht et al. (2005);
Silvaggi et al. (2006); Gaballa et al. (2008); Saito et al. (2009).
e. Silvaggi et al. (2005); Eiamphungporn and Helmann (2009).
f. TARs were unique if the overlap was less than 85% between the
two conditions.
Columns LB and M9 show number of occurrences in that particular
category and Unique are unique occurrences in the two media
combined.
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probes with signal above background fall within putative 5′
UTRs as they are determined in this study, whereas
probes in the 3′ UTRs only comprise 2.7% of the
expressed probes, which is even fewer than for intergenic
UTRs (3.2%). This corresponds to 1648/1633 (LB/M9)
transcripts with a defined 5′ UTR and 1371/1506 (LB/M9)
with defined 3′ UTRs. The majority of this difference
between 5′ and 3′ UTRs may be explained by their differ-
ence in length, as is shown in Fig. 1E. The median lengths
are 47 and 36 nt for 5′ and 3′ UTRs respectively (signifi-
cant in a two-sided Wilcoxon rank sum test with a P-value
of 1 ¥ 10-24). This is opposite to what is observed in higher
organisms, such as in the study of David et al. (2006) in
Saccharomyces cerevisiae, where the 3′ UTRs are found
to be longer than the 5′ UTRs. It does however corre-
spond well to the previous discovery that the average
length of the 3′ UTRs is increasing as a function of the
organismal complexity (Mazumder et al., 2003). These
findings point at emphasis on 5′ UTRs or lack thereof on
3′ UTRs compared with higher organisms in transcrip-
tional and post-transcriptional control in B. subtilis.
Already well-studied examples of such 5′ UTR-mediated
control in B. subtilis is the control of the tryptophan operon
and S-adenosyl methionine (SAM) riboswitch (Grundy
and Henkin, 1998; Gollnick et al., 2005).
Novel protein-coding genes
The new annotation by Barbe et al. has identified 171
putative novel protein-coding genes increasing the
amount of protein-coding genes in B. subtilis to 4244 and
here we report the first expression data covering these. In
general the novel protein-coding genes are expressed at
lower signals compared with the remaining protein-coding
genes with expression means of 3.0 and 3.9 respectively
(Fig. 1B). Additionally only 70% are found to be expressed
above background signal, which is less than the protein-
coding genes in general (77%). This combined with the
short lengths of the newly annotated genes (median 159
versus 258 aa for remaining) and the fact that some of
these were found to have sequence errors explains why
these have not been annotated before.
We have investigated whether the novel protein-coding
genes are expressed mono- or polycistronic and we find
that 26 of the 119 expressed genes are encoded mono-
cistronic, which may provide experimental evidence for
the existence of these genes. The novel protein-coding
genes are listed in Table S4 together with their expression
values and the genes annotated to the TAR they
belong to.
An interesting monocistronic expressed new gene is
ybzH, within the pro1 prophage-like element (see
Fig. 2A), positioned on a transcript with clearly defined
boundaries. RLM-RACE mapped the TSS to 7 nt down-
stream of our observed boundary and exactly at a pre-
dicted +1 of SigA factor binding site. Additionally, a Rho-
independent terminator is predicted at the transcript end.
Regarding functionality, Barbe et al. reported BLAST hits
with high similarity to proteins of the arsenic resistance
transcriptional regulator family (ArsR) from different Bacilli
and Geobacilli species. This is in agreement with findings
that prophages have been shown to confer protective
traits to heavy metals such as arsenic (Cervantes et al.,
1994).
Alternative ORFs as the result of TAR identification
The transcriptional map also uncovers irregularities in the
current annotation, e.g. the region containing the anno-
tated translation start site or stop codon is not expressed.
The discrepancy in the annotations of these genes might
be due to sequence errors at the time of annotation;
however, re-sequencing and re-annotation efforts of
Barbe et al. seem to have corrected several of these
irregularities. An example is the ykvS gene that was
re-annotated from 143 to 62 aa and is now confined within
the observed transcript (see Fig. S2, at 1447 kb).
Examples of irregularities between gene annotation and
TARs are cgeD, ybcL, ybcM, ycgN, yxxF, yqjD and ydbO
(Fig. S2). However irregularities may also be explained by
alternative internal promoters. The latter is the case of the
hisC, tyrA and aroE operon which is transcribed from a
promoter residing inside the trpA gene (see Fig. S2, at
2372 kb) (Gollnick et al., 2005).
Expression of prophage elements
The data generated here are well suited for a systematic
investigation of the prophage elements in B. subtilis and
Fig. 2. Expression of different regions of the B. subtilis genome during growth, where the position and direction of genes are indicated with
arrows. Expression on the Watson strand is blue, Crick strand is magenta and the colour intensity also indicates signal strength.
A. Expression in the 210–212 kb region in LB showing new protein-coding gene ybzH expressed monocistronic.
B. Expression during growth in LB medium in the region 1231–1236 kb, showing expression of the novel non-coding RNA ncr22.
C. Antisense expression in the region 2598–2603 kb in LB (shd77) of sigA.
D. As (C), but expression in M9.
E. Antisense expression in the region 372–377 kb in LB (shd15-shd17) of tlpC, hxlB, hxlA and hxlR.
F. As (E), but expression in M9.
G. Antisense expression in the region 2890–2898 kb during growth in LB (shd83) of the operon ilvBHC-leuABC.
H. As (G), but expression in M9.
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we have examined the expression of the prophage ele-
ments PBSX, SPb and skin, and the prophage-like ele-
ments pro1–7 (Zahler et al., 1977; Wood et al., 1990;
Takemaru et al., 1995; Nicolas et al., 2002). The function-
ality of the genes expressed from the prophage elements
during exponential growth would be expected to be
involved in control of the bistable lysogenic equilibrium,
conferring immunity to the phages or to be functional
genes obtained via hitch-hiking. Genes with unknown
functions that are expressed during exponential growth
from within these elements are then likely not to be induc-
ing the lytic cycle, but confer beneficial traits during
growth in the natural habitat (Lazarevic et al., 1999).
In previous microarray studies large clusters of genes in
prophage elements were found to be expressed at low
levels (Helmann et al., 2001). Our analysis reveal that this
is in particular true for the skin element and to some
degree for pro2 and pro7 (Figs S5 and S6). Characteristic
of these clusters is that their expression are at extremely
low levels, indicating that even low expression of these
genes is undesirable during exponential growth.
This trend is not observed to the same extent within the
SPb prophage, where there are low, but not non-existing,
basal gene expression levels. Additionally the sublancin
genes and neighbouring area (bdbB to sunI ) are highly
expressed within SPb and exemplify that prophage genes
may confer beneficial traits that are not essential. yolA in
SPb is the highest expressed gene within the prophage
elements and is one of the highest expressed in the entire
genome (above the 98% quantile). The gene encodes a
155 aa protein predicted to contain a signal peptide and is
hence a putatively exported protein.
The prophage and prophage-like elements PBSX,
pro3, pro4 and to some extent pro5 show high levels of
gene expression. For the PBSX element it is in agree-
ment with previous observations (Krogh et al., 1996) and
coincides with the fact that it has similar base composi-
tion to the native B. subtilis sequence in contrast to
typical AT-rich prophage elements (Nicolas et al., 2002).
These expression profiles indicate limited phage func-
tionality or viability of PBSX, pro3, pro4 and pro5,
whereas skin, pro1 and pro7 may contain gene products
undesirable during exponential growth. Expression of all
genes, including prophage and prophage-like elements,
are listed in Table S2.
Identification of novel non-coding RNAs
In order to extract high-confidence new non-coding RNAs
we have set-up a list of criteria that should be fulfilled. In
total we extract 84 non-coding RNAs from segments that
fulfil the following criteria: (i) no annotated transcription
according to the latest GenBank version (AL009126.3),
(ii) higher signal level than neighbouring segments, (iii)
higher signal than the corresponding antisense region,
(iv) maximum 5% of the probes cross-hybridize to other
regions of the genome (using a BLAT-scoring scheme;
Kent, 2002), and (v) if shorter than five probes, the signal
should be observed in both media. These putative non-
coding RNAs (ncRNAs) (ncr1–84) are listed in Table S5.
They have a median length of 197 nt and range from 55 to
571 nt. From E. coli it is known that the functions of
ncRNAs cover a wide range (Kawano et al., 2005). Fig-
ure S7 shows how conserved the ncr genes are across
species. We annotate 65% (55) of the ncrs with experi-
mental or predicted sigma factor binding sites and 70%
(59) with an experimental or predicted Rho-independent
terminator.
Of the 16 already known ncRNAs in B. subtilis, other
than rRNAs and tRNAs, we identify 10: surA, ssrSB,
ssrSA, bsrF, bsrG, bsrH, bsrI, fsrA, scr and ssrA (Ando
et al., 2002; Suzuma et al., 2002; Silvaggi et al., 2006;
Gaballa et al., 2008; Saito et al., 2009). The remaining
ncRNAs bsrC, bsrD, bsrE, surC, SR1 and polC-ylxS are
not identified in our study (Licht et al., 2005; Silvaggi
et al., 2006; Saito et al., 2009). Even though we do not
identify the bsrE transcript, we do find ncr40 expressed
from the opposite strand at the same genomic location
(Saito et al., 2009). However as there are expression from
both strands in this region ncr40 may be an antisense
transcript of bsrE. Reasons for the absence of the other
RNAs might for surC and polC-ylxS be that they were
identified as being expressed under sporulating condi-
tions (Silvaggi et al., 2006). Regarding the bsrC and the
SR1 transcripts the regions are expressed (ydaG-ydaH
and slp-speA respectively); however, segments are not
identified. The bsrC segment is joined with the upstream
gene and SR1 is weakly expressed and is therefore not
identified as a segment in our analysis; however, visual
inspection reveals a possible transcript at the position
(Licht et al., 2005). bsrD is actually well defined in M9;
however, it fails to meet the criteria as it is only two probes
and not present in LB (Saito et al., 2009). In addition to
these non-coding RNAs, 22 riboswitches such as purine,
SAM, TPP, FMN, glycine and lysine, and T-box elements
are identified as ncr elements (Barbe et al., 2009). This
leaves 54 non-coding RNA elements not previously
described.
An example of a novel putative non-coding transcript is
ncr22, which is located between yizD and yjbH and is a
clearly defined transcript showing high expression in both
media (Fig. 2B). Using 5′ RLM-RACE we map the TSS to
18 nt upstream of the observed boundary; however, we
are not able to identify a probable sigma factor binding
site (Fig. 3B). A Rho-independent terminator sequence is
positioned in the 3′ of the transcript where the stem-loop
is folded from the last 16 nt of the transcript and 5 nt
outside the 3′, and the T-tail following these. This results in
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a transcript of 133 nt, which when folded using RNAfold
seems to fold into a stable structure with a minimum free
energy (MFE) of -33.8 kcal mol-1. Additionally the ncr22
transcript is highly conserved in the Bacillus, Geobacillus
and Staphyloccocus genera providing supporting evi-
dence for this transcript (Fig. S7). As most bacterial
ncRNAs act in a trans-acting regulatory role, we have
searched for mRNA targets for ncr22 using targetRNA
(Tjaden et al., 2006; Vogel and Wagner, 2007). Interest-
ingly the best hit is in the 5′ of the carbon starvation-
induced protein messenger (cstA). The interaction
between the two RNAs occur from +13 to -22 (relative to
the start codon) in the cstA transcript, covering the region
containing the Shine–Dalgarno (SD) sequence, and
nucleotides 61–95 in ncr22 (Fig. 3B). In E. coli cstA is
under translational control of the RNA-binding protein
CsrA and the sRNAs CsrB and CsrC (Dubey et al., 2003);
however, the CsrA homologue in B. subtilis does not
seem to have binding affinity for the cstA transcript (simi-
larity search using CsrA-binding domains; Yakhnin et al.,
2007). The above suggests that cstA may be under trans-
lational control in B. subtilis not by CsrA but possibly by
ncr22.
Identification of antisense RNAs
We identify 127 TARs fulfilling the same criteria as for
non-coding RNAs, except that they are expressed anti-
sense to already known genes with an overlap of more
than 10%. We term these shadow genes and name the
TARs shd1–shd127; details on these are listed in
Table S6. The median length of shadow expressed tran-
scripts is 681 nt and ranges from 197 to 3516 nt.
A possible function of these antisense transcripts is as
cis-acting regulators, as described by Eiamphungporn
and Helmann (2009) for the yabE gene and Silvaggi et al.
(2005) for yqdB. In this study we detect antisense expres-
sion to yabE (shd4) during growth in both media and in
addition an antisense signal (shd3) for the upstream gene
yabD (Fig. S2, at 49 kb). Likewise we observe the other
known B. subtilis antisense transcript ratA (shd80)
expressed in both media as antisense to yqdB (Silvaggi
et al., 2005).
As an example of a novel antisense transcript shd77
should be mentioned since this could potentially be of
significant importance as it is expressed antisense to
sigA, the principal sigma factor during vegetative growth
(Haldenwang, 1995) (Fig. 2C and D). Sigma A and E
binding sites are predicted at -10 and +10, respectively, of
the observed 5′-TAR boundary. This finding adds to the
complexity of the regulation of the yqxD-dnaG-sigA
operon, which is already known to be controlled via at
least seven different promoters (Wang et al., 1999). Fur-
thermore, we have experimentally verified the TSS of
shd15 (Fig. 2E and F and Table S3) and found it to cor-
respond to the TAR TSS prediction and identify a putative
Fig. 3. A. Average genomic DNA signal
intensity over Kingsford predicted terminators
(Kingsford et al., 2007). Position 0
corresponds to the middle nucleotide of the
predicted terminator. Blue: Watson strand;
magenta: Crick strand.
B. The ncr22 transcript and ~100 nt upstream
and downstream. Grey: intergenic nt; blue:
identified transcript; underlined: transcription
start site (+1) determined by 5′ RLM-RACE
and stem-loop of terminator sequence; green:
last part of terminator stem-loop and T-tail not
within the identified transcript.
C. Fold of ncr22 transcript using RNAfold,
coloured as base-pair probabilities. Blue
equals zero and red equals 1. The two arrows
indicate binding sequence to cstA transcript
upstream of the start codon.
TARs in the genome of Bacillus subtilis 7
© 2009 The Authors
Journal compilation © 2009 Blackwell Publishing Ltd, Molecular Microbiology
SigA site with -35: TTGATT and -10: TATGAT. This
transcript appears to be one of three antisense tran-
scripts (shd15–17) antisense to tlpC, a methyl-accepting
chemotaxis protein, hxlAB, formaldehyde detoxification
system and hxlR, which encodes a positive regulator of
hxlAB.
If antisense transcripts are acting as negative cis-
regulatory elements the signal levels of sense and anti-
sense ratio would be expected to anticorrelate which
should be possible to observe if there are differential
regulation between the conditions tested. Generally, and
in line with expectations, we do see anticorrelation
(Pearson correlation -0.22) when comparing antisense
and sense ratios (LB versus M9) (Fig. S8). When investi-
gating this for anti-yabE (shd4) the antisense transcript
level increases 1.1 log2-fold (LB to M9) with a concomi-
tant 2.7 log2-fold decline in the sense yabE signal.
However, this trend may not always be observed if mul-
tiple regulatory mechanisms control the sense expression
or the area is not differentially expressed, as exemplified
by the antitoxin ratA (shd80) with the log2 antisense and
sense ratios of -0.9 and -1.1. The antisense–sense tran-
script pair with the strongest change observed when com-
paring LB with M9 medium is shd83, which partially
overlaps leuA and ilvC in the ilvBHC-leuABC operon
(Fig. 2G and H). The products of the operon are enzymes
involved in branched chain amino acid synthesis and the
full-length mRNA is subjected to transcriptional regulation
by tRNALeu T-box in the 5′ UTR, CodY, CcpA, TnrA and
processed into smaller units (Mäder et al., 2004; Shivers
and Sonenshein, 2005). Due to the many regulatory
modes of the ilvB operon further experiments are needed
to understand whether the observed expression change
can be explained by antisense RNA expression.
The fraction of sense coding sequence covered by anti-
sense transcripts seems to be divided in two distributions,
transcripts covering close to or full length of genes and
another existing of transcripts only partially covering
genes (Fig. S8). The groups are exemplified by the two
already known antisense transcripts anti-yabE and ratA,
which are predicted to cover 72–80% and ~35% of the
coding sequences respectively (see Fig. S2, at 49 and
2678 kb, and Table S6; Silvaggi et al., 2005; Eiamphung-
porn and Helmann, 2009).
In addition to this some of the antisense transcripts
seem to be UTRs that overlap genes on the opposing
strand. We annotate eight of the transcripts as putative
overlapping 5′ UTRs and 26 as putative 3′ UTRs. A closer
inspection of the latter reveals that 35% of these have
start sites in a 50 nt range of an experimental or predicted
Rho-independent terminator (for such an example see
shd49, Fig. S2 at 1261 kb). This suggests that some 3′
UTR antisense transcripts may arise from terminator
read-through events.
We predict sigma factor binding sites for 42% (50%
when leaving out putative overlapping 3′ UTRs) of the
antisense transcripts near the observed 5′ TSSs. Further-
more, only 17% (22) of the antisense transcripts were
predicted to have an Rho-independent terminator at the
3′, which is significantly lower than what is observed for
the identified non-coding RNAs (70%).
As Xu et al. (2009) report bi-directional promoters as a
source of antisense transcription in S. cerevisiae, we
investigated whether such a phenomenon could also
explain some of the antisense transcription in B. subtilis.
We identified putative sigma factor binding sites on the
opposite strand of the predicted antisense TSS and in the
case of 16 (13%) antisense TSSs a predicted or experi-
mental site was identified. These findings point at anti-
sense transcription in B. subtilis as a ‘directed’ effort and
perhaps to a lesser extent the result of bi-directional
promoters.
Sequence and structurally conserved 3! UTRs
During the extraction of non-coding RNAs 39 putative
ncrs were excluded, due to cross-hybridizing probes
within the transcripts. An investigation of these revealed
that a group of genes have a long 3′ UTR (~220 nt) with
high sequence similarity and according to RNAfold a
highly stable secondary structure (see Fig. 4 and Fig. S9).
The latter will in our data be apparent by a local decline in
signal in both RNA and DNA hybridizations, hence
causing the TAR to be split up into a gene containing TAR
and a downstream ncr-like TAR. The nine genes having
these conserved 3′ UTRs are listed in Table 2 along with
their function (known/predicted). A closer inspection
reveals that most of these are somehow membrane-
associated, either physical sitting in the membrane, in
complex with a membrane protein, or being exported.
One possible exception is ytvA, which is a blue-light-
sensing protein positively regulating the sigma-B pathway.
Figure 5A shows RNA and DNA hybridization of a ncr-like
TARs downstream of efeN (former ywbN) together with
the predicted structure (Fig. 5B). Experimentally we
mapped the efeN 3′ UTR using 3′ RLM-RACE to 225
nucleotides downstream of the efeN stop codon, hereby
showing that the conserved sequence is indeed part of
the transcript (Fig. 5C).
EfeN is a substrate of the twin-arginine translocase
(Tat) protein translocation system and is expressed as a
part of the efeUMN operon. The operon has been shown
to be regulated by Fur (ferric uptake regulator) and EfeN
is predicted to function as a Fe(III) permease of the dye-
decolorizing Dyp-peroxidase family (Jongbloed et al.,
2004; Ollinger et al., 2006). Interestingly the Tat system is
able to transport folded proteins and proteins with bound
cofactors and to some extent only correctly folded pro-
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teins are transported (DeLisa et al., 2003). As previous
studies on EfeN in B. subtilis have focused on the Tat
signal peptide the expression of efeN coding sequence
has been performed via a xylA-efeN-myc cassette,
without the conserved 3′ UTR (Jongbloed et al., 2004).
From this it has been observed that while EfeN expressed
from the xylA-efeN-myc cassette has been identified in
extracellular extracts, the wild-type EfeN has never been
detected either inside or outside the cell (H. Antelmann
and J.M. van Dijl, pers. comm.). To this respect we, in
these expression data, see that during vegetative growth,
efeU, efeM and efeN are expressed at high rates
(Table S2). From this we speculate that the 3′ UTR of the
efeN transcript may have a function in regulating the
translation and/or the physical location of EfeN. Upon
completion of folding or cofactor binding the protein would
be available for translocation or insertion into the
membrane. In E. coli Tat proofreading exists, where a
protein binds and hereby blocks the Tat signal peptide, so
that it is shielded from the translocase until proper assem-
bly has been completed (DeLisa et al., 2003). Examples
of these Tat signal binding peptides in E. coli are TorA and
NapD (Maillard et al., 2007), of which no homologues are
found in the Bacilli.
Another possible function of the 3′ UTRs could be to
inhibit 3′ directed RNA degradation as double-stranded
RNA and stable helical regions have been shown to block
the activity of the major 3′ exoribonuclease in B. subtilis
PNPase and RNase II. Additionally the 3′ exoribonuclease
RNase R, which has been shown to be able to degrade
double-stranded RNA and RNA with secondary struc-
tures, needs a single-stranded RNA tail to be active. It has
been reported to be active with single-stranded tails of
more than 40 nt, and was demonstrated not to be active
on RNA with only a 12 nt single-stranded tail (Oussenko
et al., 2005). The single-stranded tail of the conserved 3′
UTRs ranges from 2 to 10 nt for phrG and efeN, respec-
tively, meaning that they may be protected from 3′ exori-
bonuclease degradation (Fig. 5 and Fig. S9).
Conclusions
Since these findings are based on the first experimental
attempt to map expression on a genome-wide scale in
Fig. 4. Multiple alignment in CLUSTALW2 (Larkin et al., 2007) of the 250 nucleotides downstream of tcyC, dagK, phrG (shared with argI), ytvA
(shared with yttB), efeN, yceJ and ydcA. efeN, yceJ and ydcA have the reverse complement of the sequence and are here aligned using the
reverse complement. Bases are coloured A = green, T = red, C = yellow, G = orange and the intensity at each position indicates base
conservation. No conservation is uncoloured.
Table 2. The nine genes with the conserved 3′ UTR and their function/predicted function.
Gene Protein function/genetic organization Reference
dagK Essential diacylglycerol kinase, lipoteichoic acid (LTA) production Jerga et al. (2007)
tcyC Part of the tcyABC operon encoding an L-cysteine uptake system Burguière et al. (2004)
ydcA Rhomboid-like membrane proteina –
yceJ Similar to multidrug-efflux transportera –
phrG Phosphatase (RapG) regulator, exported, divergent of argI Ogura et al. (2003)
argI Arginase, part of rocDE-argI operon (RocE: arginine permease) Gardan et al. (1995)
yttB Similar to multidrug resistance protein,a divergent of ytvA –
ytvA Blue-light sensor, positive regulator of the sigma-B pathway Gaidenko et al. (2006)
efeN Similar to Dyp-type peroxidases,a Tat-translocated protein Jongbloed et al. (2004)
a. BLAST search result.
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B. subtilis, they are to a large extent allowing us to refine
our knowledge about the B. subtilis transcriptome. But
since almost 1:5 of the currently annotated protein-coding
genes are not expressed in this study more studies using
a large spectrum of different growth conditions and per-
turbations are needed in order to reveal the full transcrip-
tional map of B. subtilis.
As this is, taken the above into consideration, a work in
progress, we report the expression map of B. subtilis in
two different media, LB and M9, as 2291 and 2464 TARs,
respectively, which in total adds to 3662 non-redundant
TARs. The predicted TARs clearly describe the spatial
expression patterns expected from genes expressed from
operons as is the case in B. subtilis. Additionally, and as
expected, a significant difference has been observed
between the length of 5′ and 3′ UTRs with medians of 47
and 36 nt respectively.
By the use of KEGG annotation we clearly see
expected differences in gene expression when comparing
the two growth sources. Regarding the novel protein-
coding genes predicted in the re-sequencing project of
Barbe and co-workers, we here report them to be
expressed at low levels compared with the previously
annotated protein-coding genes although 70% (119) of
them are expressed above background levels. Addition-
ally 26 of these are found to be expressed on monocis-
tronic transcripts, providing experimental evidence for
their existence. The TSS of yzbH has here been mapped
using 5′ RLM-RACE. Furthermore the annotation of seven
genes did not match well with the expression signals
seen, suggesting re-annotation of these.
An analysis was also performed on prophage and
prophage-like elements, revealing large clusters of genes
from the skin element, pro2 and pro7, that are not
expressed. On the contrary PBSX, pro3, pro4 and pro5
show high expression and we identify an uncharacterized
putative exported protein, yolA, within the SPb prophage
to be among the most abundantly expressed genes on the
genome.
We discover a range of high-confidence novel features
covering 84 non-coding RNAs and 127 antisense
transcripts. We identify 10 out of the 16 known ncRNAs
known in B. subtilis (excluding tRNAs and rRNAs), a puta-
tive ncRNA on the opposite strand of bsrE and 22
Fig. 5. A. Expression of the genomic area near efeN as an example of the identified conserved, stable structure forming 3′ UTRs. Watson
strand is blue, Crick strand is magenta and the results from the DNA hybridization are shown in a colour gradient from dark green (low signal)
to yellow (high signal). The grey bar indicated the location of the 3′ UTR transcript.
B. RNA structure, folded using RNAfold, of 220 nt downstream of stop codon of efenN coloured as base-pair probabilities. Blue equals zero
and red equals 1.
C. 3′ sequence of efeN containing transcript. Grey: efeN CDS, and intergenic nt; green: RLM-RACE primer; red: efeN stop codon; blue: 3′
UTR identified by RLM-RACE and the sequence folded in (B); underlined: the conserved sequence.
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riboswitches. Additionally the 5′ of ncr22 was mapped
using RLM-RACE and it may act as a putative trans-
acting inhibitor on translation of the carbon starvation
protein gene cstA. Regarding the antisense transcripts,
27% of them could be overlapping 5′ or 3′ UTRs and 50%
of the non-3′ UTR antisense transcripts have predicted
sigma factor binding sites near the observed TSS. The
TSSs of 16 antisense transcripts are opposing an experi-
mental or predicted sigma factor binding site and may be
products of bi-directional promoters. The expression of
antisense transcripts was found to be anticorrelated to
their sense counterparts.
In addition, the analysis of gDNA hybridization has led
us to discover stable structures in the 3′ UTRs of several
transcripts and one of these tails was experimentally veri-
fied for EfeN, a Tat-translocated protein.
Experimental procedures
Design of the tiling array BaSysBio Bsub T1
A total of 385 000 feature NimbleGen arrays have been
designed, using OligoWiz 2.0 (Wernersson and Nielsen,
2005), with long iso-thermal probes (45–65 nt) covering the
entire genome of B. subtilis #168 Trp+ (AL009126.2) in 22 nt
intervals on each strand and an 11 nt offset between the
strands. The microarray design and data are available at the
Gene Expression Omnibus (GEO) database at NIH as
‘BaSysBio Bacillus subtilis T1385K array version 1’ with the
records GPL8486 and GSE16086 respectively. The data
were remapped to the re-sequenced genome (AL009126.3)
using BLAT (BLAST-like alignment tool) and 383 probes were
removed due to low match (Kent, 2002; Barbe et al., 2009).
The bacterial strain, growth conditions and sample
processing
Three B. subtilis #168 Trp- cultures were grown in LB medium
and three in M9 medium at 37°C and 120 r.p.m. until
the OD600 had reached a value of 0.5. Generation times
for B. subtilis in the experiments were 26 and 78 min
respectively. Media compositions were: LB (Sigma-Aldrich):
10 g l-1 Tryptone, 5 g l-1 yeast extract and 5 g l-1 NaCl; M9:
0.3% glucose, 0.1 mM CaCl2, 1 mM MgSO4, 0.05 mM FeCl3,
8.5 g l-1 Na2HPO4·2H2O, 3 g l-1 KH2PO4, 1 g l-1 NH4Cl,
0.5 g l-1 NaCl, 1 mg l-1 MnCl2, 1.7 mg l-1 ZnCl2, 0.43 mg l-1
CuCl2·2H2O, 0.6 mg l-1 CoCl2·6H2O and 0.6 mg l-1
Na2MoO4·2H2O. A total of 25 ml from each culture was trans-
ferred to a 40 ml tube 1/3-filled with crushed ice and spun at
7000 r.p.m. for 5 min, after which the supernatant was dis-
carded and the cell pellet frozen by dumping the closed tube
into liquid nitrogen. Total RNA was extracted by the use of the
FastRNA PRO Blue Kit from Qbiogene as recommended by
the supplier, but with an additional shake in the FastPrep
instrument and a 1 min incubation on ice between the two
shakings. DNA was extracted (from four independent cultures
grown in LB under the same conditions as described above)
using the DNeasy Blood tissue kit from Qiagen as recom-
mended by the supplier. Both RNA and DNA were send to
NimbleGen labelled and hybridized to the BaSysBio Bsub T1
chip using a protocol for strand-specific hybridization devel-
oped during this work (the BaSysBio protocol), and the
NimbleGen-standard protocol for double-stranded DNA
respectively. All samples were labelled with Cy3 and in the
case of RNA first-strand cDNA was produced by random
priming and Actinomycin D inhibition of the reverse tran-
scriptase polymerase effect (as suggested by Perocchi et al.,
2007). We found that the optimal enzyme concentration was
40 mg ml-1.
RNA ligase-mediated rapid amplification of cDNA ends
(RLM-RACE)
Transcription start sites were mapped for five transcripts
using FirstChoice® RLM-RACE Kit (Ambion) following the
manufacturer’s protocol. DNase-treated RNA from an inde-
pendent LB experiment was used as template and nested
PCR was performed using primers listed in Table S3. Single-
band PCRs were purified using Qiaquick PCR Purification Kit
(Qiagen) and multiple bands were excised from gels and
purified using Qiaquick Gel Extraction Kit (Qiagen) and
sequenced. Transcript end mapping was performed for efeN
by poly-adenylating DNase-treated RNA using Poly(A) Poly-
merase (Epicentre Biotechnologies) and Firstchoice® RLM-
RACE kit (Ambion) following manufacturer’s protocol. Only a
single PCR was needed for the 3′ RLM-RACE and the
primers are listed in Table S3.
Data preprocessing, segmentation and TAR creation
Segmentation was performed using the Structural Change
Model (SCM) described by Huber et al. (2006), in the Biocon-
ducter package tilingArray. We used default settings allowing
3000 segment to be created for each strand with a maximum
length of 400 probes (~8800 bp). Normalization by reference
(gDNA data) was not used as it according to our benchmark-
ing decreased performance, and the optimal detection limit
(background) was determined to the 60% quantile (2.2 log2
signal) of the signal intensities. Following the segmentation
we created the resulting TARs by accepting all segments
above background and joining neighbouring segments if the
five probes on each side of a breakpoint were all above
background, and when a Student’s t-test did not rejected the
hypothesis that these two sets of probes belonged to the
same signal-intensity distribution (P-value > 1e-10). Finally
short TARs (< 5 probes) between two highly expressed seg-
ments were removed. The resulting list of TARs is shown in
Table S1.
Assessment of breakpoints
To determine the accuracy of the TAR breakpoint predictions
these were benchmarked against the 654 experimentally
verified TSS, which were extracted from the DataBase of
Transcriptional regulation in B. subtilis (DBTBS, release 5)
(Sierro et al., 2008), and 425 experimentally verified Rho-
independent terminators (Hoon et al., 2005). Both the sigma
factor binding sites and Rho-independent terminator annota-
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tion was transferred to the re-sequenced genome
(AL000926.3) using BLAT (Kent, 2002). The TAR-signal ends
were adjusted 9 and 51 nucleotides downstream to optimally
predict TSS and TES. The belonging receiver operating char-
acteristic (ROC) curves (Swets, 1988) are shown in Fig. S3.
Annotation of TARs and UTRs
Known genes were annotated to the TAR with the maximal
overlap to it, and only if more than 50% of the gene was
covered by the given TAR. The reported 5′ UTR lengths are
the distances from the 5′ end of the given TAR to the start of
the first ORF in the TAR (if any) and likewise the 3′ UTR
lengths are the distances from the stop codon of the last ORF
to the TAR 3′ end. Internal UTRs were calculated as the
distance between stop and start for two neighbouring ORFs
inside TARs.
Sigma factor and terminator predictions
All identified transcripts were annotated with experimentally
verified sigma factor binding sites and Rho-independent ter-
minator sequences (Hoon et al., 2005; Sierro et al., 2008).
The co-ordinates of the above were transferred to the
re-sequenced genome (AL009126.3) using BLAT. Additionally
the transcripts were also annotated with predicted sigma
factor binding sites from two sources, sigma A sites from
Jarmer and co-workers and sigma A, B, E, D, G, F, K, H, X,
W predicted by a HMMbuild from all known alignments from
DBTBS (Release 5) (Jarmer et al., 2001; Sierro et al., 2008).
The HMM was created using HMMbuild and HMMcalibrate
and was used by HMMsearch to search in the sequences
100 nt upstream and 50 nt downstream the TSS. The sigma
factors I, M, Y, Z and YlaC and YvrI had too few known sites
to build HMMs. Terminators were predicted using TransTer-
mHP 2.0 and in the case of more than one terminator within
50 nt of the TES the closest one was used for annotation
(Kingsford et al., 2007).
KEGG analysis
KEGG annotations for B. subtilis were downloaded from
the KEGG website (September 2008) (Kanehisa et al., 2008).
KEGG annotations were counted for the genes present
exclusively expressed in the LB medium, the M9 medium and
genes expressed in both (common). From each of these
three categories, the five most occurring annotations were
selected and the occurrences were plotted as shown in
Fig. 1.
Identification of novel ncRNAs
Segments of five or more probes without known annotation
according to the latest GenBank annotation (AL009126.3)
and no ORF predicted by EasyGene (Nielsen and Krogh,
2005) were accepted as putative novel ncRNAs if they were
expressed above background and neighbouring segments,
contained a maximum of 5% potentially cross-hybridizing
probes and had higher signal level than same area on the
opposite strand. Segments with less than five probes fulfilling
the criteria and expressed in both media were also accepted
as possible ncRNAs. In addition, all potentially novel ncRNAs
were inspected visually. The ncRNAs were named ncr1–
ncr84 and are listed in Table S5. We also searched the first
100 nt of each ncRNA for ribosome binding sites with SD
(AGGAGG) and 4–10 nt after that a start codon (ATG/CTG/
GTG), resulting in five of these coding for small putative
CDSs. The DNA sequences corresponding to the 84 seg-
ments that passed the above criteria were extracted from the
genome sequence (AL009126.3), and were compared by
BLAST to all available Firmicute genome or plasmid
sequences [34 species within 42 strains resulting in 225
entries from the CBS Genome Atlas Database version 2.0
(Hallin and Ussery, 2004)] (Altschul et al., 1990). For each
species the best hit was recorded as per cent identity over the
entire ncRNA length. These results are shown in Fig. S7.
Identification of antisense RNAs
Segments were subjected to the same criteria as for iden-
tification of novel ncRNAs, except expression did not have
to be higher than on the opposing strand. Additionally the
transcripts are antisense to a known gene (GenBank:
AL00926.3) with an overlap of more than 10%. The identi-
fied antisense transcripts were manually curated leading to
127 transcripts that were named shd1–127 and are listed in
Table S6.
3! UTR identification
Transcripts with a conserved 3′ UTR structure were identified
based on multiple alignment of the 220 nucleotides down-
stream of all genes, performed using CLUSTALX2 (Larkin et al.,
2007). Structures were made using RNAfold v. 1.6 and the
Vienna RNA web suite (Gruber et al., 2008).
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3.2 Perspectives
We hope that the B. subtilis community will investigate and use our findings by
integrating the data into their own research. An example is that we were contacted
by the editor of Molecular Microbiology, Dr. John Helmann, informing us that
when observing shd83 (shown in Figure 2G and H) he fifteen years ago identified
a SigA binding site that matches the TSS of that antisense transcript.
Regarding the conserved 3’ UTRs that we identified in the efeN transcript, we
hypothesized that this might be a part of a translational control mechanism similar
to the Tat-proofreading in E. coli. A recent study in E. coli [112] showed that a
DNase (TatD) was crucial for the Tat-proofreading, which could add more to the
hypothesis of the 3’ UTR tail. Interestingly, we identified an antisense transcript
(shd3 ) for yabD, a gene coding for a protein that contains a TatD DNase domain.
With collaborators at University Medical Center Groningen (UMCG) we are
currently investigating the effects of the non-coding RNA ncr26. ncr26 is a 351
nt putative non-coding RNA expressed from a predicted SigW/SigX promoter for
both conditions tested. No protein has been identified from the sequence and from
ncr26 – experiments it seems to be involved in protein secretion. At the moment
we are analyzing tiling array data from this and other related mutants. Regarding
ncr22, the non-coding transcript hypothesized to have translational regulatory
control on cstA, we are hoping to start similar experiments.
Chapter 4
Characterizing a Saccharomyces
cerevisiae mutant
Saccharomyces cerevisiae is an eukaryotic organism widely used in the industry
for fermentation purposes, for baking (bakers yeast) and for the production of re-
combinant proteins and bioethanol. In 1996 it became the first eukaryotic genome
to be sequenced and it is one of the best studied model organisms for eukaryotic
life with more than 40.000 research publications [113]. There are an abundance of
data available from almost any aspect of biological research making S. cerevisiae
an obvious model for systems biology [114].
Together with Carlsberg Research Center (CRC) we engaged in characteriz-
ing a S. cerevisiae BY4741 mutant, a strain that was created and published by
Alper et al. in Science, 2006 [115]. The purpose of that study was to develop
a strain with improved tolerance towards glucose and ethanol as these charac-
teristics are important in very high gravity fermentations in the industry. This
form of fermentation is characterized by high sugar concentration in the beginning
and high ethanol concentration in the end of the batch run. As it has previously
been found that tolerance to ethanol and glucose mixtures is not controlled at
monogenic level, the authors employed a global Transcription Machinery Engi-
neering (gTME) approach. Here random mutagenesis is applied to key proteins in
the transcription with the target of the particular study, SPT15, being a TATA-
binding protein. Modulation of TATA-binding proteins has previously been shown
to induce changes in the specificity of RNA polymerase II towards promoters and
may therefore be used to induce changes in gene expression of multiple genes. A
mutant with three mutations in SPT15 (termed spt15-300 ) was found to display
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Figure 4.1 – Experimental setup and outlier removal. a. two factor ANOVA
setup, the factors “genotype” and “medium” are shown and the number of biological
replicates indicated inside the box. *: One array was removed as an outlier from
this group. b. Density plot of probe intensities. The light blue line represents the
outlier.
increased glucose and ethanol tolerance.
In the original publication DNA microarray analysis in combination with gene-
knockout and overexpression analysis of SPT15 targeted genes were applied, how-
ever they were not able to identify the genetic network responsible for the pheno-
type. Our collaborators at CRC attempted to use the spt15-300 allele in indus-
trial important strains, however they found that the increased tolerance phenotype
could only be reproduced in media with small amounts of the amino acid leucine.
Interestingly the BY4741 strain is deleted for the LEU2 gene involved in the
biosynthesis of leucine and rescuing this deletion abolished the differences. We
therefore re-investigated the DNA microarray data from the original publication
with regard to leucine uptake, synthesis and utilization.
4.1 Paper II
The DNA microarray experiment originally performed was designed as a two-
factor ANOVA (Figure 4.1a). For the analysis the authors only used the unstressed
conditions – hence they only assessed the genotype effect and ignored samples from
the glucose/ethanol conditions. On the contrary we analyzed the experiment as
a two-factor ANOVA approach, removing one sample from the spt15-300 and 5%
ethanol, 60 g/l glucose group because we identified it as an outlier (Figure 4.1b).
From the analysis we found that the stress induced by glucose and ethanol
significantly regulates expression of roughly half of the known genes (3100 genes
at FDR = 0) in S. cerevisiae. Likewise the genotype effect (spt15-300 mutation)
significantly regulates 700 genes (FDR = 0), indicating that both pertubations
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have large impact on the cells. In a situation like this, being able to focus on a
few biological pathways can greatly enhance the chance of success.
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Successful fermentations to produce ethanol require microbial strains that have a high tolerance to glucose
and ethanol. Enhanced glucose/ethanol tolerance of the laboratory yeast Saccharomyces cerevisiae strain
BY4741 under certain growth conditions as a consequence of the expression of a dominant mutant allele of the
SPT15 gene (SPT15-300) corresponding to the three amino acid changes F177S, Y195H, and K218R has been
reported (H. Alper, J. Moxley, E. Nevoigt, G. R. Fink, and G. Stephanopoulos, Science 314:1565–1568, 2006).
The SPT15 gene codes for the TATA-binding protein. This finding prompted us to examine the effect of
expression of the SPT15-300 allele in various yeast species of industrial importance. Expression of SPT15-300
in leucine-prototrophic strains of S. cerevisiae, Saccharomyces bayanus, or Saccharomyces pastorianus (lager
brewing yeast), however, did not improve tolerance to ethanol on complex rich medium (yeast extract-peptone-
dextrose). The enhanced growth of the laboratory yeast strain BY4741 expressing the SPT15-300 mutant allele
was seen only on defined media with low concentrations of leucine, indicating that the apparent improved
growth in the presence of ethanol was indeed associated with enhanced uptake and/or utilization of leucine.
Reexamination of the microarray data published by Alper and coworkers likewise suggested that expression of
genes coding for the leucine permeases, Tat1p and Bap3p, were upregulated in the SPT15-300 mutant, as was
expression of the genes ARO10, ADH3, ADH5, and SFA1, involved in leucine degradation.
Improvement of stress tolerance in microorganisms applied
in industrial fermentations for the production of ethanol is of
major interest (26, 34). Based on screens for ethanol sensitiv-
ity/tolerance in Saccharomyces cerevisiae (12, 16–18, 35, 37, 40),
it appears that this trait in yeast is possibly controlled by sev-
eral genes acting in concert. Using global transcription machin-
ery engineering (gTME), a tool to reprogram gene transcrip-
tion for eliciting new phenotypes important for technological
applications, Alper et al. (2) found mutants of S. cerevisiae with
improved glucose/ethanol tolerance. In that work, mutated
versions of the SPT15 gene, which codes for the TATA-binding
protein, were generated by random in vitro mutagenesis and
expressed in the laboratory strain BY4741. The authors iden-
tified one dominant allele, SPT15-300, which corresponds to
the three amino acid changes F177S, Y195H, and K218R, that
conferred increased tolerance of the yeast to ethanol (2). Al-
though extensive analyses, such as transcriptional profiling and
deleting and overexpressing individual genes, were carried out,
a particular pathway or a genetic network responsible for the
observed growth gain of the SPT15-300-expressing strain could
not be identified (2). During our attempts to analyze the effect
of the mutant SPT15-300 alleles in various yeast species of
industrial importance, we discovered that the described im-
provement of growth in the presence of ethanol of the standard
laboratory strain BY4741, the strain used by Alper et al. (2), is
associated with improved uptake and/or utilization of leucine
on media containing small amounts of leucine.
MATERIALS AND METHODS
Strains, media, and molecular procedures. The Saccharomyces strains inves-
tigated in this study were S. cerevisiae strains BY4741 (MATa his3D1 leu20
met150 ura30) (5), in which the LEU2 gene is completely deleted (obtained
from Euroscarf, Frankfurt, Germany), and Y55 (23) derivative JT20150 (MAT
MAL1) (obtained from J. M. Thevelein, Katholieke Universiteit, Leuven, Bel-
gium); S. bayanus NRRL Y-11845 (MCYC 623) (7, 20) (provided by C. P.
Kurtzman, Microbial Genomics and Bioprocessing Research Unit, Peoria, IL);
and S. pastorianus W-34/70 (25) (obtained from Hefebank Weihenstephan, Fre-
ising, Germany).
Yeast cells were cultured aerobically in complex rich medium YPD (1%
[wt/vol] yeast extract, 2% [wt/vol] peptone), 2% [wt/vol] glucose) (32) supple-
mented when necessary with G418 (final concentration of 100 or 300 g/ml as
indicated), synthetic complete minimal (SC) medium (6.7 g/liter yeast nitrogen
base [without amino acids] supplemented with amino acids as specified in ref-
erence 32) without uracil (SCUra) and a modified composition containing five
times the amount of leucine (i.e., 150 mg/liter instead of 30 mg/liter) (SCUra
5  Leu), SC lacking leucine (SCLeu), yeast synthetic complete (YSC) me-
dium (6.7 g/liter yeast nitrogen base [without amino acids] supplemented with
Qbiogene CSM-URA [a commercial amino acid mixture]) lacking uracil (con-
taining 100 mg/liter leucine) as described by Alper et al. (2), and YSC lacking
leucine (prepared as described for YSCUra, with Qbiogene CSM-LEU [2]). SC
media were buffered (pH 5.5) with 1% (wt/vol) succinic acid and 0.6% (wt/vol)
NaOH. SC and YSC media were supplemented with glucose and/or ethanol as
indicated. S. cerevisiae strains were incubated at 20 or 30°C (as indicated), and S.
bayanus and S. pastorianus were cultivated at 20°C. Saccharomyces species were
transformed by use of the lithium acetate method (3).
Escherichia coli strain DH5 (Invitrogen A/S, Taastrup, Denmark) was used
for plasmid selection/propagation and cultivated as described previously (31).
* Corresponding author. Mailing address: Carlsberg Laboratory, Gamle
Carlsberg Vej 10, DK-2500 Copenhagen Valby, Denmark. Phone: 45
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Plasmid constructions. Standard recombinant DNA manipulations were per-
formed as described previously (31). DNA-modifying enzymes were obtained
from Invitrogen (Invitrogen A/S, Taastrup, Denmark), New England Biolabs
(Medinova Scientific A/S, Glostrup, Denmark), and Promega (Promega Biotech
AB, Nacka, Sweden) and used as recommended by the suppliers. PCRs were
carried out with Phusion high-fidelity DNA polymerase (Finnzymes, Medinova
Scientific A/S, Glostrup, Denmark). DNA sequencing and oligonucleotide syn-
thesis were performed by Eurofins MWG (Ebersberg, Germany); oligonucleo-
tide sequences are available on request.
SPT15 expression vectors (Table 1) were constructed basically as described by
Alper et al. (2). As displayed in Table 1, four vector sets were constructed.
(i) One set of SPT15 variants (see below) was inserted into vector pCJR2 (a
CEN-based vector with a native S. cerevisiae TEF1 promoter and G418 selection),
which was constructed by cloning a 852-bp SacI-PvuII-fragment of p416TEF (24)
(obtained from ATCC, LGC Standards AB, Boras, Sweden) containing the wild-
type S. cerevisiae TEF1 promoter into a 4471-bp SacI-EcoRV-digested vector frag-
ment of pCJR1. This plasmid was constructed by cloning a 1,447-bp BglII (blunt
ended by DNA polymerase [Klenow fragment])-SacI fragment (KanMX4 cas-
sette) of pUG6 (15) (obtained from Euroscarf, Frankfurt, Germany) into a
3,082-bp TthIII1 (blunt ended with Klenow fragment)-SacI vector fragment of
pRS315 (33).
(ii) The second set of SPT15 expression vectors was constructed identically to
pCJR2, except that the wild-type S. cerevisiae TEF1 promoter was exchanged
with mutant version 2 as described previously (1, 27). To accomplish this, a
403-bp SacI-XbaI-digested synthetic DNA fragment (GenScript, Piscataway, NJ,
USA) containing the mutant TEF1 promoter (1) was used to replace the native
SacI-SpeI-digested promoter.
(iii) A third set of SPT15 vectors (CEN-based vector, mutant S. cerevisiae TEF1
promoter, URA3 selection) was constructed by inserting SacI-EagI-digested frag-
ments of pCJR7 (1,434-bp fragment with S. cerevisiae-type SPT15) or pCJR8
(1,430-bp fragment with S. cerevisiae-type SPT15-300) into a 4,805-bp SacI-EagI-
digested vector fragment of p416TEF.
(iv) A fourth set of SPT15 vectors (CEN-based vector, mutant S. cerevisiae
TEF1 promoter, LEU2 selection) was constructed by inserting SacI-EagI-di-
gested fragments of pCJR7 (1,434-bp fragment with S. cerevisiae-type SPT15) or
pCJR8 (1,430-bp fragment with S. cerevisiae-type SPT15-300) into a 6,005-bp
SacI-EagI-digested vector fragment of pRS315.
The lager brewing yeast, Saccharomyces pastorianus, is a hybrid of S. cerevisiae
and a Saccharomyces species related to S. bayanus (21, 25). Genes in the genome
of lager brewing yeast that have high identity with genes found in S. cerevisiae are
called S. cerevisiae type, while genes more distantly related are called non-S.
FIG. 1. Growth assays for ethanol tolerance of SPT15 transformants. S. cerevisiae strains BY4741 and Y55, S. bayanus NRRL Y-11845 (MCYC
623), and S. pastorianus W-34/70 were used. Tenfold serial dilutions of cultures were spotted on YPD agar plates supplemented with 8% ethanol.
Plates were photographed after 4 days of incubation at 20°C. Media were supplemented with G418 for plasmid selection. SPT15 expression was
under the control of the wild-type S. cerevisiae TEF1 promoter. For comparison, S. cerevisiae strain BY4741 with the control vector pCJR2 was
spotted on the first lane of each plate.
TABLE 1. Constructed SPT15 expression vectorsa
Vector Selectionmarker Promoter Insert
pCJR2 G418 PTEF1 Multiple-cloning site
pCJR3 G418 PTEF1 S. cerevisiae-type SPT15-300
pCJR4 G418 PTEF1 S. cerevisiae-type SPT15
pCJR5 G418 PTEF1 Non-S. cerevisiae-type SPT15
pCJR6 G418 PTEF1 Non-S. cerevisiae-type SPT15-300
pCJR7 G418 PTEF1mut2 S. cerevisiae-type SPT15
pCJR8 G418 PTEF1mut2 S. cerevisiae-type SPT15-300
pCJR11 URA3 PTEF1mut2 S. cerevisiae-type SPT15
pCJR12 URA3 PTEF1mut2 S. cerevisiae-type SPT15-300
pCJR17 LEU2 PTEF1mut2 S. cerevisiae-type SPT15
pCJR18 LEU2 PTEF1mut2 S. cerevisiae-type SPT15-300
a See “Plasmid constructions” in Materials and Methods.
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cerevisiae type. SPT15 gene variants (Table 1) were obtained as follows: (i) a
753-bp BamHI (blunt ended with Klenow fragment)-SpeI-digested S. cerevisiae-
type SPT15 fragment was amplified from S. cerevisiae BY4741 genomic DNA by
PCR, (ii) a 749-bp SpeI-SmaI-digested S. cerevisiae-type SPT15-300 fragment
was obtained as a synthetic gene (GenScript, Piscataway, NJ) according to the
mutant sequence as described by Alper et al. (2), (iii) a 775-bp SpeI-EcoRV-
digested non-S. cerevisiae-type SPT15 fragment was amplified from S. pastorianus
W-34/70 genomic DNA by PCR, and (iv) a fragment containing non-S. cerevisiae-
type SPT15-300 was constructed by cloning a 259-bp SpeI-BglII-digested 5
fragment of non-S. cerevisiae-type SPT15 (in which the BglII site was introduced
by silent mutation using PCR) to a 504-bp BglII-SmaI digested 3 fragment of S.
cerevisiae-type SPT15-300 (exchange of gene fragments was possible, since the
encoded S. cerevisiae-type and non-S. cerevisiae-type Spt15 proteins differ only at
amino acids 31 and 36). The correct sequence of each vector was confirmed by
DNA sequencing.
Growth and ethanol tolerance assays. The growth phenotypes of SPT15 trans-
formants were examined as described by Alper et al. (2). In short, yeast trans-
formants were precultured in YSC (2) or SC (32) medium containing various
amounts of glucose as indicated and diluted to an optical density at 600 nm
(OD600) of 0.01 in fresh medium supplemented with various amounts of ethanol
as indicated. The OD600 was measured after 20 h of incubation at 30°C with
shaking. In the case of G418 selection, YSC media were supplemented with 300
g/ml G418. The ethanol tolerance of SPT15 transformants was analyzed on
plate assays in which solid medium (as indicated) was supplemented with 6% or
8% ethanol (as indicated). Tenfold serial dilutions of cell cultures, pregrown in
appropriate media (as indicated), at an OD600 of 1.0 (initial dilution) were
spotted on plates. Growth assays were performed in triplicate. Results of rep-
resentative experiments are shown.
FIG. 2. Growth of transformants of S. cerevisiae strain BY4741 harboring URA3-based (A) or LEU2-based (B) vectors without insert (control)
or with SPT15 or SPT15-300 on different defined media in the presence or absence of 6% ethanol. SPT15 expression was under the control of the
mutant S. cerevisiae TEF1 promoter, i.e., PTEF1mut2. Tenfold serial dilutions of cell cultures were spotted on the plates. Plates were photographed
after 2 (A) (2% glucose), 3 (B) (2% glucose), 4 (B) (2% glucose plus 6% ethanol), and 7 (A) (2% glucose plus 6% ethanol) days of incubation
at 30°C.
TABLE 2. Growth of S. cerevisiae BY4741 transformants in
YSC medium
Plasmid selection
Avg OD600  SEM with:
Control
plasmid SPT15 SPT15-300
Uracil prototrophy 0.006  0.001 0.009  0.001 0.038  0.002
G418 resistance 0.042  0.005 0.028  0.002 0.092  0.005
a Transformants were incubated for 20 h at 30°C with shaking. Cultures were
inoculated to an OD600 of 0.01 in YSC medium with 2% glucose and 6% ethanol.
SPT15 and SPT15-300 expression was under the control of the weaker TEF1
promoter (PTEF1mut2; URA3 or G418 resistance selection). Cultivations were
performed in triplicate.
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Microarray analysis. The microarray data (accession no. GSE5185) were
downloaded from the Geo Expression Omnibus database (4) and analyzed using
R and Bioconductor (13). Array “GSM116825” (SPT15-300 plus 60 g/liter glu-
cose and 5% ethanol) was identified as an outlier and removed, and only probes
specific for S. cerevisiae were used in our analyses. rma was used for quantile
normalization and probe index calculations, and these were subsequently nor-
malized using Qspline (19, 39). For statistical testing, two-factor analysis of
variance was used, with the factors “genotype” (i.e., wild type versus SPT15-300)
and “medium” (i.e., 20 g/liter glucose [medium A] versus 60 g/liter glucose and
5% ethanol [medium B]). The false-discovery rate (FDR) was estimated using a
Monte Carlo approach, and statistical significance was set at an FDR of 0.005.
RESULTS AND DISCUSSION
Encouraged by the report by Alper and coworkers (2), we
were interested in applying gTME to yeasts in order to im-
prove their ethanol tolerance and ultimately fermentation per-
formance. As a first step, we decided to evaluate the effect of
the SPT15-300 mutant allele identified by Alper et al. (2) in
various yeast species of industrial importance. The lager brew-
ing yeast, Saccharomyces pastorianus, is a hybrid between S.
cerevisiae and a Saccharomyces species related to S. bayanus
(21, 25). Genes in the genome of lager brewing yeast that show
a high percentage of sequence identity to genes found in S.
cerevisiae are called S. cerevisiae type, while genes more dis-
tantly related are called non-S. cerevisiae type. We introduced
the three point mutations identified in SPT15-300 in both types
of genes, and the wild-type and mutant SPT15 genes were
subsequently inserted into plasmids under the control of the
wild-type S. cerevisiae TEF1 promoter. Since ethanol sensitiv-
ity/tolerance screens are generally performed in rich complex
media, i.e., YPD supplemented with various amounts of etha-
nol ranging from 6 to 12.5% (12, 16–18, 35, 37, 40), we ana-
lyzed the growth of SPT15 transformants of S. cerevisiae
BY4741 and Y55 (JT20150), S. bayanus NRRL Y-11845, and
S. pastorianus W-34/70 on rich complex solid medium (i.e.,
YPD) supplemented with 8% ethanol. This ethanol percentage
was arbitrarily chosen in order to analyze “ethanol-resistant”
and “ethanol-sensitive” yeasts (such as S. cerevisiae Y55 and S.
pastorianus W34/70, respectively) under one single condition. Un-
fortunately, none of the yeasts harboring the mutant SPT15-300
gene displayed the expected improved ethanol tolerance (Fig.
1). As a control and in order to repeat the experiments de-
scribed by Alper et al. (2), plasmids that carried the wild-type
and mutant SPT15 genes under the control of the weaker
mutant version of the S. cerevisiae TEF1 promoter were con-
structed (1, 2, 27). In agreement with the findings of Alper et
al., we found that the S. cerevisiae laboratory strain BY4741
transformed with SPT15-300 showed an apparent increase in
ethanol tolerance in liquid YSC medium (2) regardless of
whether the SPT15 genes were expressed from a URA3- or a
G418 selection-based plasmid (Table 2). Evaluation of the
contribution of promoter strength to the appearance of etha-
nol tolerance in cells expressing SPT15-300 (i.e., comparison of
SPT15 expression using the native and mutant S. cerevisiae
TEF1 promoters) demonstrated that the effect was stronger
when the native promoter was used than when the weaker
mutant version was used (data not shown). The enhanced
ethanol tolerance of cells carrying the SPT15-300 allele was
also apparent on SC plates with 30 mg/liter leucine but not on
SC plates containing 150 mg/liter leucine (Fig. 2A). When
transformants were grown in YSC medium that contained 100
mg/liter leucine, prepared as described by Alper et al. (2), the
enhanced ethanol tolerance was only marginally manifested
(Fig. 2A). In the absence of ethanol, the enhanced growth of
cells with the SPT15-300 allele was also noticeable on SCUra
medium with 30 mg/liter leucine (Fig. 2A). Thus, the apparent
FIG. 3. Growth (OD600) of S. cerevisiae strain BY4741 expressing
the SPT15-300 mutant gene relative to that of cells expressing the
wild-type SPT15 gene (expression was under the control of the mutant
S. cerevisiae TEF1 promoter, i.e., PTEF1mut2). Cells were inoculated in
SC media with 20, 60, 100, or 120 g/liter glucose. Cultivation analyses
were performed in triplicate (error bars display standard deviations).
(A) Cells expressing SPT15-300 or SPT15 from a URA3 plasmid were
inoculated into SCUra containing 30 mg/liter leucine (open squares),
or cells expressing SPT15-300 or SPT15 from a LEU2 plasmid were
inoculated into SCLeu (closed triangles). (B) Cells expressing
SPT15-300 or SPT15 from a URA3 plasmid were inoculated into
SCUra containing 30 mg/liter leucine in the absence of ethanol
(open squares) or in the presence of 4% (closed squares), 5% (closed
circles), or 6% (open triangles) ethanol. (C) Cells expressing SPT15-
300 or SPT15 from a LEU2 plasmid were inoculated into SCLeu in
the absence of ethanol (open squares) or in the presence of 6%
ethanol (closed squares).
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improved ethanol tolerance could be related to the improved
growth of the SPT15-300 mutant in media containing smaller
amounts of leucine. The S. cerevisiae laboratory strain BY4741
is deficient in leucine biosynthesis due to the deletion of the
LEU2 gene, encoding 	-isopropylmalate dehydrogenase, the
third enzyme in leucine biosynthesis (5). Therefore, we exam-
ined the effect of the SPT15 wild-type and mutant alleles in-
serted into a LEU2-containing plasmid in BY4741 cells trans-
formed to leucine prototrophy. Cells containing either the
wild-type or the mutant allele grew equally well on solid media
lacking leucine (SCLeu) whether or not ethanol was present
(Fig. 2B). This indicated that the observed increased growth of
cells harboring the SPT15-300 allele indeed is related to im-
proved uptake and/or utilization of leucine.
We also tested the growth of the transformed cells in liquid
SC-based media containing different amounts of glucose (Fig.
3). In cells transformed with URA3-based plasmids, the SPT15-
300 mutant showed enhanced growth in SCUra medium con-
taining 30 mg/liter leucine at all glucose concentrations tested,
while cells transformed with LEU2-based plasmids did not
show this effect of the SPT15-300 allele (Fig. 3A). In SCUra
media containing 30 mg/liter of leucine and 5% or 6% ethanol,
growth was severely slowed and thus the apparent growth ad-
vantage of the SPT15-300 mutant was reduced (Fig. 3B). How-
ever, at 4% ethanol the growth advantage of the mutant was
still noticeable, in particular at lower glucose concentrations
(Fig. 3B). When the growth experiments were performed with
liquid SC medium containing 20 g/liter glucose and 150 mg/
liter leucine, the growth advantage of the mutant SPT15-300
allele was absent (1.1-fold growth improvement; standard de-
viation, 0.0 [data not shown]). In the presence of 4, 5, or 6%
ethanol, the fold growth improvement was limited (1.7 to 1.8;
standard deviation, 0.1 [data not shown]). As was the case on
solid media, cells transformed with the wild-type and mutant
SPT15 alleles on a LEU2 plasmid grew equally well in SCLeu
media with different glucose concentrations, without or with
6% ethanol (Fig. 3C).
These growth experiments illustrate that the enhanced growth
of cells with the SPT15-300 mutant allele could be distin-
guished only in media with limiting amounts of leucine and
FIG. 4. Reevaluation of the expression data published by Alper et al. (2), specified to genes involved in leucine uptake (A), leucine degradation
(B), and leucine biosynthetic (C) pathways in S. cerevisiae obtained from SGD (http://www.yeastgenome.org). The color map under each gene
shows the scaled regulation of each gene (z score), with green being less expressed and red highly expressed. The color map is organized so that
the rows represent the genotype (upper, wild-type SPT15; lower, mutant SPT15-300) and the columns represent the applied media (left, medium
A [20 g/liter glucose]; right, medium B [60 g/liter glucose, 5% ethanol]) (see yellow box). All genes except ADH2, ADH3, ADH5, and LEU4 are
significant (FDR of 0.005) for medium B. Genes for which expression is significantly changed by the genotype (wild-type versus SPT15-300) are
indicated with a single asterisk; those that are significantly altered by the genotype and medium are highlighted by a double asterisk. The LEU2
gene is deleted in the BY4741 strain. Abbreviations: ex. cell., extracellular; int. cell., intracellular.
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when expressed from plasmids that do not complement the
LEU2 mutation in BY4741 (i.e., URA3- or G418 selection-
based plasmids). This implies that the beneficial growth advan-
tage of cells expressing the SPT15-300 mutation is the result of
enhanced uptake and/or improved utilization of leucine.
The ethanol sensitivity of S. cerevisiae strains with single-
gene deletions (commonly leucine auxotrophic strains) has
been determined mainly in rich complex media (12, 16–18, 35,
37, 40). Therefore, a possible effect of ethanol on leucine
uptake and/or utilization has not been reported in these global
screens. However, impairment of amino acid transport and/or
utilization in yeast by ethanol has been described (11). Re-
cently, Hirasawa et al. reported that tryptophan uptake might
be inhibited by high concentrations of ethanol (16). Overex-
pression of TAT2, encoding a high-affinity tryptophan and ty-
rosine permease (30), yielded yeast cells that acquired a higher
tolerance toward ethanol (16). Likewise, the known growth
defect of S. cerevisiae leu2 strains (e.g., BY4741) on SC media
(8) could be alleviated by overexpression of TAT1 or BAP2
(both encoding amino acid permeases that transport leucine
[14, 30]) or by reintroducing LEU2 (8). Several studies have
demonstrated that the amount of leucine provided in com-
monly used synthetic media is limiting for growth of leucine-
requiring strains, and authors therefore recommend supple-
menting synthetic media with at least 400 mg leucine per liter
(6, 29).
Based on the growth phenotypes, we decided to reinvesti-
gate the microarray data published by Alper et al. (2), now
focusing on uptake and metabolism of leucine. Genes involved
in the uptake and degradation of leucine showed differential
expression due to the SPT15-300 mutations but also in the
presence of increased glucose and ethanol (medium B). The
TAT1 gene, which codes for a tyrosine and tryptophan amino
acid permease, and the BAP3 gene, which codes for a branched-
chain amino acid permease, showed increased expression in cells
with the mutant SPT15-300 allele in both media (i.e., media A
and B) compared to cells harboring the wild-type SPT15 (Fig.
4A). BAP2 (coding for another branched-chain amino acid per-
mease) showed a similar expression profile but was not signif-
icant at a FDR of 0.005. These three genes code for permease
proteins that are able to transport leucine across the plasma
membrane (14, 30), and increased expression of TAT1 and
BAP2 has been shown to alleviate reduced growth of BY4741
on SC media (8). A majority of the genes involved in leucine
utilization and degradation show statistically significant differ-
ential expression for the SPT15-300 mutations (a genotype
effect, i.e., an effect on gene expression when comparing cells
expressing the SPT15-300 allele to those expressing the wild-
type allele). ARO10, coding for one of the Ehrlich pathway
decarboxylases involved in leucine degradation, is signifi-
cantly upregulated both by the SPT15-300 mutations and by
the presence of increased glucose and ethanol (Fig. 4B)
(38). Additionally ADH3, ADH5, and SFA1, coding for al-
cohol dehydrogenases, show upregulated expression in the
SPT15-300 mutant compared to wild-type SPT15 cells, sug-
gesting that higher rates of NADH reoxidation via 3-methyl-
butanal reduction in the SPT15-300 mutant could account for
the increased fitness of cells with the SPT15-300 allele under
leucine-limiting conditions. Finally, genes involved in leucine
biosynthesis were downregulated by the presence of ethanol
(Fig. 4C). Expression of the ILV5 and LEU1 genes was only
slightly changed due to the presence of the SPT15-300 muta-
tions compared to wild-type SPT15 (genotype effect), though
the direction of the response was unchanged. As expected, the
LEU2 gene showed only background expression, while genes
coding for branched-chain amino acid aminotransferases, i.e.,
BAT1 and BAT2, showed inverse expression correlating with
the cells transitioning from logarithmic to growth-arrested
phase (10). It is therefore likely that the improved growth of
the SPT15-300 mutant under leucine-limiting conditions is due
to increased uptake and utilization of leucine (9, 28, 36).
Alper et al. (2) unambiguously demonstrated that gTME is
applicable to S. cerevisiae for altering its properties. Unfortu-
nately, the properties of cells with the mutant SPT15-300 allele
did not result in increased ethanol-tolerant phenotypes of yeast
in rich complex media, but the application of gTME has been
reported to improve xylose fermentation in S. cerevisiae (22).
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4.2 Perspectives
In the original publication of the SPT15-300 mutant the authors attempted to
identify the underlying genetic changes of the mutant using among others, a Sys-
tems Biology based approach including protein-protein interaction networks. S.
cerevisiae is one of the best characterized model organisms, with unparalleled
depth of protein-protein interaction knowledge, however the pertubations had very
large impact on cellular transcription, probably concealing the true underlying bi-
ology. Here we with the added information of additional laboratory experiments
were able to take a more directed approach analyzing the data at the level of
biological pathways.

Part III
Systems biology in disease
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Chapter 5
Alzheimer’s Disease - the ADIT
project
This chapter is about the work that we have performed as a part of the European
Union (EU) Framework Programme 6 (FP6) project: “Design of Small Molecule
Therapeutics for the Treatment of Alzheimer’s D isease Based on the Discovery
of I nnovative Drug Targets” (ADIT). It is one of three large integrated projects
from FP6 that spans from basic molecular and cellular understanding of the dis-
ease to the identification, validation and development of drug targets. The project
was launched in June 2005 with eight partners in several EU countries and Siena
Biotech S.p.A. in Italy as the coordinating partner. The project aims at identify-
ing novel drug targets for Alzheimer’s Disease (AD) and to develop small molecule
drugs targeting these. In this process we have been involved in identifying bi-
ological entities suitable for drug targeting part of creating the base for further
progress in the project. To do this we have performed gene expression profiling
using Affymetrix DNA microarrays on a rat AD model and used integrative ap-
proaches to understand the neuronal response.
The work presented in the following is unpublished but will, hopefully, be part
of future patent applications. Currently two targets from the gene expression
profiling have progressed to small molecule (hit and lead) identification and opti-
mization, and additional three targets have progressed to immunohistochemistry
in human post-mortem brain tissue. The chapter is organized with an introduction
to AD, a short discussion of the drug discovery process taken and a manuscript in
preparation covering the identification of ADAM23 as associated with AD.
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5.1 Introduction to Alzheimer’s Disease
Alzheimer’s Disease (AD) is the most common neurodegenerative disease and
causes dementia that leads to a progressive pattern of cognitive impairments [116].
It is named after the German researcher Dr. Alois Alzheimer that in 1906 pre-
sented the case of “Frau Auguste D.”, a patient that had developed an unusual
dementia at age 51. Here he described the main pathological hallmarks of AD, the
marked neurofibrillary tangles, widespread presence of plaques and neuronal degen-
eration [117]. The severe degree of degeneration in AD is obvious from Figure 5.1
where a brain from an AD patient is compared to a brain from a non-demented
person of similar age.
The disease consists of four clinical stages: Pre-dementia, early/mild dementia,
moderate dementia and severe dementia with an average survival after clinical
diagnosis of 5 to 8 years. Typically other diseases such as pneumonia followed
by myocardial infarctions and sepsis (a whole-body inflammation) is the cause of
death [116]. The clinical manifestations of AD begins from mild impairment in
acquiring new information (pre-state) to a rapid decline in cognitive abilities such
as memory, learning, language and reading resulting in changes of the personality
such as depression, delusion, restlessness, aggression and disorientation. The cog-
nitive decline has been described artistically by William Utermohlen (1933-2007)
which was diagnosed with Alzheimer’s Disease and decided to visualize the pro-
gression through self-portraits painted at different time points – gradually closer to
his death (see Figure 5.2) [118]. The character of the disease naturally sets a high
strain on the caretakers and family with high social and emotional impact [116].
The average annual costs of AD is estimated to US$80-100 billion and 55 billion
euro in the US and EU, respectively, resulting in a very high economical impact
on society. As AD occurs with an increasing rate in elderly people (∼4.5 million
total in the US and 42% in the population above 84 years of age) coupled with
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increasing life expectancy, AD threatens to become an even larger burden on so-
ciety [119–121].
Even though AD has been known for more than a century and been studied in-
tensively, e.g. a search for “Alzheimer’s Disease” on Pubmed retrieves more than
48.000 abstracts, no curative therapy exist [122]. There are four symptomatic
medications approved for AD that have two different modes of actions. Three
of the medications inhibit the breakdown of acetylcholine by the enzyme acetyl-
cholinesterase. This increases the concentration of acetylcholine in the brain which
counteracts the loss of this neurotransmitter caused by failing and dying choliner-
gic neurons [123]. The other type of treatment is based on the neurotransmitter
glutamate and is focused on the inhibition of NMDA receptors. Because gluta-
mate is such as powerful neurotransmitter too high concentrations can, via the
NMDA receptor, lead to excitotoxicity and neuronal death [124]. However the two
approaches, and a combination hereof, have shown only little curative effect and
in addition especially the acetylcholinesterase inhibitors are associated with side
effects [125,126]. There is therefore a high unmeet medical demand for medications
with curative effects on AD.
(a) 1996 (b) 1997 (c) 1997
(d) 1998 (e) 1999 (f) 2000
Figure 5.2 – Six self-portraits by the artist William Utermohlen 1933-2007 describ-
ing his gradual decent into the dementia of Alzheimer’s Disease.
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Genetics of Familial AD
In general AD can be categorized into two categories, one being Familial Alzheimer’s
Disease (FAD) and the other being Late-Onset Alzheimer’s Disease (LOAD). The
FAD form is caused by mutations in the amyloid beta (A4) precursor protein
(APP), presenilin 1 (PSEN1) or presenilin 2 (PSEN2) and is therefore inherited
- hence a familial form of AD. The disease phenotype is autosomal-dominant,
meaning that a heterozygous state of a mutation in any of these genes is enough
to cause disease. Additionally FAD is characterized by occurring before the age
of 60, but is a rare form of AD responsible for only a fraction (< 5%) of the total
amount of cases [127, 128]. Understanding the genetics of FAD and AD in gen-
eral sparked with the discovery that the Amyloid-β (Aβ) peptide, present in the
brain plaques of AD patients, was also found in Down syndrome patients [129].
The Amyloid Precursor Protein (APP) was cloned and it was discovered to be
located on chromosome 21, the same chromosomal area that is copied in Down
syndrome (trisomy 21) [130,131]. From this several mutations in the APP protein
was discovered in AD patients leading to the understanding that the Aβ peptide
is naturally occurring in the brain, but also that perturbations in the processing
of APP to Aβ may be at the core of the disease [132]. However this also added
new questions regarding AD as mutations in APP could only explain FAD and
not LOAD and additionally only 10% of the FAD cases had mutations in the APP
gene. This began further investigations of disease causing alleles for FAD and lead
to the identification of PSEN1 and PSEN2. These proteins are located at the
catalytic center of γ-secretase, one of the protein complexes involved in processing
of APP to Aβ [133,134]. To date all cases of autosomal dominant AD cases (FAD)
can be explained through Aβ [135].
Genetics of Late-Onset AD
On the contrary LOAD which comprises by far the majority of AD cases (>95%)
does not show obvious familial aggregation and is hence also termed sporadic
AD [136]. It occurs in patients older than 65 years of age and the risk of devel-
oping LOAD increases rapidly with age to almost 50% among those older than
85 [121]. The genetics of LOAD has proven more difficult to assess than FAD,
however it was discovered in 1993 that the 4 allele of Apolipoprotein E (APOE )
is a large risk factor for developing the disease [137–139]. In humans the APOE
gene exists in three different polymorphic alleles, 2, 3 and 4 with the 3 allele
being the most frequent one (77%). The 2 and 3 alleles are not associated with
Alzheimer’s disease, whereas the APOE -4 allele has been shown to be implicated
in more than 50% of LOAD cases [139]. Additionally gene dosage of this allele
increases the risk of developing the disease and minimizes the age of onset. This
was shown in a study by Corder et al. where 90% of the persons with this genotype
developed LOAD [137]. The APOE protein is involved in brain-cholesterol trans-
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port where APOE delivers cholesterol and other lipids from astrocytes to neurons.
Additionally it may be involved in signaling pathways with functionalities such
as neuronal migration and synaptic plasticity, and binding and trafficking of Aβ.
However the role of APOE in AD it is not completely understood [139].
Although the APOE -4 allele is a risk factor for developing LOAD, the iden-
tification of additional genetic risk factors have proven to be a challenging task.
Where the APOE locus has a large impact on the risk of developing LOAD, other
risk alleles are thought to have small penetrance. These alleles demand high sta-
tistical power to be identified, exemplified by the Genome-Wide Association Study
(GWAS) of Coon et al. where 1086 brain donors (664 AD cases, 422 controls) were
assayed for Single Nucleotide Polymorphisms (SNPs) associated with Alzheimer’s
Disease [136,140]. χ2-test for disease association revealed only one very significant
SNP1, which is in strong Linkage Disequilibrium (LD) with the APOE locus (Fig-
ure 5.3). However recently two very large studies of Harold et al. and Lambert
et al. both identify another apolipoprotein, clusterin (CLU), also know as APOJ,
as a risk factor for LOAD [10, 11]. Interestingly APOE and APOJ are the most
abundant apolipoproteins in the central nervous systems [141,142]. At the time of
writing 35 genes in total have been associated with LOAD [8].
In addition to the genetic component of LOAD, which is thought to comprise
60% or more of the disease susceptibility, environmental risk factors are also in-
volved [136, 143]. As previously mentioned, age is a large risk factor for AD, but
other factors such as long-term hypertension, diabetes and obesity, viral infections
and neuroinflammation, chronic stress and head injury have been associated with
the disease. On the contrary protective factors have also been described, among
them are intellectual stimulation and social interactions, regular physical activity
as well as vitamin and omega-3 fatty acid rich diets [144].
The amyloid hypothesis
During the development of Alzheimer’s Disease the pathological hallmarks neuron
degeneration, plaques and neurofibrillary tangles appear at different stages. Ex-
tracellular plaques that consists of mostly of Aβ and also cellular material are the
first to appear during the disease development with intracellular neurofibrillary
tangles (NFTs) consiting of hyperphosphorylated microtubule-associated protein
tau (MAPT) appearing downstream of these. The disease progression mainly
develops from the transentorhinal and entorhinal cortex, and hippocampal area
with plaques, NFTs and neuronal dysfunction and loss, spreading throughout the
cerebral cortex [145–147]. There have been many discussions regarding which of
these that are the primary disease causing effects [148, 149]. For example, it is
not well established how Aβ exerts toxic effects on neurons and the amount of
1Although in the study GAB2 was identified having weak association to LOAD when samples
were divided according to APOE -4 allele status
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Figure 5.3 – GWAS using the Affymetrix 500K GeneChip by Coon et al. [140].
-log10 to expected vs. observed p-values is shown from χ2 test of disease association
between cases and controls. The very significant SNP is in strong LD with the
APOE locus.
Aβ plaques does not correlate well with cognitive impairment. Although it has
been suggested that the amount of soluble oligomeric Aβ peptides correlate with
cognitive impairment this is still disputed [150, 151]. On the contrary NFTs cor-
relate well with cognitive impairment, and studies of Frontotemporal Dementia
and Parkinsonism linked to chromosome 17 (FTDP17) show that tau mutations
are sufficient to trigger neuronal degeneration [152]. However tau aberrations and
NFTs are thought to develop downstream in time of Aβ plaques as these are not
observed in in FTDP17 [149]. Issues like these are plenty-fold within the AD field,
underlining the complexity and the lack of thorough understanding of the disease.
Still the amyloid hypothesis is the most supported hypothesis for AD [148].
Generation of Aβ
Amyloid-β is generated from the processing of APP. APP is a transmembrane
protein expressed in a variety of cells in different isoforms, with the most abun-
dant form in the brain of 695 aa (APP695). The protein undergoes proteolytic
cleavage by either α- or β-secretases, and the resulting peptides from both pro-
cessing pathways are cleaved by γ-secretase (Figure 5.4). If APP is first cleaved by
α-secretase, the subsequent cleavage by γ-secretase results in the production of a
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Figure 5.4 – Different fates of APP upon proteolytic cleavage by α, β and γ
secretase. (Left) Intial cleavage by β secretase generates toxic Aβ species, whereas
(Right) initial cleavage by α secretase generates the non-toxic fragment P3.
non-toxic secreted peptide (P3). However if β-secretase is the first to cleave APP,
the additional cleavage by γ-secretase results in the generation of the toxic species,
Aβ40 and Aβ42 [145]. In addition to the above peptides, the α- and β-secretase
pathways also generates the sAPPα and sAPPβ peptides of which the latter can
be cleaved to the N-terminal APP peptide (N-APP) [153,154]. Furthermore from
both proteolytic pathways the APP IntraCellular Domain (AICD) is produced.
Regarding the secretases, α-secretases are members of the A Disintegrin And
Metalloprotease (ADAM) family where ADAM9, ADAM10, ADAM17 and ADAM19
have been associated to the cleavage of APP, whereas β-secretase has been defined
as beta-site APP-cleaving enzyme 1 (BACE1) [155–158]. γ-secretase is thought
to be composed of presenilins 1 or 2 (PSEN1/2), which as mentioned above are
among the genes involved in the development of Familial AD, nicastrin, Aph-1 and
Pen-2 [159].
Function of APP and derived peptides
The complete functionality of APP and its derived peptides is not completely un-
derstood, however it is suggested that APP processing controls signaling for mul-
tiple physiological functions. Processing via the α-secretase pathway the sAPPα
peptide is involved in promoting neuronal survival and neurite outgrowth [154,160].
On the contrary processing via BACE1 and hence the β pathway generates prod-
ucts that impair and deactivate neuronal function and viability. Long-Term-
Potentiation (LTP), which is the basis for inducing learning and memory is in-
hibited by nanomolar concentrations of oligomeric Aβ42 and it can trigger anti-
synaptic function. Generation of N-APP have recently been shown to induce axon
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Figure 5.5 – Drug development pipeline. Cost of the steps increases dramatically as
the candidates are progressed towards clinical evaluation and the market. Adapted
from [162].
pruning and neuron death by binding to death receptor 6 (DR6). It is important
to emphasize that even the “negative” functions of APP signaling are necessary
physiological behavior, e.g. to control precise neuronal connectivity (N-APP) and
to prevent over-excitation of neurons (Aβ42) [154]. To add to the complexity of
APP mediated signaling Puzzo et al. (2008) has shown that picomolar concentra-
tions of Aβ42 actually can enhance LTP, the opposite of nanomolar concentrations
of Aβ42 [161]. Additionally the AICD peptide, generated from both processing
pathways, can form a transcriptionally active complex with Fe65 and Tip60 [160].
5.2 Drug discovery in ADIT
The process of drug discovery and design can be described as beginning with iden-
tifying an unmeet need or by the discovery of a new disease, until the arrival of
a new drug. In the case of AD, the unmeet need is huge as no curative therapies
exist and as incidence correlates with increasing age. This is emphasized by the
many ongoing clinical trials for AD where, by the time of writing this thesis, at
least 11 drug candidates were in clinical phase II or III [163].
The initial step in drug development for a particular disease, is to establish the
targets involved in the pathology of the disease. In this project focus has been
on the traditional small molecule drug targets such as G-Protein-Coupled Recep-
tors (GPCRs), nuclear receptors, ligand- and voltage-gated ion channels [164,165].
These protein families are generally relatively easy to drug due to their function
and localization. Additionally proteins that require inhibition and not activation
has been preferred as it is more likely to design a small molecule that can block
the function of an enzyme or ion-channel, compared to increase the efficiency of a
protein that, by nature, is already very efficient. The latter may in some cases be
possible if an inhibitor of the protein can be targeted.
Identification of a gene target gives rise to target validation, which is the process
of gathering scientific information through either literature mining or experiments.
Several approaches have been applied for this, ranging from qPCR verifications to
immunohistochemistry in human post-mortem AD brains and AD transgenic mice
models. To functionally validate the role of a target, single-cell imaging in combi-
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Step Technology
Target identification Transcriptomics, Proteomics
Confirmation of differential expression qPCR
Non-experimental evaluation IP, Literature, AD focused pathways
Experimental evaluation (mRNA) Gene expression profile in human tissues panel and post-
mortem AD brains
Experimental evaluation (protein) Target analysis in AD transgenic animals and human post-
mortem AD brains
Functional validation Neuronal viability to Aβ by overexpression and silencing
Table 5.1 – Technologies used in target identification and validation in the ADIT
project.
nation with protein over-expression and RNAi has been used – all the techniques
that has been applied are summarized in Table 5.1.
When a target is validated as having a functional and drugable role screening
for chemical compounds begins. The approach for this is to use High-Throughput
Screening (HTS), where numerous chemical compounds from compound libraries
are tested for activity against the target. The hits that are identified do usually
only have some degree of activity and have to be further developed to lead can-
didates and lead series. For this several parameters has to be considered such as
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) proper-
ties, bioavailability and the Lipinski rule-of-five. Additionally the activity against
the drug target has to be optimized while reducing the activity against unrelated
targets to prevent side effects [166]. This, and other experiments, progresses the
lead candidates into one or few clinical candidates which are advanced through
clinical phases leading to a fully developed drug (Figure 5.5). As the cost of de-
veloping novel drugs increases dramatically while progressing through the drug
discovery pipeline, it is important to avoid continuation of non-optimal targets,
hits and leads. The average spending per chemical entity developed as a drug is
US$500-800 million [167].
5.3 Transcriptomics of Alzheimer’s Disease
The system used to model AD was primary cultures of rat cortical neurons treated
with Aβ peptides, which induces dendritic degeneration and apoptosis of the neu-
rons [168]. Previous studies utilizing this model have mainly focused on the late
events in the neuronal response whereas this approach aims at the early response.
These effects may contain more disease-relevant mechanisms than later stages – as
effects measured at late stages are likely to be secondary and tertiary effects.
The gene expression changes were investigated using the Affymetrix Gene Chip
Rat genome 230 2.0 arrays in a total of 6 experimental batches (Table 5.2). Several
forms of amyloid-β peptides exists and at least 18 different forms have been deter-
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mined in AD patients [169]. The, believed, most pathological relevant species are
Aβ1-42 and to a lesser degree Aβ1-40, however laboratory experiments using Aβ1-42
peptide is not trivial. Issues of formulation of the peptide and reproducibility of
the results have led to widespread use of the non-naturally occuring Aβ25-35 pep-
tide. Although an artificial truncated peptide, it has proven to give reproducible
results and to elicit neuronal toxicity and biochemical changes observed in animal
models and AD patients [170]. This peptide was therefore the primary peptide
applied in the experiments. The use of Aβ1-42 was attempted in batch 4, however
formulation of this peptide was later shown to be inaccurate and a re-formulated
version was assayed in batch 6.
5.4 Materials and methods
Primary neuronal cultures
Pure primary cortical cultures were prepared from E16 embryos of Sprague-Dawley
rat neocortex by mechanical dissociation and cultured in Neurobasal medium
supplemented with B27 (Invitrogen). All experiments were carried out accord-
ing to the ECC guidelines for animal care (DL 166/92, application of the Euro-
pean Communities Council Directive 86/609/EEC). Cultures were maintained in
a humidified incubator at 5% CO2 at 37
◦C and grown in 96-well plates (200 µl
medium/well). The stimulant (Aβ25-35, Aβ35-25, Aβ1-42 or Aβ42-1) was applied
for the indicated times (0, 45, 120, 180 or 240 min) at concentrations at 1, 10 or
50 µM. The Aβ peptides were rehydrated in sterile water and incubated for 2 h
at 37◦C to allow fibril formation prior to treating cells. RNA was extracted using
the RNAeasy Plus Mini Kit and RNA quality was verified by the use of Agilent
Bioanalyzer.
RNA extraction, microarray data generation and analysis
1 µg RNA per stimulation condition was converted into cDNA, and biotin-labeled
aRNA was synthesized using the MessageAmpTM II-Biotin Enhanced Kit (Am-
bion) according to the manufacturers instructions. The samples were hybridized
to Gene Chip Rat genome 230 2.0 Array (Affymetrix), comprising 31.000 probe
sets representing over 28.000 rat genes. The arrays were stained, washed and
scanned according to the manufacturer’s instructions. The data was analyzed us-
ing R and Bioconductor [171]. Raw probe intensities were normalized using qspline
and expression index calculations were performed using rma [78, 172]. Statistical
testing was performed using either t-test or anova and were performed using logit-
transformation and at probe-level [173]. The false discovery rate (FDR) [86] was
estimated using a Monte Carlo approach and used to determine statistical signifi-
cance.
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Batch Inoculates Concentration (µM) Replicates Timepoints (min) Arrays
1 control, Aβ25-35 50 3 0, 45, 240 9
2 control, Aβ25-35 50 3 0, 45, 240 8
3 control, Aβ25-35 50 3 0, 45, 120, 180, 240 13
4 control, Aβ25-35, Aβ1-42,
Aβ35-25
50 3 0, 45, 240 12
5 control, Aβ25-35 1, 10 3 0, 45, 240 18
6 control, Aβ25-35, Aβ1-42,
Aβ35-25, Aβ42-1
50 5 0, 240 30
All 90
Table 5.2 – Microarray experiments performed in the ADIT project
5.5 Results
Microarray data
The microarray experiments were performed from January 2006 (batch 1) to July
2008 (batch 6). Performing DNA microarray experiments over an extended period
of time will generate data biases due to changes in the experimental environment.
This is observed by Singular Value Decomposition of the data resulting in a clear
separation of batches in four clusters (Figure 5.6). Prior to batch 4, the experi-
ments had primarily investigated the reproducibility of batch 1 and attempted to
expand the time resolution by two time points of 120 and 180 minutes of stimu-
lation. For batch 4 a reversed peptide Aβ35-25 was applied to test the specificity
of the Aβ25-35 response and to eliminate genes responding to peptides in gen-
eral. Additionally, to compare the data generated from Aβ25-35, the pathological
Aβ1-42 peptide was applied, however the peptide formulation was later demon-
strated to be of unsure quality. Due to the inter-batch differences revealed from
the SVD, a reference data-set for use in target identification analyses was chosen.
For this benchmarking of each batch against four gene sets were performed, where
the gene sets was composed by AD genes from Metacore, genes co-occurencing
in PubMed abstract with “Alzheimer” or “Amyloid-β”, AD neuronal inflamma-
tion literature and proteins identified from phospho-proteomic approaches within
the ADIT project (Figure 5.7). As there were no major overall differences in the
performances and that batch 1 had already been extensively used for target iden-
tification this batch was chosen as the reference set. By selecting the reference set
we decided to investigate Aβ25-35 concentration response in batch 5.
For the last approach, batch 6, a new formulation of Aβ1-42 was used to attempt
to finish what had begun in batch 4 – comparing the truncated peptide with the
pathological one. A SVD of the data clearly reveal differences between the two
peptides, however the reversed Aβ42-1 show similar effects as the functional peptide
(Figure 5.6b). Again this emphasizes the value of Aβ25-35 in in vitro settings, where
the reversed Aβ35-25 elicits a response similar to saline control. Issues with non-
reproducible results and non-functional control experiments would not be limited
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Figure 5.6 – Singuar Value Decomposition (SVD) of microarray data. a. All DNA
microarrays experiments run in the ADIT project, each array is represented by the
batch number. b. Top 1000 ranked genes from ANOVA of batch 6 data. Arrays are
represented and colored by stimulant added. Control: cyan, Aβ25-35: red, Aβ35-25:
green, Aβ1-42: black, Aβ42-1: blue.
to the target identification approaches, but would additionally be a problem for
the functional validation assays.
5.6 Perspectives
Current status on drug discovery in the project is that lead molecules have been
identified for two targets and these are currently being progressed to lead devel-
opment. Additionally a third target is undergoing High-Throughput Screening to
identify small molecule hits. Two of the targets originates from the transcriptomic
approaches whereas a third target was identified from pre-existing knowledge. Ad-
ditionally it has not been possible to progress targets from proteomic approaches.
At the moment we are in the initial phases of setting up experiments for pro-
filing the transcriptional response of neurons when exposed to lead molecules and
known target antagonists in combination with Aβ. From these experiments we
hope to investigate the mode of action of the lead compounds and possibly iden-
tify side effects. Additionally a manuscript is in preparation for the discovery of
ADAM23, which is presented below.
5.7 Paper III
In this manuscript we have used a method originally devised for prioritization of
disease candidate genes within linkage intervals [15]. In this approach we prioritize
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Figure 5.7 – Fraction of benchmark set identified as a function of genes proposed
from batch 1–4 sorted by statistical significance. Batch 1–3 is based on Aβ25-35 treat-
ment whereas batch 4 is based on Aβ1-42 treatment. Batch 1: black striped, batch
2: red full, batch 3: green dotted, batch 4: blue striped and random performance:
black full.
the significant genes from the microarray study based on protein interactions and
the association of each protein in the resulting networks to Alzheimer’s Disease.
From this we identified A Disintegrin And Metalloprotease 23 (ADAM23) as highly
prioritized, and as co-localized and interacting with several core AD proteins.
Investigation of ADAM23 protein expression in human post-mortem brain tissue
of AD cases revealed it to be up regulated and localized in NeuroFibrillary Tangles
(NFTs), one of the pathological hallmarks of AD. However some of the experiments
in the project has not yet been performed and we are currently performing or
planning the following,
• Immunostaining has only been performed using one antibody (Anti-ADAM23
propetide domain – Abcam 28304) and there could be possible cross-reaction
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with ADAM22 propeptide domain. We are in the process of reproducing the
results with another antibody.
• Up regulation of ADAM23 in AD brain tissue is currently being tested us-
ing Western blotting analysis to allow for statistical evaluation of ADAM23
expression.
• We intend to investigate the expression of ADAM23 protein and its localiza-
tion pattern at different stages of AD development.
• Additionally we are considering to perform qPCR of RNA extracted from
post-mortem brain tissue to investigate if known splice variants are differ-
entially expressed. At least three different transcript variants have been
described for ADAM23, which differ in the C-terminal part [174].
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ADAM23 is associated with Alzheimer’s Disease in the
human brain
Simon Rasmussen1, David C. Hondius2, Jeroen J.M. Hoozemans2, Henrik
B. Nielsen1, and Søren Brunak1
1 Center for Biological Sequence Analysis, Department of Systems Biology,
Technical University of Denmark, DK-2800 Lyngby, Denmark
2 Department of Pathology, VU University Medical Center, Amsterdam, The
Netherlands
Abstract
Gene expression profiling, in combination with integrative protein-phenotype
data, was used to investigate the early response of rat cortical neurons to
amyloid-beta (Aβ25-35). From this A Disintegrin And Metalloprotease 23
(ADAM23) was identified as the only differentially regulated gene in an
interaction network of proteins associated with AD such as APOE, CLU,
APLP1/2 and APBB1. Using immunohistochemical staining of ADAM23
protein levels in post-mortem Alzheimer’s Disease brain tissue, ADAM23
was found to have increased expression in neurons of the temporal cortex.
The expression was observed as tangle-like staining suggesting that the in-
creased expression of ADAM23 protein is associated with neurofibrillary tan-
gles (NFTs) in human AD. However, as ADAM23 is normally localized at
the cell membrane in neurites, this suggests that the increased protein levels
does not confer to an increase of ADAM23 functionality. ADAM23 function-
ality is thought to be through its integrin binding domain in cell-extracellular
matrix signaling and to mediate axonal growth. Additionally ADAM23 has
been found to bind the cellular prion protein, which has recently been shown
to mediate Aβ inhibition of Long-Term Potentiation. From this we suggest
that ADAM23 is neuroprotective.
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5.8 Introduction
Alzheimer’s Disease (AD) is the most common neurodegenerative disease leading
to progressive cognitive impairment and dementia. AD pathology is characterized
by the major hallmarks, extracellular amyloid plaques and intracellular neurofibril-
lary tangles (NFTs). The most established hypothesis of AD pathogenesis is based
on the amyloid-beta (Aβ) peptide where imbalance in Aβ production and clear-
ance is hypothesized as the primary cause of AD [149,175]. The second hallmark,
NFTs primarily constitutes of aberrantly phosphorylated Microtubule-Associated
Protein Tau (MAPT), an important protein in the dynamics of the microtubules.
In AD, NFTs are primarily observed in neurons and their occurrence correlates well
with the severity of cognitive impairment [176, 177]. For Late-Onset Alzheimer’s
Disease (LOAD), which comprises by far the majority of AD cases, the epsilon-4
(4) allele of apolipoprotein E (APOE) has been identified as carrying a significant
part of the genetic heritability. Recently very large scale Genome-Wide Associa-
tion (GWA) studies have associated clusterin (CLU), another apolipoprotein, with
LOAD, however the majority of genes associated, except APOE, are characterized
by low penetrance [10,11,178].
To study AD, we employed primary cultures of rat cortical neurons treated with
Aβ peptides inducing dendritic degeneration and apoptosis of the neurons [168].
Using DNA microarrays and proteomic approaches this model has previously been
employed to characterize the molecular response of neurons to Aβ [179–182]. These
are mainly focused on late events whereas this approach aims at the early Aβ
response increasing the likelihood of discovering primary events in the neuronal
response [183].
A Disintegrin And Metalloprotease 23 (ADAM23) is a member of the ADAM
family of transmembrane proteins of which ADAM11, ADAM22 and ADAM23
are predominantly expressed in the nervous system and conserved in mammals
[184, 185]. Specifically ADAM23 is found highly expressed in the cerebral cor-
tex pyramidal cells, in the CA1 and CA3 pyramidal cells of the hippocampus
and cerebellar Purkinje cells [186–188]. The metalloprotease domain, which is a
characteristic feature of ADAM proteins seem to be inactive in ADAM23 and func-
tionality is thought to be mediated via the integrin binding domain. This domain
has been found to bind αvβ3 integrin of nervous cells promoting cell adhesion
and signaling [189,190]. Additionally ADAM23 has been found to mediate neurite
outgrowth as binding of LGI1 to ADAM23 in vitro stimulates neurite outgrowth
in hippocampal and cortical cultures [186]. Furthermore, a study by Costa et
al. (2009) showed that ADAM23 can bind via its integrin domain to the cellular
prion protein PrPC [191]. Mice devoid of ADAM23, die by postnatal day 14, show
less dendritic arborization in vivo and develop severe tremor and ataxia [186,192].
Other members of the ADAM family have been related to AD, such as ADAM9,
ADAM10, ADAM17 and ADAM19 which have been associated with α-secretase
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and cleavage of the amyloid precursor protein (APP), however ADAM23 has not
been associated with the disease before [155,157,158].
Here we use gene expression profiling of an Aβ rat model and a protein-
phenotype integrative approach to identify ADAM23 as differentially regulated
and part of a disease candidate complex interacting with core AD proteins. When
investigating ADAM23 expression in AD human post-mortem tissue we found in-
creased ADAM23 protein levels and that this is localized with NFTs in neurons.
5.9 Materials and Methods
Primary neuronal cultures
Pure primary cortical cultures were prepared from E16 embryos of Sprague-Dawley
rat neocortex by mechanical dissociation and cultured in Neurobasal medium
supplemented with B27 (Invitrogen). All experiments were carried out accord-
ing to the ECC guidelines for animal care (DL 166/92, application of the Euro-
pean Communities Council Directive 86/609/EEC). Cultures were maintained in
a humidified incubator at 5% CO2 at 37
◦C and grown in 96-well plates (200 µl
medium/well). The stimulant (Aβ25-35) was applied at a concentration of 50µM
and the neurons were incubated for 45 mins or 4 hours. The Aβ peptides were
rehydrated in sterile water and incubated for 2 h at 37◦C to allow fibril formation
prior to treating cells. RNA was extracted using the RNAeasy Plus Mini Kit and
RNA quality was verified by the use of Agilent Bioanalyzer.
RNA extraction, microarray data generation and analysis
1 µg RNA per stimulation condition was converted into cDNA, and biotin-labeled
aRNA was synthesized using the MessageAmpTM II-Biotin Enhanced Kit (Am-
bion) according to the manufacturers instructions. The samples were hybridized
to Gene Chip Rat genome 230 2.0 Array (Affymetrix), comprising 31.000 probe
sets representing over 28.000 rat transcripts. The arrays were stained, washed
and scanned according to the manufacturer’s instructions. The data was analyzed
using R and Bioconductor [171]. Raw probe intensities were normalized using qs-
pline and expression index calculations were performed using rma [78, 172]. The
false discovery rate (FDR) [86] was estimated using a Monte Carlo approach, and
statistical significance was set at an FDR < 0.01 and absolute fold change of log2
> 0.5. Only rat genes with human ortholog genes/proteins (Ensembl) were con-
sidered resulting in 121 human orthologs for further analysis. The microarray data
is available at the Gene Expression Omnibus (GEO) database as GSE0000.
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Phenotype association
Phenotype analysis was essentially performed as Lage et al. except human or-
thologs identified from the micrarray analysis were used as input rather than link-
age intervals [15]. In short, for each input gene a virtual pull-down of protein-
protein interactions is made. This protein interaction data consist of a pool
from seven of the largest databases on human interactions and additionally in-
ferred inter-species model organism data, resulting in a network of ∼62.000 high-
confidence interactions. The virtual pull-down is performed by a Bayesian predic-
tor ensuring only high-confidence and interactions supported by network topology,
literature, reliable small-scale interaction experiments or a combination of these.
Next, for each of the proteins in the network, termed candidate complexes, similar-
ity to Alzheimer’s Disease is calculated based on text-mining of Online Mendelian
Inheritance in Man (OMIM) records. This score is a measure of phenotypic overlap
between phenotypes associated with the proteins in the candidate complexes and
Alzheimer’s Disease. The OMIMs considered were AD1-14 and Amyloid beta A4
precursor protein, AD susceptibility to mitochondrial and AD familial early-onset,
with coexisting amyloid and prion pathology (OMIMs: 104300, 104310, 607822,
606889, 602096, 605526, 606187, 607116, 608907, 609636, 609790, 611073, 611152,
611154, 104760, 502500, 605055). Lastly a second Bayesian predictor scores the
candidate complexes by the phenotypes associated with the complex and they are
ranked according to how likely the protein complex is involved in Alzheimer’s Dis-
ease of all input genes considered. The sum of all posterior probabilities of adds
to 1 [15]. Clustering of phenotype similarity (OMIMs) were done using the cosine
similarity scores as a distance measure using hierarchical clustering in R.
Human post-mortem brain tissue
Human brain specimens of probable AD, other dementias and age-matched non-
demented control cases were obtained at autopsy with a short post mortem interval
(The Netherlands Brain Bank, Amsterdam, The Netherlands). Clinical diagnosis
was defined according to DSM-III-R criteria and the severity of dementia was
evaluated according to the Global Deterioration Scale of Reisberg (GDS) [193].
Neuropathological evaluation was performed on formalin fixed, paraffin embedded
tissue from different sites, including the frontal cortex (F2), temporal pole cortex,
parietal cortex (superior and inferior lobule), occipital pole cortex and the hip-
pocampus (essentially CA1 and entorhinal area of the parahippocampal gyrus).
The distribution and the density of neurofibrillary tangles was determined using
Bodian staining and immunohistochemistry for hyperphosphorylated tau. Senile
plaques were stained with the methenamine silver method [194]. Staging of AD
was evaluated according to Braak and Braak [147,195].
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Immunohistochemistry of brain tissue
Sections from the temporal cortex (5 µm thick) were mounted on superfrost plus
tissue slides (Menzel-Gla¨ser, Germany) and dried overnight at 37◦C. For all stain-
ings sections were deparaffinised and subsequently immersed in 0.3% H2O2 in
methanol for 30 min to quench endogenous peroxidase activity. Normal sera and
antibodies were dissolved in phosphate-buffered saline (PBS) containing 1% (w/v)
bovine serum albumin (BSA, Boehringer Mannheim, Germany). Sections were
treated in 10 mM pH 6.0 sodium citrate buffer heated by autoclave during 10
minutes for antigen retrieval. For the detection of ADAM23 sections were in-
cubated overnight at 4◦C with rabbit anti-ADAM23 (1:1600 dilution, Abcam).
After washing with PBS sections were incubated with EnVision solution (goat
anti-mouse/rabbit HRP, undiluted, DAKO, Glostrup, Denmark). Color was de-
veloped using 3,3’-diaminobenzidine (DAB, EnVision Detection system/HRP, 1:50
dilution, DAKO, 10 minutes) as chromogen. Sections were counterstained with
hematoxylin and mounted using Depex (BDH Laboratories Supplies, Poole, Eng-
land).
5.10 Results
Phenotype association identifies ADAM23 candidate complex
Investigating the response of rat cortical neurons stimulated with Aβ25-35 for 45
minutes or 4 hours revealed 121 significantly regulated genes that could be mapped
to a human ortholog. These were used as input for the phenotype association study
where candidate protein complexes were generated for 112 of the input genes. Each
of the proteins in the complexes are linked to their corresponding phenotypes and
assessed for similarity to Alzheimer’s Disease phenotypes. This yields posterior
probabilities of the input genes being involved in AD for the 112 candidate protein
complexes times the 17 phenotypes (Figure 5.8a). For 12 of the 17 phenotypes, the
protein complex generated by the ADAM23 input gene has high scoring posterior
probabilities. As the AD OMIMs aim at describing the Alzheimer’s Disease pheno-
types – albeit slightly different phenotypes – they are not completely independent
from each other. By clustering the pair-wise cosine similarity scores distinct clus-
ters are formed where the candidate complex derived from ADAM23 is the top
scoring candidate complex in all clusters except one (Figure 5.8b). Only two other
candidate complexes, created from cAMP-dependent protein kinase catalytic sub-
unit beta (PRKACB) and beta-sarcoglycan (SGCB), have posterior probabilities
greater than 0.2.
The candidate complex generated from ADAM23 (Figure 5.9), contains pro-
teins that are associated with the amyloid hypothesis such as Apolipoprotein E
(APOE), amyloid precursor protein binding B1 (APBB1 / Fe65), APP-like protein
1 and 2 (APLP1/2) and the prion protein (PRNP). Additionally clusterin (CLU),
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Figure 5.8 – a. Posterior probabilities of Bayesian predictor for phenotype associ-
ation between significant genes from the microarray experiment and 17 Alzheimer’s
disease OMIM records. ADAM23 candidate complex posterior probabilities are
shown in red. b. Hierarchical clustering of OMIM record cosine similarity scores
showing that the OMIMs are not independent of each other.
which has been found in two recent genome-wide association studies to be associ-
ated with AD [10, 11], is also identified in the complex. The interactions in this
part of the network are from a study of Schmitt-Ulms et al. (2004) investigating
the lipid-raft membrane micro-enviroment of the prion protein in mice [196]. These
can therefore not be strictly defined as observations of protein-protein binding, but
rather co-localizations and putative protein-protein binding. However ADAM23
has recently been shown to physically bind the cellular prion protein (PrPC) and
to function as a receptor for LGI1, a secreted protein associated with forms of
epilepsy [186, 191]. Additional proteins with phenotype similarities with Familial
AD (AD1: 104300) in the protein network are L1CAM and RYR1. L1CAM is a
neural recognition molecule involved in axonal growth and mutations in L1CAM
are responsible for X-linked hydrocephalus, whereas the latter, RYR1 is a sar-
coplasmatic/endoplasmatic reticulum Ca2+ release channel expressed in muscle
and brain [197,198].
ADAM23 was in the microarray experiment found to be down regulated by
log2 -0.5, whereas none of the other genes coding for the proteins in the ADAM23
candidate complex were significantly regulated (data not shown).
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Figure 5.9 – ADAM23 candidate complex where each node is a protein and edge an
interaction. The proteins are colored according to phenotype similarity to Familial
AD (AD1: 104300), where white: no similarity, green: similar, yellow: highly similar
and red: identical. An interaction between YWHAZ and ADAM23 was removed as
it was not supported in the literature and the recent published interaction between
ADAM23 and LGI1 was added [186].
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a b c
Figure 5.10 – Immunohistochemistry of ADAM23 in AD and control tissue. a.
ADAM23 staining in the temporal cortex of a non-demented age-matched control
case. b. The temporal cortex of an AD case, showing tangle-like (arrow) staining
of ADAM23. c. As b, but at greater magnification.
Immunohistochemistry of ADAM23 in human AD brains
Investigation of ADAM23 protein levels in human post-mortem brain tissue re-
vealed increased expression of ADAM23 in AD brain tissue compared to non-
demented age-matched control cases (Figure 5.10). Staining of ADAM23 revealed
intracellular tangle-like structures in neurons indicating that increased levels of
ADAM23 protein is localized in neurofibrillary tangles. In addition, a diffuse cy-
toplasmic staining of ADAM23 was observed in both AD and control cases (not
shown). This is in good agreement with the findings of Goldsmith et al. (2004)
which identified a small cytoplasmic fraction of ADAM23 in healthy rat brain neu-
rons [188]. (To add: We are performing Western Blotting experiments quantifying
the differences statistically).
5.11 Discussion
Using a well-established in vitro rat model of Aβ induced neuro-toxicity we iden-
tified several differentially regulated genes. By applying a protein-phenotype inte-
grative approach to these data ADAM23 was identified as the only differentially
regulated gene in a protein interaction network based on membrane co-localization
and putative interaction with AD-associated proteins APOE, APBB1, APLP1/2
and CLU. Additionally PrPC and LGI1 are identified as part of the network.
ADAM23 has not previously been associated with AD and we therefore investi-
gated protein expression level in the temporal cortex of AD human post-mortem
brain tissue. On the contrary of what could have been expected from the transcrip-
tomics data, the immunohistochemistry demonstrated increased levels of ADAM23
staining of AD cases compared to non-demented control cases. The discrepancy
could be explained by the different conditions of the two systems such as the organ-
isms studied, Aβ species, concentration of Aβ and by applying an in vitro system
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for studying complex tissue and disease. One may speculate that the decrease in
the in vitro system reflects an early/fast response. The increase observed in post
mortem brain tissue could be due to post-transcriptional events such as alterna-
tive splicing, increased translation or decreased removal. However the important
finding is that ADAM23 is the only differentially regulated transcript in an early
response to Aβ of several core AD related genes.
The immunohistochemistry of ADAM23 revealed a tangle-like staining sug-
gesting that the increased protein levels of ADAM23 in AD brains is localized in
neurofibrillary tangles. This indicates that the increased expression of ADAM23
does not confer to an up regulation of ADAM23 functionality, rather retainment in
the cytosol, compared to normal membrane bound localization in neurites, would
correspond to non-functional ADAM23. An explanation for the association with
NFTs, could be that the aggregation of tau and the dysfunction of the microtubule
system might impair transport and correct docking of ADAM23 along the axons of
the neurons [176]. As the functionalities of ADAM23 is as a regulator of neuronal
growth, cell differentiation and integrin contact between cells and the extracellu-
lar matrix this can be expected to have detrimental effects on neuronal viability
and signaling. This and the finding that ADAM23 transcript is down regulated
as an early response of neurons to Aβ suggests that ADAM23 is neuroprotective.
Increased expression of ADAM23 protein in AD could be a survival response of
the neurons.
Interestingly ADAM23 has recently been shown to co-localize and bind to the
cellular prion protein (PrPC), which mediates brain derived Aβ inhibition of Long-
Term Potentiation (LTP) in hippocampal CA3 and CA1 pyramidal cells [191,199].
Additionally PrPC has been identified as an inhibitor of β-secretase cleavage of
APP and shown to reduce Aβ formation, and other members of the ADAM pro-
tein family, ADAM10 and ADAM17, has been shown to process PrPC [200, 201].
Overlapping functionality between ADAM23 and PrPC such as involvement in
axonal growth, cell adhesion and cell-matrix adhesion and the identification of
ADAM23 and PrPC as molecular binders implicate ADAM23 as functionally linked
to PrPC [202–204]. Whether ADAM23 can influence the activity or processing of
PrPC remains to be seen, however the loss of function of ADAM23 could be im-
portant for the role of PrPC in AD.
Interactions between ADAM23 and the other proteins identified in the candi-
date complex provide additional interesting links to AD. The 4 allele of APOE
compose the largest genetic risk factor for LOAD and recently CLU, another
apolipoprotein has been associated with the disease. Interestingly APOE was
originally associated with AD when it was identified as localized with NFTs be-
fore genetic studies identified the 4 allele as a risk factor for LOAD [205]. However
currently no physical interaction has been shown between ADAM23 and these.
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5.12 Conclusion
Using gene expression profiling and integration with protein-phenotype interac-
tion data ADAM23 is identified as member of a network consisting of core AD-
associated proteins. Immunohistological staining of human post-mortem brain
tissue revealed that ADAM23 protein levels are significantly increased in AD tis-
sue compared to non-demented control. The functionality of ADAM23 as involved
in signaling and neurite outgrowth suggests that stressed neurons could benefit
from increased ADAM23 levels, however localization with NFTs implicate that
ADAM23 functionality is not effectively increased. The physical interaction be-
tween ADAM23 and PrPC may suggest a role of ADAM23 in regulating PrPC
activity and hereby Aβ production or Aβ toxicity. The co-localization in lipid
rafts with other core AD proteins such as APOE and CLU may provide interest-
ing alternative pathways to consider.
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Chapter 6
Probiotic bacteria and human
health
Microorganisms use many strategies for avoiding the immune system. Of particular
interest in this study is the scheme of inducing an intracellular focused response
(viral) as an extra-cellular organism. In the case of Lactobacillus acidophilus, which
is considered beneficial to human health (probiotic), it has been shown in clinical
trials to reduce the risk of viral infections [206–208]. In the light of the current
(H1N1) and future influenza epidemics this may prove valuable. In the study we
investigate the mechanism by which this can occur and show that it is primarily
mediated by Toll-Like Receptor 2 (TLR2).
6.1 Introduction to the relevant immunology
The immune system is highly complex and this prompted my previous professor
in immunology, Ib Søndergaard, to say,
“You do not understand anything of immunology, until you
understand all of immunology.”
Here I will nonetheless try to give a short overview with relation to the topic
studied in this paper. Immunology may be divided into two categories – the innate
which is non-specific and the adaptive which is specific and can acquire memory.
Additionally the adaptive immune system can be divided into two subsystems, the
humoral and the cellular immunity. The former is mediated by B cells and plasma
cells through antibodies, whereas the latter is mediated by T cells.
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Innate Immunity
The first line of defence against infections is the innate immune system, which is
comprised of a set of barriers that the pathogen must cross. First, the anatomic
barriers (skin and mucous membranes) prevent entry of microbes into the host
organism by acting as mechanical barriers as well as creating a hostile environment
for the microbes. Next, physiologic barriers such as temperature and pH are an
array of defences that the body employ. However once inside the host, pathogens
have to deal with phagocytic barriers - cells such as monocytes, tissue macrophages,
dendritic cell and neutrophils which ingest and kill foreign microorganisms. Finally
there are inflammatory barriers where tissue damage and detection of pathogens
results in an influx of phagocytic cells as well as vascular fluid containing anti-
bacterial serum proteins into the affected area.
Innate and adaptive immunity are closely associated. An example of this is
that phagocytic cells are vital for the initiation of an adaptive immune response.
Additionally, many signaling cytokines are released during an adaptive response
affecting the innate immune system. During antigenic challenge both the innate
and the adaptive immune systems work together to eliminate the pathogen [209].
Adaptive Immunity
The adaptive immune response reacts to specific foreign microorganisms or mo-
lecules. This response is very specific, and can differentiate between very subtle
differences in protein structure. Accordingly, the immune system is capable of
generating an enormous amount of different recognition molecules to be able to
recognize unique structures on antigens. When the immune system has responded
to a pathogen, immunological memory is generated, resulting in a faster and more
efficient response should the pathogen be re-encountered. This attribute of the
adaptive immunity can confer life-long immunity against many diseases and is the
reason for vaccination. The most important cells in the adaptive immune response
are the B-lymphocytes, the T-lymphocytes and the antigen-presenting cells [209].
Dendritic Cells
Dendritic Cells (DCs) exist throughout the body as immature DCs in tissue where
they may locate antigen. They are a part of the innate immune system but has an
important role in triggering the adaptive immune system. Immature DCs specialize
in using a variety of membrane receptors to capture protein antigens and process
them to form MHC-peptide complexes. Various stimuli, such as tissue damage,
inflammatory mediators, microorganisms, and chemokines, cause DCs to mature
and migrate out of the nonlymphoid tissues into the blood and lymph system to
present the antigen to T-cells and Natural Killer (NK) cells. Both macrophages
6.2. PAPER IV 91
and DCs express proteins that recognize particular microbial molecules, known as
Pattern Recognition Receptors (PRR). An important group of PRRs is called Toll-
Like Receptors (TLRs) which recognize lipoproteins, polysaccharides, peptides and
nucleic-acids and are important for initiating an appropriate immune response
[210].
6.2 Paper IV
For this manuscript a time series of microarray experiments were performed, in
an exploratory attempt, to investigate DC maturation when stimulated with the
probiotic bacteria L. acidophilus NCFM. DCs were stimulated for 4, 10 or 18 hours
allowing time-resolved investigation corresponding to early, intermediate and late
stages of maturation. However the transformation from immature DCs to mature
DCs corresponds to a large change in cell phenotype, which is reflected by the
number of genes differentially expressed. Using an ANOVA >3300 genes were
significantly differentially expressed (at FDR = 0) compared to non-stimulated
immature DCs, which is an overwhelming number to consider for analysis. To
provide a starting point for downstream analysis we clustered gene expression
data using PAM clustering and used these for GO term enrichment. This revealed
that genes involved in generating a viral response were among the highest up
regulated genes and our collaborators therefore initiated laboratory experiments
investigating the mechanism by which this could occur. The work is an example
of transcriptomics data being used for data-driven hypothesis generation.
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Abstract
Lactobacilli are probiotics that, among other health promoting effects,
have been ascribed immunostimulating and virus preventive properties. Cer-
tain Lactobacillus spp. have been shown to possess strong IL-12 inducing
properties. As IL-12 production depends on the up-regulation of type I inter-
ferons (IFN), we hypothesized that the strong IL-12 inducing capacity of Lac-
tobacillus acidophilus NCFM in murine bone marrow derived dendritic cells
(DC) is caused by an up-regulation of IFN-β, which subsequently induces
IL-12 and the dsRNA binding toll like receptor (TLR)-3. The expression of
the genes encoding IFN-β, TLR-3, IL-12 and IL-10 in DC upon stimulation
with L. acidophilus NCFM was determined. L. acidophilus NCFM induced a
much stronger expression of Ifn-β, Il-12 and Il-10 compared to the synthetic
dsRNA ligand Poly I:C, whereas the levels of expressed Tlr-3 were similar.
Whole genome microarray gene expression analysis revealed that other genes
related to the viral defense were significantly up-regulated and among the
strongest induced genes in DC stimulated with L. acidophilus NCFM. The
ability to induce IFN-β was also detected in another L. acidophilus strain
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(X37), but was not a property of other probiotic strains tested i.e. Bifidobac-
terium bifidum Z9 and Escherichia coli Nissle 1917. The IFN-β expression
was markedly reduced in TLR-2 -/- DC, dependent on endocytosis, and the
major cause of the induction of Il-12 and Tlr-3 in L. acidophilus NCFM
stimulated DC. Collectively, our results reveal that certain lactobacilli trig-
ger the expression of viral defense genes in DC in a TLR-2 manner depended
on IFN-β.
6.3 Introduction
Lactic acid bacteria (LAB) are inhabitants of the gastrointestinal (GI) tract, and
some species are considered to have probiotic properties offering a number of bene-
fits to health and well being [211–213]. Some probiotics have been shown to reduce
the risk of virus infections such as the common cold and influenza [206–208]. So
far, the mechanisms causing the reductions in respiratory tract infections and
other symptoms are unknown. It is likely that these positive effects are due to
the ability of probiotics to modulate immune stimulatory responses upon interac-
tion with dendritic cells (DC). DC are central gatekeepers and regulators of the
immune response interacting with mucosally encountered antigens, including the
gut microbiota and viruses. The innate immune cell activation occurs predomi-
nantly through the interaction of TLRs and other pathogen recognition receptors
on the surfaces of antigen presenting cells [214]. Exposure to microorganisms in-
duces up-regulation of surface markers and the production of several cytokines
that modulate the function of DC [215]. Probiotics exert differential stimulatory
effects on DC in vitro, giving rise to varying production of different cytokines and
accordingly different effector functions [216, 217]. Members of the lactobacillus
and bifidobacterium genera are well-recognized for their probiotic properties, but
also certain other bacteria, including some Escherichia coli strains, have shown to
exert probiotic features.
Upon viral infection, type I interferons (IFN), cytokines with anti-viral and
immune-regulatory functions, are produced. Toll-like receptors (TLRs) of DC
have emerged as key transducers of type I IFN during viral infections [218]. TLR-
3, a receptor localized in the endosomal compartment, recognizes dsRNA motifs of
viruses and Poly I:C (a synthetic dsRNA), and induces the transcription of type I
IFNs (IFN-β and IFN-β) [219,220]. Type I IFNs exert their antiviral function by
binding specifically to a unique receptor (IFNAR), thereby initiating a signaling
cascade that controls the expression of hundreds of interferon-stimulated genes
(ISGs) and other genes involved in an innate host response against viruses [221].
Type I IFNs, although best known for their antiviral properties, are potent reg-
ulators of cell growth and can modulate both innate and adaptive immune re-
sponses. Synthesis of type I IFNs was originally associated with viral infections,
however, many pathogenic bacteria are equally able to induce the up-regulation of
type I IFN, leading to modulation of the innate antibacterial response [222]. Sev-
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eral Gram-negative bacteria, such as Salmonella enterica Serovar Typhimurium,
Shigella flexneri and Escherichia spp., stimulate type I IFN synthesis in phago-
cytosing cells [222]. Recently, pathogenic Gram-positive bacteria, such as group
A and B Streptococcus spp. [223–225], Listeria monocytogenes [226, 227], and the
spirochetal bacterium Borrelia burgdorferi [228] were likewise reported to induce
the production of high quantities of type I IFN during infection. Manusco et
al. [225] reported that the production of type I IFNs was critical for the clear-
ance of infection by the host. In relation to intracellular bacteria, in particular
TLR-3, TLR-7 and TLR-9 are involved in the type I IFN induction [229], whereas
in connection with other bacteria, TLRs and other pathogen recognition recep-
tors on the cell surface are of particular importance. However, no clear picture
of which receptors are involved exists or which role these receptors play in the
bacterial induced of IFN-β production. For Streptococcus spp. and Listeria spp.,
the intracellular located TLR-9 was essential for the induction of IFN-β in in vitro
stimulated monocytes or DC [223, 227]. In Borrelia burgdorferi, the induction
of IFN-β was independent of TLR-2 [228]. Only for the Gram negative Pseu-
domonas auroginosa, a role of TLR-2 has been suggested in the induction of a
pro-inflammatory response in human monocytes [230]. It was demonstrated that
a TLR-2 and mannose receptor synergistically were involved in the induction of
the cytokines TNF-α, IL-6 and IL-1β. However, IFN-β was not included in the
study. To our knowledge, neither lactic acid bacteria nor commensal bacteria have
the capability to induce IFN-β in DC upon stimulation.
TLR-mediated IL-12p70 synthesis has been reported to be strongly reduced
in the absence of type I IFN [231], demonstrating a critical role of type I IFN in
controlling the production of the pro-inflammatory cytokine IL-12p70. We have
previously reported that certain members of the Lactobacillus genus, including
L. acidophilus, demonstrated remarkable IL-12 inducing properties [232]. On ac-
count of these observations, we hypothesized that L. acidophilus, despite its non-
pathogenic phenotype and health promoting properties, is able to induce IFN-β
production in DC and consequently help mature DC into anti-virus phenotype
cells.
The aim of this study was to investigate whether L. acidophilus has the abil-
ity to induce the anti-viral defense gene expression in DC. We analyzed the gene
expression profile of TLR-3 and IFN-β, key players involved in viral defense, in
murine bone marrow derived DC in vitro stimulated with L. acidophilus NCFM.
Genome wide microarray analysis confirmed our hypothesis showing a general,
significant up-regulation of anti-viral defense genes. The IFN-β inducing prop-
erty was likewise detected in another L. acidophilus strain, but not in a probiotic
bifido or E. coli strain. This ability to induce IFN-β was dependent on TLR-2
recognition and required phagocytic activity in the DC. Our results reveal that, in
contrast to Poly I:C, the expression of Tlr-3 in L. acidophilus stimulated DC was
dependent on the production of IFN-β. This study is the first to report that L.
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acidophilus NCFM, a widely used probiotic bacterium, is able to induce the viral
defense in murine bone marrow derived DC.
6.4 Materials and Methods
Bacterial strains, growth conditions and preparation of
UV-killed bacteria
Lactobacillus acidophilus NCFM (Danisco, Copenhagen, Denmark), L. acidophilus
X37 (Copenhagen University, Department of Food Microbiology, Faculty of Life
Sciences, Denmark), Bifidobacterium bifidum Z9 (Copenhagen University, Depart-
ment of Food Microbiology, Faculty of Life Sciences, Denmark), which are all
considered to have probiotic properties, were grown anaerobically overnight at 37
◦C in de Man Rogosa Sharp (MRS) broth (Merck, Darmstadt, Germany) and sub-
cultured twice. Cells were harvested by centrifugation at 2,000 x g for 15 min,
washed twice in phosphate-buffered saline (PBS, Bio Whittaker, East Rutherford,
NJ, USA) and resuspended in 1/10 the growth volume of PBS. The bacteria were
killed by 20 min exposure to UV light. Escherichia coli Nissle 1917 O6:K5:H1
(Statens Serum Institut, Copenhagen, Denmark), a Gram negative probiotic bac-
terium, was grown aerobically overnight at 37 ◦C in Luria-Bertani (LB) broth
(Merck) and killed by a 45 min exposure to UV-light. The bacteria were stored at
-80 ◦C, the concentration was determined as the content of dry matter per ml upon
lyophilisation, and the dry weight was corrected for buffer salt content. Absence
of viable cells was verified by plating the UV-exposed bacteria on MRS and LB
agar.
Generation of murine dendritic cells
Bone marrow-derived dendritic cells (DC) were prepared as previously described
[216]. Briefly, bone marrow from wild type (WT) or TLR-2-/- knock out C57BL/6
mice was flushed out from the femur and tibia and washed twice in sterile PBS.
3×105 bone marrow cells were seeded into Petri dishes in 10 ml RPMI 1640 (Sigma-
Aldrich, St. Louis, MO) containing 10% (v/v) heat-inactivated fetal calf serum
supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), glutamine
(4 mM), 50 µm 2-mercaptoethanol (all purchased from Cambrex Bio Whittaker)
and 15 ng/ml murine GM-CSF (harvested from a GM-CSF transfected Ag8.653
myeloma cell line). The cells were incubated for 8 days at 37 ◦C in 5 % CO2
humidified atmosphere. On day 3, 10 ml of complete medium containing 15 ng/ml
GM-CSF was added. On day 6, 10 ml were removed and replaced by fresh medium.
Non-adherent immature DC were harvested on day 8.
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Stimulation of murine dendritic cells with bacteria
Immature DC (2× 106 cells/ml) were resuspended in fresh medium supplemented
with 10 ng/ml GM-CSF, and 500 µl/well were seeded in 48-well tissue culture
plates (Nunc, Roskilde, Denmark). The stimuli were suspended in medium and
added (100 µl/well) in a final concentration of 10 µg/ml (L. acidophilus NCFM, L.
acidophilus X37 and E. coli Nissle 1917) and 40 µg/ml (B. bifidum Z9). Optimal
bacterial concentrations were determined in a previous study [232]. As a positive
control, Poly I:C (InvivoGen, San Diego, CA, USA), a synthetic analog of dsRNA,
was added in a final concentration of 10 µg/ml. The cell cultures were incubated
at 37 ◦C in 5 % CO2.
Immunstaining and flow cytometry
DC were harvested and resuspended in cold PBS containing 1 % (v/v) fetal bovine
serum and 0.15 % (w/v) sodium azide (PBS-Az) containing anti-mouse FcγRII/III
(3 µg/ml, BD Biosciences, San Jose, CA, USA) to block non-specific binding of
antibody reagents. The cells were stained with phycoerythrin (PE)-conjugated
anti-mouse MHCII, allophycocyanin (APC)-conjugated anti-mouse CD86, PE-
conjugated anti-mouse CD11c (Southern Biotech, Birmingham, AL). Analysis was
performed using BD FACSarray flow cytometer (BD Biosciences) based on count-
ing 10.000 cells. The geometric mean fluorescence intensity (MFI) was determined
representing the level of expression.
Effect of endocytic activity during stimulation
DC were pre-treated with cytochalasin D (0.5 µg/ml), chlorpromazine (25 µg/ml),
methyl-β-cyclodextrin (1 mM) (Sigma-Aldrich), or medium alone for 1 h at 37 ◦C
in 5 % CO2 prior to addition of L. acidophilus NCFM (10 µg/ml) or Poly I:C (10
µg/ml) as previously described [233]. The cells were harvested after 3 h incubation
at 37 ◦C in 5 % CO2, and RNA was extracted.
IFN-β inhibition assay
Mouse IFN-β polyclonal antibody (R&D Systems, Minneapolis, USA) was added
to the DC in different concentrations (0.01 µg/ml, 1 µg/ml, 10 µg/ml and 50
µg/ml) immediately after addition of L. acidophilus NCFM (10 µg/ml). The cells
were harvested after 10 h of stimulation at 37 ◦C in 5 % CO2, and RNA was
extracted.
RNA extraction
Murine DC were harvested at various stimulation time points, homogenised by
QIAshredder (Qiagen, Ballerup, Denmark), and RNA was extracted using the
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RNeasy Plus Mini Kit (Qiagen). RNA quality was verified by Bioanalyzer (Agilent,
Santa Clara, USA), and the concentration was determined by Nanodrop (Thermo,
Wilmington, USA).
Microarray analysis
Immature DC from three C57BL/6 mice were stimulated with L. acidophilus
NCFM, and DC cells were harvested after 4 h, 10 h and 18 h. RNA was extracted,
1 µg RNA per stimulation condition was converted into cDNA, and biotin-labeled
aRNA was synthesized using the MessageAmpTM II-Biotin Enhanced Kit (Am-
bion, Austin, TX, USA) according to the manufacturers instructions. The aRNA
samples were hybridized to Gene Chip Mouse genome 430 2.0 Array (Affymetrix,
Santa Clara, CA, USA), comprising 45.000 probe sets representing over 34.000
mouse genes. The arrays were stained, washed and scanned according to the
manufacturer’s instructions. The microarray data was analyzed using R and Bio-
conductor [73]. Raw probe intensities were normalized using qspline and expres-
sion index calculations were performed using rma [78, 83]. For statistical testing,
ANOVA was performed using stimulation time as factor where all untreated sam-
ples were treated as one group. The false discovery rate (FDR) was estimated
using a Monte Carlo approach, and statistical significance was set at an FDR of
0 yielding 4947 highly significant probe sets corresponding to 3319 unique genes
annotated by Mouse Genome Informatics (MGI) [234].
Quantitative Real Time PCR analysis
DCs were harvested after 2 h, 4 h and 10 h of stimulation. RNA was extracted,
and 1µg of total RNA was reverse transcribed by the TaqMan Reverse Transcrip-
tion Reagent kit (Applied Biosystems, Foster City, USA) using random hexamer
primers according to the manufacturer’s instructions. The obtained cDNA was
stored in aliquots at -80 ◦C. For the selection of primer and probe sequences,
the regions coding for the genes investigated were retrieved from the GenBank
EMBL databases. Following gene sequences were applied: TLR-3 (NM 126166),
IFN-β (NM 010510), IL-12 p40 (NM 008352), IL-10 (NM 010548) and beta actin
(NM 007393). Primers and probes were designed using the software Primer Ex-
press 3.0 (Applied Biosystems) and tested for specificity by the basic alignment
search tool BLAST. HPLC purified forward and reverse primers were manufac-
tured by DNA Technology (Aarhus, Denmark). The probes were labelled with the
5’ reporter dye 6-carboxy-fluorescein (FAM) and the 3’ quencher dye NFQ-MGB
(Applied Biosystems). Sequences of primers and probes are listed in Table B.1.
Primer and probe concentrations were optimized and to determine the efficiency
of the amplifications dilution, standard curves were made for each set of primers
and probe (data not shown). The amplifications were carried out in a total volume
of 20 µl containing 1×TaqMan Universal PCR Master Mix (Applied Biosystems),
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forward and reverse primer (concentration 900 nM each), 200 nM TaqMan MGB
probe, and purified target cDNA. The cycling parameters were initiated by 20 sec
at 95 ◦C, followed by 40 cycles of 3 sec at 95 ◦C and 30 sec at 60 ◦C using the
ABI Prism 7500 (Applied Biosystems). Amplification reactions were performed
in triplicate, and DNA contamination controls were included. The amplifications
were normalised to the expression of beta actin. Relative transcript levels were
calculated applying the equation described by Pfaﬄ [235].
Cytokine quantification by ELISA
After 24 h of stimulation, culture supernatants were collected and stored at – 80
◦C for later cytokine analysis. The production of murine IL-12(p70), IL-10, IL-
6, TNF-α and IFN-β was analysed using commercially available enzyme-linked
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, USA).
Statistical analysis
Statistical calculations were performed using the software program GraphPad
Prism 5 (San Diego, CA, USA). For each experiment, results were analysed by
ANOVA with Bonferroni as post test, and p-values of < 0.05 were considered
significant.
6.5 Results
Lactobacillus acidophilus NCFM induces IFN-β and TLR-3
up-regulation in murine dendritic cells
The expression of the genes encoding IFN-β and TLR-3 was determined after 2 h,
4 h and 10 h of stimulation with L. acidophilus NCFM and Poly I:C (Figure 6.1A).
The two stimulators gave rise to highly distinct expression patterns. The strongest
up-regulation of Ifn-β was detected after stimulation with L. acidophilus NCFM,
as it was only slightly up-regulated after 2 h (38-fold) but reached a significant
maximum after 4h (589-fold) that declined to 100-fold after 10 h. Contrary to L.
acidophilus NCFM, the synthetic dsRNA analogue Poly I:C induced a strong ex-
pression of Ifn-β after 2h (180-fold). However, this induction decreased to 20-fold
after 4 h and was raised to 220-fold again after 10 h. The highly potent Ifn-β
inducing property of L. acidophilus NCFM was additionally confirmed by ELISA
(Figure 6.1B), as the protein production of IFN-β was more than 5-times higher
in DC stimulated with L. acidophilus NCFM compared to Poly I:C (1639 pg/ml
versus 318 pg/ml, respectively). Both L. acidophilus NCFM and Poly I:C strongly
sustained Tlr-3 expression after 4 h and 10 h stimulation, indicating that L. aci-
dophilus NCFM is capable of triggering up-regulation of TLR-3 to the same extent
as the synthetic ligand Poly I:C. Stimulation with L. acidophilus NCFM resulted
6.5. RESULTS 99
Figure 6.1 – L. .acidophilus NCFM induces gene expression of IFN-β and TLR-
3. Bone marrow derived DC were stimulated with L. acidophilus NCFM and Poly
I:C (10 µg/ml) for 2 h, 4 h and 10 h. RNA was extracted, and the induction of
the genes encoding IFN-µ and TLR-3 was determined by RT-PCR analysis. The
mRNA levels were normalised to the relative expression of beta-actin. The error bars
depict the mean value +/- standard error of three individual measurements from
one experiment. The data represent one of at least 7 independent experiments, ∗
P<0.05.
in upregulation of the surface markers CD40 and CD86 (Figure 6.2), showing that
the DC mature upon stimulation with L. acidophilus NCFM.
L. acidophilus NCFM was also observed to induce a much stronger expression
of the pro-inflammatory cytokine IL-12 and the regulatory cytokine IL-10 (Fig-
ure 6.3A). IL-12 and IL-10, as well as the pro-inflammatory cytokines IL-6 and
TNF-α, were detected in high concentrations measured by ELISA in the super-
natants of DC stimulated with L. acidophilus NCFM, whereas the concentration
of these cytokines upon stimulation with Poly I:C was just slightly increased as
compared to non-stimulated cells (Figure 6.3B).
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Figure 6.2 – Maturation profile of murine DC upon incubation with L. acidophilus
NCFM. Flow cytometric analysis of expression of the surface markers CD40 and
CD86 in DC after stimulation with L. acidophilus NCFM.
Identification of multiple virus-defence related genes by genome
wide expression analysis in dendritic cells stimulated with
Lactobacillus acidophilus NCFM
Genome wide microarray analysis was performed to further investigate the up-
regulation of virus-related genes during stimulation of DC with L. acidophilus
NCFM. To generate a comprehensive view of the expression profile, samples were
harvested at different time points (4 h, 10 h and 18 h). Differential expression
was assessed using ANOVA resulting in 3319 significant regulated genes at a false
discovery rate (FDR) of 0 (p-value < 1e-4). These findings point to a very strong
response of DC upon stimulation, which is in good agreement with the pheno-
typical changes (e.g. production of cytokines and up-regulation of various surface
markers) observed. The data generated were deposited in NCBI’s Gene Expression
Omnibus [236] and are accessible through GEO Series accession number GSE18460.
Focusing on genes that are virus-defense related, we used the Gene Ontology
(GO) term GO:0009615 ’Response to virus’ to test whether the distribution of
their expressions was different from the entire distribution. The Wilcoxon rank
sum test (Mann-Whitney test) with a p-value of 3 × 10−11 revealed a strong,
significant up-regulation of these genes (Figure 6.4). The induction of virus re-
lated genes was most prominent for the gene encoding Rsad2 (700-fold). Rsad2
(Radical S-adenosyl methionine domain containing 2), also known as viperin, en-
codes a cytoplasmic antiviral protein induced by interferons. This protein impairs
virus budding by disrupting lipid rafts at the plasma membrane, a feature which
is essential for the budding process of many viruses [237]. The genes encoding
TGTP2 (interferon-induced T-cell specific GTPase), ISG15 (interferon-stimulated
gene 15), interferon-regulatory factor (IRF-7) and toll-like receptor 3 (TLR-3), all
involved in the viral immune defence and induced by IFN-β, were likewise among
the highest significantly up-regulated.
In addition to the genes in the ’Response to virus’ GO term, microarray data
analysis revealed a significant induction of numerous genes related to viral in-
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Figure 6.3 – L. acidophilus NCFM induces significant higher expression of the
cytokines IL-12, IL-10, IL-6 and TNF-α compared to Poly I:C. A. Bone marrow
derived DC were stimulated with L. acidophilus NCFM and Poly I:C (10ng/ml)
for 2 h, 4 h and 10 h. RNA was extracted, and the induction of the genes coding
for IL-12 and IL-10 was determined by RT-PCR analysis. The mRNA levels were
normalised to the relative expression of beta-actin. B. Protein concentration of IL-
12, IL-10, IL-6 and TNF-α was measured by ELISA in the supernatant 24 h after
stimulation of DC with L. acidophilus NCFM and Poly I:C (10ng/ml). The error
bars depict the mean value +/- standard error of three individual measurements from
one experiment. The data represent one of at least 7 independent experiments. ∗
P<0.05.
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fection (Table B.2). The majority of these genes are classical Interferon Sensi-
tive Genes (ISG) induced upon stimulation with IFN-β, e.g. members of the
interferon-stimulated gene 56 family (ISG56), which are known to be strongly in-
duced in response to virus infection, type I IFNs and dsRNA. In mouse, this family
comprises three members (ISG56, ISG54, and ISG49) which associate with large
protein complexes and block the translation pathway at different steps [238, 239].
Another strongly induced gene belonging to the classical family of ISGs codes for
the well studied antiviral enzyme double-stranded RNA-dependent protein kinase
(EIF2AK2, also termed PKR), which phosphorylates various substrates including
the protein synthesis initiation factor eIF2α and acts by blocking the transla-
tion of viral RNA [240]. The 2’-5’oligoadenylate synthetases (OAS), a family of
enzymes activated by dsRNA, were likewise strongly induced. These enzymes
produce 2’-5’linked oligoadenylates activating the latent ribonuclease RNase L,
which degrades viral mRNA [241]. The Myxovirus-resistance (Mx) proteins, IFN-
inducible GTPases, were up-regulated in a similar manner. These proteins have a
wide antiviral spectrum against different types of viruses and form complexes with
dynamin, which disrupts intracellular transport or interferes with the activity of
viral polymerases [242].
Induction of anti-viral mechanisms in dendritic cells is confined
to certain probiotic strains
To elucidate whether the induction of the antiviral response is unique for L. aci-
dophilus NCFM, universal for L .acidophilus strains, or a common property of
probiotics, we further stimulated DC with another L. acidophilus (X37), a B. bi-
fidum strain (Z9), and the Gram negative probiotic E. coli Nissle 1917. Gene
expression analysis by RT-PCR revealed that L. acidophilus X37 was similarly
able to trigger a virus response, as the genes encoding IFN-β and TLR-3 were
significantly induced (Figure 6.5A). In contrast, neither B. bifidum Z9 nor E. coli
Nissle 1917 gave rise to a strong up-regulation. Both strains resulted in a small
peak of Ifn-β expression after 2 h of stimulation, followed by a rapid decrease to
almost background level and a lower and less sustained up-regulation of Tlr-3 tran-
scription compared to the L. acidophilus strains. The rapid but low up-regulation
of Ifn-β transcription upon stimulation with bifidobacteria and E. coli Nissle 1917
corresponded to the peak observed upon stimulation with Poly I:C. However, stim-
ulation with Poly I:C showed a reemerging rise in the transcription after 10 h. The
results obtained for Ifn-β were verified on a protein level by ELISA (Figure 6.5B).
The highest production of IFN-β was measured upon stimulation of DC with L.
acidophilus X37, which induced 18 times more IFN-β compared to E. coli Nissle
1917. L. acidophilus NCFM induced the production of IFN-β more than 14 times
compared to E. coli Nissle 1917, whereas DC stimulated with B. bifidum Z9 did
not produce detectable levels of IFN-β.
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Figure 6.4 – L. acidophilus NCFM induces expression of multiple genes related to
viral immune defence. Bone marrow derived DC from three mice were individually
stimulated with L. acidophilus NCFM for 4 h, 10 h and 18 h, RNA was extracted,
and microarray analysis was performed. Heatmap of log2 fold changes versus no
stimulation for all probes on the array. Probe sets are sorted according to maximal
log2 fold change at any time point. Green and red colours represent up and down
regulations, respectively. In column “V” the position of genes in the gene ontology
term GO:0009615 “Response to virus” is presented as black lines together with
the significance of this distribution in a two-sided Wilcoxon Rank sum test (Mann-
Whitney). Detailed expression of the genes is shown rightmost.
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Figure 6.5 – L. acidophilus strains, but not B. bifidum and E. coli, induce IFN-β
expression in DC. A. Bone marrow derived DC were stimulated with L. acidophilus
NCFM, L. acidophilus X37, E. coli nissle 1917 (10 µg/ml) and B. bifidum Z9 (40
µg/ml) for 2 h, 4 h and 10 h. RNA was extracted, and the induction of the gene
encoding IFN-β and TLR-3 was determined by RT-PCR analysis. The mRNA
levels were normalised to the relative expression of beta-actin. B. Bone marrow
derived DC were stimulated with L. acidophilus NCFM, L. acidophilus X37, E. coli
nissle 1917 (10 µg/ml) and B. bifidum Z9 (40 µg/ml) for 24 h. The supernatant
was harvested and protein concentrations were measured by ELISA. The error bars
depict the mean value +/- standard error of three individual measurements from
one experiment. The data represent one of at least three independent experiments,∗
P<0.05.
Induction of IFN-β and TLR-3 is dependent on TLR-2
The bacterial strains investigated in this study, capable of inducing strong Ifn-β
and Tlr-3 expression levels, were also the strains that gave rise to a high IL-12
production. As we previously have found that the IL-12 production is to a great
extent dependent on TLR-2 stimulation [232], we hypothesized that TLR-2 might
likewise be involved in the stimulation of DC with L. acidophilus, leading to the
transcription of Ifn-β and Tlr-3 (along with other virus related genes).
To investigate whether TLR-2 is required for the induction of IFN-β (or whether
the induction of IFN-β requires TLR-2 recognition), we generated bone marrow
derived DC from WT and TLR-2 -/- deficient mice. The expression of the gene en-
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coding IFN-β was determined in DC upon stimulation with L. acidophilus NCFM,
Poly I:C, E. coli Nissle 1917, and B. bifidum Z9 after 2 h, 4 h and 10 h. As de-
picted in Figure 6.6A, the lack of TLR-2 resulted in a dramatic decrease in the
Ifn-β expression peak after 4 h induced by L. acidophilus NCFM. The Ifn-β ex-
pression profile was only moderately affected upon Poly I:C stimulation, with a
slight increase in Ifn-β expression after 2 h and a decrease after 10 h. In contrast,
when the DC were stimulated with either B. bifidum Z9 or E. coli Nissle 1917, the
weak expression peaks observed after 2 h in wild type DC were markedly increased
in TLR-2 -/- cells. Thus, whereas the absence of TLR-2 was central for the IFN-β
production upon stimulation with L. acidophilus NCFM, TLR-2 seemingly exhib-
ited the opposite role upon stimulation with E. coli Nissle 1917 and B. bifidum
Z9, as the Ifn-β induction was higher in TLR-2-/- DC. Our gene expression re-
sults were confirmed by the presence of IFN-β in culture supernatants measured
by ELISA after 24 h of stimulation Figure 6.6B).
Figure 6.7 illustrates the expression of Tlr-3 upon stimulation of WT DC and
TLR-2 -/- DC with L. acidophilus NCFM, Poly I:C, E. coli Nissle 1917, and B.
bifidum Z9 for 2 h, 4 h and 10 h . In case of L. acidophilus NCFM and Poly I:C,
the expression of Tlr-3 was not affected by the absence of TLR-2 after 2 h and 4
h. However, after 10 h Tlr-3 was significantly reduced in TLR-2 -/- DC compared
to WT DC. In TLR-2-/- DC stimulated with E. coli Nissle 1917, the expression
of Tlr-3 was, in contrast to WT DC, only slightly lower (1-fold after 2 h, 4 h and
10 h). Upon incubation of DC with B. bifidum Z9, the up-regulation of Tlr-3 was
increased in TLR-2 -/- DC compared to WT DC at all time points.
To further investigate the dependency of IL-12 on IFN- β, and hence indirectly
on TLR-2, we followed the Il-12 gene expression profile (Figure 6.8) and mea-
sured the protein production of IL-12 and three other cytokines (IL-10, IL-6 and
TNF-α) in WT and TLR-2 -/- DC upon stimulation with L. acidophilus NCFM,
Poly I:C, B. bifidum Z9, and E. coli Nissle 1917. The expression profiles of Il-12
corresponded to the expression of Ifn-β, which were also reflected in the protein
concentration of IL-12 and IFN-β measured in the supernatants by ELISA after
24 h of stimulation. In contrast, Il-10 induction was largely unaffected upon stim-
ulation with L. acidophilus NCFM, Poly I:C, and E.coli Nissle 1917. However,
in TLR-2-/- DC stimulated with B. bifidum Z9 the Il-10 induction was signifi-
cantly reduced (Figure 6.9). For all for stimulation regimes, the TNF-α protein
concentration was slightly reduced in the supernatants of TLR-2 -/- DC, whereas
IL-6 concentration was increased upon E. coli stimulation and decreased upon L.
acidophilus stimulation (data not shown).
Taken together, these results show that TLR-2 plays an important role in the
strong induction of IFN-β in DC upon stimulation with L. acidophilus NCFM.
This observation is also reflected in the expression of the genes encoding IL-12
and TLR-3. In contrast, the same genes were largely unaffected when DC were
stimulated with Poly I:C. In case of E. coli Nissle 1917 and B. bifidum Z9, TLR-2
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Figure 6.6 – IFN-β stimulating activity of L. acidophilus NCFM is dependent on
TLR-2. A. Bone marrow derived DC from both WT and TLR-2 -/- were stimulated
with L. acidophilus NCFM, Poly I:C, E. coli nissle 1917 (10 µg/ml), and B. bifidum
Z9 (40 µg/ml) for 2 h, 4 h and 10 h. RNA was extracted, and the induction
of the gene coding for IFN-β was determined by RT-PCR analysis. The mRNA
levels were normalised to the relative expression of beta-actin. B. Bone marrow
derived DC from both WT and TLR-2 -/- were stimulated with L. acidophilus
NCFM, Poly I:C, E. coli nissle 1917 (10 µg/ml), and B. bifidum Z9 (40 µg/ml)
for 24 h. The supernatant was harvested and protein concentrations of IFN-β were
measured by ELISA. The error bars depict the mean value +/- standard error of
three individual measurements from one experiment. The data represent one of at
least two independent experiments. ∗ P<0.05 values (WT versus TLR-2 -/-) are
indicated.
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Figure 6.7 – The TLR-3 stimulating activity of L. acidophilus NCFM is dependent
on TLR-2. Bone marrow derived DC from both WT and TLR-2 -/- were stimulated
with L. acidophilus NCFM, Poly I:C, E. coli nissle 1917 (10 µg/ml), and B. bifidum
Z9 (40 µg/ml) for 2 h, 4 h and 10 h. RNA was extracted, and the induction of
the gene coding for TLR-3 was determined by RT-PCR analysis. The mRNA levels
were normalised to the relative expression of beta-actin. The data represent one of
at least two independent experiments. ∗ P<0.05 values (WT versus TLR-2 -/-) are
indicated.
seems to hold a suppressive role.
The clathrin-mediated endocytic pathway is required for the
induction of IFN-β and TLR-3 upon stimulation with L.
acidophilus
Poly I:C stimulated IFN-β induction in DC has recently been shown to depend
on clathrin mediated endocytosis [233]. We have observed in previous studies that
a prerequisite for a strong IL-12 response upon stimulation with L. acidophilus
is that the bacterium is intact [232]. As a consequence, we speculated that the
IFN-β and IL-12 inducing mechanism could involve phagocytosis or endocytosis
triggering events. Accordingly, we used pharmacological inhibitors to investigate
whether bacterial uptake of L. acidophilus NCFM is required for the induction of
IFN-β, and, in turn, IL-12 and TLR-3. The effect of cytochalasin D (phagocy-
tosis inhibitor), methyl-β-cyclodextrin (calveolae-mediated endocytosis inhibitor)
and chlorpromazine (clathrin-mediated endocytosis inhibitor) on the stimulation
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Figure 6.8 – Induction of Il-12 in DC stimulated with various probiotic bacteria
and Poly I:C is dependent on TLR-2. Bone marrow derived DC from both WT and
TLR-2 -/- were stimulated with L. acidophilus NCFM, Poly I:C, E. coli nissle 1917
(10 µg/ml), and B. bifidum (40 µg/ml) for 2 h, 4 h and 10 h. RNA was extracted,
and the induction of the gene coding for IL-12 was determined by RT-PCR analysis.
The mRNA levels were normalised to the relative expression of beta-actin. The data
represent one of at least two independent experiments. ∗ P<0.05 values (WT versus
TLR-2 -/-) are indicated.
profile of DC after incubation with either L. acidophilus NCFM or Poly I:C was
investigated Figure 6.10). Upon stimulation with L. acidophilus NCFM, the ex-
pression of the genes encoding IFN-β, TLR-3 and IL-12 was significantly inhibited
when the DC were pre-treated with cytochalasin D and chlorpromazine. This in-
hibition was absent when the DC were pre-treated with methyl-β-cyclodextrin.
The pharmacological inhibitors did not have the same impact on the expression
of the gene encoding IL-10, as only a slight reduction was observed. We ob-
tained similar results when DC were stimulated with Poly I:C. Pre-treatment with
cytochalasin D and chlorpromazine of DC had a significant inhibitory effect on
the expression of the genes coding for IFN-β and TLR-3, whereas pre-treatment
with methyl-β-cyclodextrin did not have an impact. Our results indicate that
the clathrin-mediated endocytic pathway participates in uptake of L. acidophilus
NCFM as an important step in the stimulation of the transcription of IFN-β and
TLR-3 and, in turn, IL-12.
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Figure 6.9 – Induction of Il-10 in DC stimulated with various probiotic bacteria
and Poly I:C is dependent on TLR-2. Bone marrow derived DC from both WT and
TLR-2 -/- were stimulated with L. acidophilus NCFM, Poly I:C, E. coli nissle 1917
(10 µg/ml), and B. bifidum (40 µg/ml) for 2 h, 4 h and 10 h. RNA was extracted,
and the induction of the gene coding for IL-10 was determined by RT-PCR analysis.
The mRNA levels were normalised to the relative expression of beta-actin. The data
represent one of at least two independent experiments. ∗ P<0.05 values (WT versus
TLR-2 -/-) are indicated.
Induction of IL-12 and TLR-3 by L. acidophilus NCFM is
dependent on IFN-β
Despite the vast difference in the Ifn-β expression profiles of DC stimulated with
L. acidophilus NCFM and Poly I:C, the Tlr-3 expression profiles obtained were
highly similar. We therefore speculated that the Tlr-3 expression was caused by
distinct mechanisms, i.e. that L. acidophilus NCFM Tlr-3 expression was induced
through the action of IFN-β and that the Poly I:C induced Tlr-3 expression was
primarily due to a direct binding of Poly I:C to TLR-3. To test the role of IFN-β
in expressing Tlr-3, we added polyclonal anti-IFN-β antibodies to the cell cultures
prior to stimulation with L. acidophilus NCFM, and measured the expression
profiles of Tlr-3 and Il-12 (Figure 6.11). We observed a dose-dependent inhibitory
effect of polyclonal IFN-β antibodies on the expression of Tlr-3 and Il-12. This
effect was strongest on Tlr-3, as the expression was almost completely inhibited
when high antibody concentration was applied. By contrast, the same antibody
concentrations reduced the expression of Il-12 by approximately 50 %, which was
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Figure 6.10 – A clathrin-dependent endocytic pathway participates in L. aci-
dophilus NCFM-induced IFN-β production. Bone marrow derived DC were pre-
treated with cytochalasin D (CytD, 0.5 µg/ml), chlorpromazine (CLP, 25 µg/ml),
methyl-β-cyclodextrin (MBCD, 1 mM) or medium alone for 1 h. Subsequently,
the cells were stimulated with L. acidophilus NCFM (10 ng/ml) and Poly I:C, (10
ng/ml). RNA was extracted, and the induction of the gene coding for IFN-β, TLR-
3, IL-12 and IL-10 was determined by RT-PCR analysis. The mRNA levels were
normalised to the relative expression of beta-actin. The data represent one of at
least four independent experiments.
confirmed by ELISA in the supernatant harvested after 24 h (data not shown).
6.6 Discussion
In this study we have shown that the probiotic bacterium L. acidophilus possesses
the capability to induce a viral defense phenotype in bone marrow derived murine
dendritic cells. Such properties have been demonstrated earlier by pathogenic bac-
teria [223,243], but to our knowledge this has not been demonstrated for bacteria
regarded as non-pathogenic or even beneficial for the immune system. The induc-
tion of viral defense mechanisms may explain the ability of some probiotic bacteria
to stimulate the immune system as demonstrated in a number of clinical trials,
including their ability to protect against viral infection.
The up-regulation of viral response genes seems to a great extent to be caused
by a rapid and strong transient up-regulation of Ifn-β, which in turn stimulates
transcription of a high number of other genes involved in viral defense. This was
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demonstrated in our microarray based kinetics study, as the gene encoding IFN-β
appeared to belong to a minor group of genes with a rapid transient profile. By this
approach we showed that virtually all genes related to viral defense were among
the most up-regulated genes and that a high number of these genes is known to
be directly regulated through the action of type I IFNs [220,221].
The up-regulation of Ifn-β in DC was much stronger upon stimulation with L.
acidophilus compared to cells stimulated with Poly I:C, E. coli Nissle 1917 and B.
bifidum Z9. The up-regulation of Ifn-β correlated with an increased expression of
Tlr-3 as well as Il-12, thus supporting the connection between IFN-β and IL-12
as found by others [231]. In contrast, the up-regulation of Tlr-3 was similar after
stimulation of DC with L. acidophilus NCFM and Poly I:C. This indicates that
up-regulation of Tlr-3 does not exclusively depend on IFN-β, but may be affected
by other mechanisms. Poly I:C has recently been shown to up-regulate IFN-β in a
TLR-3 dependent manner in HEK293 cells and DC [244], hence there is evidence
that ligand binding to TLR-3 induces IFN-β and, conversely, that IFN-β is able
to induce Tlr-3 expression. This may explain our observation that Tlr-3 is up-
regulated to the same extent upon Poly I:C stimulation as upon L. acidophilus
NCFM stimulation despite the considerable difference in the produced IFN-β.
Not all probiotic bacteria were able to induce an up-regulation of Ifn-β and
Tlr-3 in DC, as demonstrated here with B. bifidum Z9, whereas another Lac-
tobacillus strain, L. acidophilus X37, induced an IFN-β and TLR-3 response in
a similar manner as L. acidophilus NCFM. Likewise, the Gram negative E. coli
Nissle 1917, also considered probiotic, was not capable of inducing a significant
expression of the genes coding for IFN-β or TLR-3. This is in accordance with the
lack of capability of these bacteria to induce an extensive IL-12 production in the
DC [232]. To which extent other probiotic bacteria are capable of inducing IFN-β
and viral defense genes is currently under investigation.
As the IL-12 response was shown to be dependent on TLR-2 in a previous
study [232], we investigated the IFN-β response in DC from TLR-2-/- mice and
found that TLR-2, as for IL-12 expression, is mandatory for an induction of IFN-
β upon L. acidophilus NCFM stimulation. In contrast, lack of TLR-2 resulted
in a marked increase of IFN-β upon stimulation with B. bifidum Z9 and E. coli
Nissle 1917. Hence, TLR-2 is not only playing a major role in the strong IL-12
and IFN-β response induced by L. acidophilus, it simultaneously plays a role in
suppression of the same response upon stimulation of DC with other bacteria, such
as B. bifidum Z9 and E. coli Nissle 1917 investigated in the present study. This
dualism in TLR-2s role is not well described. Whereas the response to the TLR-
2 ligand Pam3Cys generally is reported to be weak [232, 245], stimulation with
whole bacteria through TLR-2 is, in a few cases, reported to give rise to a strong
pro-inflammatory response [228,232].
In human DC, IFN-β was found to be induced through a clathrin dependent en-
112 CHAPTER 6. PROBIOTIC BACTERIA AND HUMAN HEALTH
Figure 6.11 – Induction of Il-12 and Tlr-3 in L. acidophilus stimulated DC is
dependent on IFN-β. Simultaneously with addition of L. acidophilus NCFM to DC,
polyclonal IFN-β antibody was added in various concentrations (0 ng/ml, 10 ng/ml,
1000 ng/ml, 10000 ng/ml and 50000 ng/ml). Cells were harvested after 10 h, RNA
was extracted and the gene expression of Il-12 and Tlr-3 was analysed by RT-PCR.
The data represent one of at least two independent experiments.
docytotic mechanism [233]. We also found that the induction of Ifn-β was related
to phagocytosis, possibly through a clathrin mediated mechanism, as addition of
both the actin inhibitor cytochalasin and the clathrin inhibitor chlorpromazine
abolished the induction of the gene coding for IFN-β. We have previously shown
that UV-killed, but intact, bacteria, in particular L. acidophilus, induce a response
corresponding to live bacteria which leads to much stronger IL-12 and TNF-β
production compared to fragments or isolated cell walls of the bacteria. Taken
together, this indicates that active uptake of the bacteria by endocytosis is im-
portant for the IFN-β induction. As TLR-2 was shown to be involved, our study
suggests that TLR-2 plays an active role in the endocytosis dependent IFN-β up-
regulation, a phenomenon that to our knowledge has not been described before.
However, whether there is a connection between the dependency of TLR-2 and
endocytosis cannot be firmly established from the presented results. Maturation
of DC is generally considered to abolish endocytosis in these cells, but a number
of studies reports that some degree of maturation may take place in DC without
abolishment of endocytosis. Weck et al. [245] found that in contrast to activation
through TLR-3 and TLR-4, activation through TLR-2 with the synthetic TLR-2
agonist Pam3Cys did not abolish endocytosis. However, in contrast to Pam3Cys,
ligands like peptidoglycan and lipopeptides present in close proximity in high num-
ber in an intact microorganism may stimulate several TLRs - or other receptors
- simultaneously and hence work through a completely distinct mechanism. Such
kind of receptor collaboration is well established for TLR-2 together with TLR-
1 or TLR-6 [246]. Moreover, Pseudomonas aeruginosa was shown to induce a
strong pro-inflammatory response by a TLR-2 and mannose receptor dependent
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mechanism [230]. The mannose receptor and TLR-2 form complexes on the cell
surface during early phagocytosis and are found co-localized in endosomes for up
to one hour after addition of the bacteria to the cells. We did not investigate the
involvement of the mannose receptor in the present study but it is by all means
conceivable that mannose receptor or another receptor collaborates with TLR-2 in
the activation of a pro-inflammatory response.
Charrel-Dennis and colleagues [223] found that only live bacteria (streptococci)
stimulated a strong induction of IFN-β, however, they compared with heat killed
bacteria while we stimulated with UV-killed bacteria. This indicates that some
protein-containing or heat vulnerable compound may be involved. Our previous
studies showed that LTA, but not Pam2Cys or Pam3Cys, was involved in the TLR-
2 dependent stimulation of IL-12 production in DC [232], but proteins or other
molecules of importance for the intact bacterium may be involved, perhaps in
collaboration with a TLR-2 ligand. Salazar and colleagues [228] stimulated mono-
cytes with Borrelia burgdorferi which responded through both a TLR-2 dependent
and TLR-2 independent pathway, but only the TLR-2 independent response lead
to an induction of IFN-β. This is in contrast to our finding, as we observed a dra-
matic effect in TLR-2-/- DC. Thus, it is indicated that different microorganisms
stimulate antigen presenting cells by distinct mechanisms giving rise to various
cellular phenotypes.
Taken together, these results add to the picture of TLR-2 as an important
receptor for both pro-inflammatory and regulatory responses in antigen present-
ing cells. Our study reveals that L. acidophilus is capable of stimulating a pro-
inflammatory and antiviral response by a TLR-2 dependent mechanism, thus
pointing towards TLR-2 as a receptor playing a central role in endocytosis de-
pendent stimulation of a pro-inflammatory response in DC.
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6.8 Perspectives
We are currently performing follow-up experiments aiming at identification of genes
central for driving the viral response when DCs are stimulated with L. acidophilus
NCFM. We have performed a microarray experiment investigating the effect of
Bifidobacterium bifido Z9 on L. acidophilus NCFM induced activation of DCs. B.
bifido is known to inhibit Lactobacilli response and a Singular Value Decomposi-
tion of the data in Figure 2.4 clearly reveals this effect.
Interestingly a Parametric Gene Set Enrichment of GO terms on the data,
testing for differences between only stimulating using L. acidophilus NCFM ver-
sus simulation by both L. acidophilus and B. bifido Z9, the only significantly term
is “Response to virus”. By clustering the gene expression data and focusing on
genes that are inhibited by adding B. bifido we hope to identify central genes in
driving the viral response induced by L. acidophilus.
As of printing the thesis, we have submitted a manuscript to PLoS ONE show-
ing that B. bifido actively inhibits L. acidophilus presumably via the JNK1/2 path-
way. The gene encoding Jun dimerization protein 2 (JDP2) was only up-regulated
in cells stimulated with B. bifidum and is a candidate gene for the inhibitory
regulation.
Part IV
Conclusions
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Chapter 7
Perspectives
Systems biology and integrative approaches are effective tools for increasing the
power of data analysis in biological science. In this thesis I have given examples of
transcriptomic data that have been integrated to achieve added biological value.
The power of the approach is best observed in our study of Alzheimer’s Disease
where protein interaction data in combination with phenotypic data identifies a
disease relevant gene. Additionally the protein-protein interaction network pro-
vides a starting point for hypothesis-generation due to the disease relevant protein
interactions. If we had not taken this approach it is not likely that ADAM23
would have been identified as a gene associated with AD. In the case of the tiling
array experiment of B. subtilis the aim was not to identify a particular gene or
protein, but rather to provide a comprehensive map of the transcriptionally ac-
tive regions and to identify novel features such as non-coding RNAs. In this case
integration with e.g. protein-protein interaction data, which is sparse for B. sub-
tilis, is not likely to improve the results. On the contrary we integrated known
and predicted sigma factor binding sites and Rho-independent terminator sites to
refine, benchmark and add value to the findings. Additionally from this we were
able to expand an existing segmentation method hereby increasing performance in
identifying known transcripts. The identification of 125 putative novel antisense
transcripts suggests that natural antisense transcription is also a pervasive feature
of prokaryotic transcriptomes.
With regard to the S. cerevisiae and the L. acidophilus work we took a more
directed approach analyzing the data at the level of biological pathways in close
contact with the underlying biology. The original authors of the S. cerevisiae data
were not successful in using systems biology approaches, such as protein interac-
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tion data, to identify the underlying genetic network of the mutant strain. This
illustrates that even though transcriptomics are very suitable for integrative ap-
proaches, the circumstances of an experiment determines to which extend success
may be expected. In this particular case we were able to use added information
from growth experiments showing that the uptake and/or utilization of leucine
could describe the increased fitness of the mutant. In the profiling experiment
using probiotic L. acidophilus NCFM to stimulate dendritic cells, we established
that the bacterium can induce a Toll-like receptor 2 dependent viral response. Here
pathway analysis revealed that virus response genes were among the strongest up
regulated genes.
Taken together this show that systems biology and integrative approaches can
improve the analysis and outcome of transcriptomics for both disease and industry
focused applications. The outcome of such approaches are, naturally, dependent
on the experimental conditions, available data and most importantly the objective
of the study.
Where are we going next?
Systems biology and transcriptomics are likely to continue to be important as-
pects of biological research. However the form in which it is performed today is
gradually changing, with Next Generation Sequencing probably replacing DNA
microarray technology due to a higher throughput, accuracy and dynamic range.
This, and a general increase in throughput of other research fields, allow data
generation and experimental designs which are not confined to traditional stud-
ies of model organisms and univariate data analysis. Instead large multivariate
experimental designs, such as cohort studies, can be used for studying complex
biological diseases and systems. The increase in depth of the biological layers that
can be analyzed and the increase in sheer data output will continue to emphasize
the importance of bioinformatics and systems biology in biological research. Issues
such as how to store, process and analyze these data are highly relevant and seem
similar to the questions asked a decade ago, when increasing amounts of genomic
and transcriptomic data began to appear. Certainly computational approaches
and data integration will be important parts of the solution and the approaches
developed for DNA microarray based methods are likely to be applicable to future
experiments.
Regarding transcriptomics, especially eukaryotic organisms will benefit greatly
from RNA-seq, as especially tiling DNA microarrays are not easily applied to large
genomes [19, 34]. Detailed investigation on the complexity of the transcriptome,
where mapping of non-coding RNAs such as natural antisense transcripts and
identification of novel splice variants are achieved, could advance interactomics
to a new level. Integration of RNA and protein interaction data may lead to new
insights into complex biological processes and diseases that has not yet been recog-
119
nized. Knowledge such as allele-specific expression and simultaneous investigation
of coding SNPs will increase the resolution of the transcriptome. Additionally,
NGS technology has already revolutionized metagenomics, where deep sequencing
of genomic DNA is used to sample biodiversity in the human microbiome or en-
vironmental samples such as different water sources and soil [35, 247, 248]. This
provides a huge potential for discovery of novel genes and investigation of the
effect of different bacterial species on human diseases. From this sequencing of
clinical pathogens directly from patients, may allow determination of individual
treatment strategies. Likewise the opportunity to study not only the human ref-
erence genome, but thousands of human genomes, can facilitate the development
of personalized medicine, where medication can be customized to the individual
patient based on their genotypes [6].

Appendix A
Paper I
This section contains supplementary material for Paper I. First are supplementary
Fig S1 and S3-9, followed by 6 pages of Fig S2. These are the pages of Fig S2
that are directly referenced to in the manuscript. Additionally the supplemen-
tary tables are not included. All of the supplementary tables are available at the
publisher web-site as Online Open material: http://www3.interscience.wiley.
com/journal/122536032/suppinfo.
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Figure S1
Histogram of degree of overlap between TARs in the two medias.  An overlap of 0 means 
that the TAR is unique to that media, whereas an overlap of 1 means that the TAR is 
identical to a tar in the other media.
Figure S3
Benchmarking of TARs. (a) Shows the ROC-like curve of found genes. The True Positives (TP) are the genes as they are 
currently annotated and the False Positives (FP) are the same regions but on the opposite strand. (b) shows how many 
of the know Transcription Start Sites (TSSs) that are found as a function of the distance between this and the observed 
breakpoint. (c) Autocorrelation of expression signal as a function of spatial organization of genes (red) or TARs (blue).
Supplementary Figure 6
Benchmarking of TARs. (a) Shows the ROC-like curve of found genes. The True Positives (TP) are the genes as 
they are currently annotated and the False Positives (FP) are the same regions but on the opposite strand. (b) 
shows how many of the know Transcription Start Sites (TSSs) that are found as a function of the distance 
between this and the observed breakpoint.
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Figure S4
Density of gene expression of sporulation regulons, LB (a) and M9 (b). The regulons are color coded as: sigF (green), 
sigE (blue), sigG (yellow), sigK (red) and all genes (black). The vertical dotted line shows background signal.  The 
composition of each regulon was taken from Steil et al., 2005 and is shown in (c).
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Figure S5
Gene expression of prophage and prophage-like elements. Upper row show phage element expression in LB media and lower 
row gene expression in M9 media. Squares represents genes in the phage elements. The color scale range from white (low 
expression) to blue (high expression).  Arrows indicate the sublancin area (bdbB to sunI) in the SPβ prophage.
SPβ:2152-2286 kb, PBSX: 1316-1347 kb, SKIN: 2653-2700 kb, pro1: 202-220 kb, pro2:529-570 kb, pro3: 652-665 kb, 
pro4:1262-1270 kb, pro5:1879-1891 kb, pro6: 2046-2073 kb, pro7: 2707-2756 kb.
Figure S6
Density plots of gene expression of prophage and prophage-like elements.  Expression for 
LB and M9 is shown blue and red, respectively. Prophage coordinates are shown in Fig. S5.
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Figure S7
Conservation plot of non coding RNAs (ncr) identified. Nucleotide sequence of identified ncrs was compared 
against all available Firmicute sequences (genome and plasmid) and the  maximum hit is plotted. The color scale 
ranges from black (0% identity) to white (100% identity).
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Figure S8
Sense overlap and antisense/ratio of antisense transcripts. (a) Fraction of sense genes (cds) overlapped by antisense 
transcript. Two distributions (< 0.7 and > 0.7) of overlaps can be seen. (b) For the 127 antisense transcripts, log2 sense 
(LB/M9) and log2 antisense (LB/M9) ratio is plotted. If antisense transcript is the primary regulator of the sense area at 
the conditions tested, the antisense and sense ratios would expect to be anti-correlated (upper left and lower right 
quarters). The number plotted corresponds to the shd nomenclature (e.g. 4 = shd4).
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Figure S9
Folding of conserved 3’UTR RNA elements.  All elements were folded using RNAfold v1.6 and bases 
are coloured according to base-pair probabilities, from 0 to 1 (purple, blue, green, yellow to red).
Figure S2
The following pages show the level of expression along the genome of Bacillus subtilis when 
growing on rich (LB) and minimal (M9) medium. The signal from genomic DNA hybridized to the 
same tiling chip (Rasmussen et al., 2009) is also shown. Each page contain two similar plots 
each presenting ~44 Kb of the genome. The two blue bands show the expression in LB and M9 
respectively on the positive strand, the two magenta bands show the minus strand. The darker 
the color the higher the expression in the given position. On top of the bands the expression 
level is plotted as a scaled version (0-10) of the log2 to the fold change (signal/background 
signal). In the middle of each plot the gDNA signal is shown for both strands, here the color scale 
is yellow-green-black, where black is low and yellow is high. Along the genome, in all 6 bands in 
the same positions, white regions indicate regions were the recent re-sequencing of the genome 
(AL009126.3) have shown either inserts or regions with very low similarity to the last version 
(see Rasmussen et al., 2009). Annotated genes are shown as black arrows in the top and the 
bottom of each plot (annotation from AL009126.3), indicating genes on the positive and negative 
strand respectively. New genes are shown as red arrows below (+ strand) and above (- strand) 
each band. Both predicted and experimentally verified terminators and sigma-factor binding sites 
are shown on top of the gDNA bands. Dark red triangles: Experimentally verified terminators, red 
triangles: Predicted terminators, stars: Experimentally verified sigma-factor binding sites, green 
dots: Predicted sigma-factor binding sites. 
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Target Primers and probes Sequence (5’ – 3’)
IFN-β (NM 010510) Forward CGGACTTCAAGATCCCTATGGA
Reverse TGGCAAAGGCAGTGTAACTCTTC
Probe ATGACGGAGAAGATGC
TLR-3 (NM 126166) Forward GATTCTTCTGGTGTCTTCCACAAA
Reverse AATGGCTGCAGTCAGCTACGT
Probe CAATGCACTGTGAGATAC
IL-12 p40 (NM 008352) Forward TGGAGCACTCCCCATTCCT
Reverse TGCGCTGGATTCGAACAA
Probe CTTCTCCCTCAAGTTC
IL-10 (NM 010548) Forward GATGCCCCAGGCAGAGAA
Reverse CACCCAGGGAATTCAAATGC
Probe CATGGCCCAGAAAT
Beta actin (NM 007393) Forward CGATGCCCTGAGGCTCTTT
Reverse TGGATGCCACAGGATTCCA
Probe CCAGCCTTCCTTCTT
Table B.1 – Primers and probes used for Real-Time PCR analysis
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Table B.2 – Significant up-regulation of interferon-induced genes in murine den-
dritic cells stimulated with Lactobacillus acidophilus NCFM.
Refseq Gene name 4h 10h 18h Description
NM 126166 TLR3 3.1 4.2 2.6 Toll-Like Receptor 3
NM 010510 IFNB1 4.1 1.9 1.2 Interferon-β
NM 021384 RSAD2 5.9 6 6.6 Interferon-induced protein Viperin
NM 020583 ISG20 3.9 5.5 5.4 Interferon-stimulated exonuclease
NM 011163 PKR 2.7 2.2 1.5 dsRNA-activated protein kinase
P56 family
NM 008331 ISG56 5.8 5.1 5.2 Interferon-stimulated gene 56
NM 008332 ISG54 5.9 5.9 5.4 Interferon-stimulated gene 54
NM 010501 ISG49 5.3 5.7 4.9 Interferon-stimulated gene 49
OAS family
NM 145209 OASL1 4.1 4.7 4.6 Oligoadenylate synthetase-like 1
NM 011854 OASL2 3.7 3.3 3 Oligoadenylate synthetase-like 2
NM 145227 OAS2 2.2 2.3 1.6 Oligoadenylate synthetase 2
NM 145226 OAS3 2.4 2.6 2.4 Oligoadenylate synthetase 3
NM 011852 OAS1G 1.9 2 1.7 Oligoadenylate synthetase 1G
NM 033541 OAS1C 1.1 1.2 1.2 Oligoadenylate synthetase 1C
Mx proteins
NM 013606 MX2 3.3 3.1 2.6 Myxovirus resistance 2
NM 010846 MX1 2.7 2.7 1.9 Myxovirus resistance 1
p200 gene family
NM 001045481 IFI203 3.4 2.9 2.5 Interferon activated gene 203
NM 008329 IFI204 2.5 3.4 2.7 Interferon activated gene 204
NM 172648 IFI205 3.1 3.2 3 Interferon activated gene 205
XM 001477431 LOC623121 4.4 5.1 4.6 Novel interferon-beta induced gene
NM 027320 IFI35 1.9 1.5 0.89 Interferon-induced protein 35
NM 133871 IFI44 3.5 4.8 4.6 Interferon-induced protein 44
Interferon-induced GTPases
NM 021792 IIGP1 4.7 5.2 4.9 Interferon inducible GTPase 1
NM 019440 IIGP2 3.1 2.3 1.8 Interferon inducible GTPase 2
NM 001039160 GVIN1 1.8 1.4 1.3 Interferon inducible GTPase
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Table B.2 – Continued
Refseq Gene name 4h 10h 18h Description
Interferon-induced helicases
NM 172689 DDX58 2.9 2.7 2.3 RNA helicase DDX58
NM 027835 IFIH1 3.6 3.5 2.6 Interferon induced with helicase C1
Protein Ubiquitination
NM 022329 ISG15 1.9 1.7 2 Interferon-stimulated gene 15
XM 001478484 HERC5 3 3.4 3.3 IFN-induced E3 protein ligase
NM 019949 UBE2L6 1.9 2.7 2.1 ISG-15-conjugating enzyme
NM 011909 USP18 3.7 3.6 3.3 Protease specifically removing ISG15
NM 023738 UBE1l 1.6 2.3 2 Ubiquitin-activating enzyme E1-like
NM 019949 UBE2l6 1.9 2.7 2.1 Ubiquitin-conjugating enzyme E2L6
XR 005074 LOC677168 4.2 4.8 4.8 Similar to ISG15 ubiquitin-like modifier
Interferon regulatory factors (IRF)
NM 016850 IRF7 4.1 4.5 4.2 Interferon regulatory factor 7
Misc
NM 028864 Zc3hav1 1.6 1.2 0.76 Antiviral zinc and RNA binding protein
NM 001038587 Adar 1.9 1.7 1.8 Adenosine deaminase (binds dsRNA)
NM 175397 Sp110 1.5 1.1 0.43 Sp110 nuclear body protein
NM 011636 Plscr1 1.1 0.35 0.2 Phospholipid scramblase 1
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